Secukinumab/Pediatric Psoriasis CAIN457A2310

AMNOG Dossier Primary Analysis

Date: 24.08.2020

Document Status: Final

Author: Monika Schwager, Winicker Norimed GmbH

Table of Contents

Tables

Patient Disposition and Baseline Characteristics

1.1 Patient Disposition and Compliance (RAN, FAS)

	Treatment Groups			
Disposition/Reason	**SEC low (N=40)**	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Randomized (RAN)	**40 (100.0)**	**40 (100.0)**	**41 (100.0)**	**121 (100.0)**
Full Analysis Set (FAS)	**40 (100.0)**	**40 (100.0)**	**41 (100.0)**	**121 (100.0)**
Study discontinuation during induction period	**1 (2.5)**	**2 (5.0)**	**0 (0.0)**	**3 (2.5)**
Reasons for study discontinuation during induction period				
Adverse event	0 (0.0)	1 (2.5)	0 (0.0)	1 (0.8)
Lack of efficacy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	1 (2.5)	1 (2.5)	0 (0.0)	2 (1.7)
Study discontinuation during maintenance period	**0 (0.0)**	**0 (0.0)**	**2 (4.9)**	**2 (1.7)**
Reasons for study discontinuation during maintenance period				
Adverse event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	1 (2.4)	1 (0.8)
Protocol deviation	0 (0.0)	0 (0.0)	1 (2.4)	1 (0.8)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Study drug during induction period				
Received study drug	40 (100.0)	40 (100.0)	41 (100.0)	121 (100.0)
Did not receive study drug	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Completed induction period on double-blind study drug	39 (97.5)	38 (95.0)	40 (97.6)	117 (96.7)
Prematurely discontinued double-blind study drug during induction period	1 (2.5)	2 (5.0)	1 (2.4)	4 (3.3)
Primary reason for premature discontinuation from double-blind study drug during induction period				
Adverse event	0 (0.0)	1 (2.5)	0 (0.0)	1 (0.8)
Lack of efficacy	0 (0.0)	0 (0.0)	1 (2.4)	1 (0.8)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Withdrawal of informed consent	1 (2.5)	1 (2.5)	0 (0.0)	2 (1.7)

	Treatment Groups			
Disposition/Reason	**SEC low (N=40)**	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Study drug during maintenance period				
Received study drug	39 (97.5)	38 (95.0)	40 (97.6)	117 (96.7)
Did not receive study drug	1 (2.5)	2 (5.0)	1 (2.4)	4 (3.3)
Completed maintenance period on double-blind study drug	38 (95.0)	37 (92.5)	34 (82.9)	109 (90.1)
Prematurely discontinued double-blind study drug during maintenance period	1 (2.5)	1 (2.5)	6 (14.6)	8 (6.6)
Primary reason for premature discontinuation from double-blind study drug during maintenance period				
Adverse event	1 (2.5)	0 (0.0)	1 (2.4)	2 (1.7)
Lack of efficacy	0 (0.0)	1 (2.5)	3 (7.3)	4 (3.3)
Pregnancy	0 (0.0)	0 (0.0)	1 (2.4)	1 (0.8)
Protocol deviation	0 (0.0)	0 (0.0)	1 (2.4)	1 (0.8)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Withdrawal of informed consent	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviations during induction period				
Subject with at least one protocol deviation	9 (22.5)	12 (30.0)	18 (43.9)	39 (32.2)
Selection criteria not met	0 (0.0)	2 (5.0)	0 (0.0)	2 (1.7)
Treatment deviation	1 (2.5)	1 (2.5)	7 (17.1)	9 (7.4)
Prohibited concomitant medication	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other deviation	8 (20.0)	10 (25.0)	11 (26.8)	29 (24.0)
Protocol deviations during maintenance period				
Subject with at least one protocol deviation	13 (32.5)	14 (35.0)	21 (51.2)	48 (39.7)
Selection criteria not met	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Treatment deviation	8 (20.0)	7 (17.5)	16 (39.0)	31 (25.6)
Prohibited concomitant medication	0 (0.0)	0 (0.0)	2 (4.9)	2 (1.7)
Other deviation	8 (20.0)	8 (20.0)	6 (14.6)	22 (18.2)

1.2 Length of Study Participation (FAS)

	Treatment Groups			
Subgroups	**SEC low (N=40)**	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Study participation in induction period				
Mean ± SD (in days)	85.1 ± 13.5	86.4 ± 19.7	87.3 ± 8.8	86.2 ± 14.5
Median (in days)	85.0	85.0	85.0	85.0
Range (in days)	9 - 106	15 - 176	78 - 134	9 - 176
Study participation in maintenance period				
Mean ± SD (in days)	277.5 ± 18.3	279.8 ± 12.0	253.7 ± 76.3	270.1 ± 47.5
Median (in days)	281.0	281.0	281.0	281.0
Range (in days)	175 - 309	223 - 309	24 - 305	24 - 309
Study participation in induction+maintenance period				
Mean ± SD (in days)	354.6 ± 58.8	351.3 ± 63.3	333.8 ± 83.3	346.5 ± 69.4
Median (in days)	365.0	365.0	365.0	365.0
Range (in days)	9 - 393	15 - 386	85 - 394	9 - 394

Duration of study participation in each period is defined as the time from the first entry up to the last entry in the respective period.

1.3 Characterization of Study Population, Demographic Characteristics (FAS)

	Treatment Groups			
Patient characteristics	**SEC low (N=40)**	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Age (years)				
Mean ± SD	13.7 ± 2.9	13.2 ± 3.2	13.5 ± 2.9	13.5 ± 3.0
Median	14.5	14.0	14.0	14.0
Range	7 - 17	6 - 17	6 - 17	6 - 17
Age group (years), n(%)				
<12	8 (20.0)	9 (22.5)	10 (24.4)	27 (22.3)
≥12	32 (80.0)	31 (77.5)	31 (75.6)	94 (77.7)
Sex, n(%)				
Male	13 (32.5)	17 (42.5)	16 (39.0)	46 (38.0)
Female	27 (67.5)	23 (57.5)	25 (61.0)	75 (62.0)
Weight (kg)				
Mean ± SD	52.6 ± 15.3	53.6 ± 20.2	52.0 ± 19.4	52.7 ± 18.3
Median	51.5	51.0	50.0	50.7
Range	21 - 85	20.5 - 116	20.5 - 105.5	20.5 - 116
Weight group (kg), n(%)				
<25	2 (5.0)	3 (7.5)	4 (9.8)	9 (7.4)
≥25 - <50	17 (42.5)	15 (37.5)	16 (39.0)	48 (39.7)
≥50	21 (52.5)	22 (55.0)	21 (51.2)	64 (52.9)
Height (cm)				
Mean ± SD	159.1 ± 14.8	156.5 ± 18.5	154.6 ± 16.5	156.7 ± 16.6
Median	160.0	159.0	158.0	160.0
Range	121 - 185	115 - 194	118 - 183	115 - 194
BMI (kg/m)				
Mean ± SD	20.3 ± 3.6	21.2 ± 4.4	21.0 ± 4.8	20.8 ± 4.3
Median	19.5	20.5	21.0	20.4
Range	14.1 - 30.7	11.1 - 33.9	13.7 - 31.5	11.1 - 33.9
Child bearing status, n(%)				
Able to bear children	17 (42.5)	16 (40.0)	16 (39.0)	49 (40.5)
Premenarche	10 (25.0)	7 (17.5)	9 (22.0)	26 (21.5)
Race, n(%)				
Caucasian	34 (85.0)	34 (85.0)	30 (73.2)	98 (81.0)
Black	1 (2.5)	1 (2.5)	0 (0.0)	2 (1.7)
Asian	1 (2.5)	2 (5.0)	3 (7.3)	6 (5.0)
Native American	3 (7.5)	3 (7.5)	8 (19.5)	14 (11.6)
Other	1 (2.5)	0 (0.0)	0 (0.0)	1 (0.8)

	Treatment Groups			
Patient characteristics	**SEC low (N=40)**	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Ethnicity, n(%)				
Hispanic/Latino	4 (10.0)	4 (10.0)	9 (22.0)	17 (14.0)
Not Hispanic or Latino	29 (72.5)	31 (77.5)	27 (65.9)	87 (71.9)
Unknown	4 (10.0)	2 (5.0)	2 (4.9)	8 (6.6)
Region, n(%)				
Africa	1 (2.5)	1 (2.5)	4 (9.8)	6 (5.0)
America	4 (10.0)	5 (12.5)	8 (19.5)	17 (14.0)
Asia	7 (17.5)	2 (5.0)	5 (12.2)	14 (11.6)
Europe	28 (70.0)	32 (80.0)	24 (58.5)	84 (69.4)

1.4 Disease History and Prior Medication (FAS)

	Treatment Groups			
Disease history	**SEC low (N=40)**	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Diagnosis of plaque-type psoriasis, n(%)				
Yes	40 (100.0)	40 (100.0)	41 (100.0)	121 (100.0)
Time since first diagnosis of plaque-type psoriasis (years)				
Mean ± SD	4.8 ± 4.3	5.4 ± 4.7	4.5 ± 3.7	4.9 ± 4.2
Median	3.8	3.3	3.9	3.8
Range	0.3 - 17.0	0.4 - 17.2	0.3 - 14.0	0.3 - 17.2
Diagnosis of psoriatic arthritis, n(%)				
Yes	5 (12.5)	3 (7.5)	3 (7.3)	11 (9.1)
No	35 (87.5)	37 (92.5)	38 (92.7)	110 (90.9)
Time since first diagnosis of psoriatic arthritis (years)				
Mean ± SD	4.7 ± 3.4	1.9 ± 2.0	1.4 ± 1.1	3.0 ± 2.9
Median	3.5	0.8	1.2	2.1
Range	1.6 - 9.7	0.7 - 4.2	0.3 - 2.6	0.3 - 9.7
Previous psoriasis therapies, n(%)				
Yes	40 (100.0)	40 (100.0)	41 (100.0)	121 (100.0)
Previous systemic therapies, n(%)				
Yes	26 (65.0)	21 (52.5)	19 (46.3)	66 (54.5)
No	14 (35.0)	19 (47.5)	22 (53.7)	55 (45.5)
Failure	24 (60.0)	17 (42.5)	14 (34.1)	55 (45.5)
no failure	2 (5.0)	4 (10.0)	5 (12.2)	11 (9.1)
Previous phototherapy or photochemotherapy, n(%)				
Yes	17 (42.5)	23 (57.5)	21 (51.2)	61 (50.4)
No	23 (57.5)	17 (42.5)	20 (48.8)	60 (49.6)
Failure	15 (37.5)	17 (42.5)	18 (43.9)	50 (41.3)
no failure	2 (5.0)	6 (15.0)	3 (7.3)	11 (9.1)
Previous topical therapy, n(%)				
Yes	32 (80.0)	36 (90.0)	38 (92.7)	106 (87.6)
No	8 (20.0)	4 (10.0)	3 (7.3)	15 (12.4)
Failure	27 (67.5)	30 (75.0)	31 (75.6)	88 (72.7)
no failure	5 (12.5)	6 (15.0)	7 (17.1)	18 (14.9)

	Treatment Groups			
Disease history	**SEC low (N=40)**	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Failure of at least one systemic therapy or phototherapy or photochemotherapy, n(%)				
Yes	31 (77.5)	28 (70.0)	26 (63.4)	85 (70.2)

1.5 Baseline Disease Characteristics (FAS)

	Treatment Groups			
Baseline disease characteristics	**SEC low (N=40)**	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Baseline PASI score				
Mean ± SD	27.6 ± 6.9	28.0 ± 8.7	28.4 ± 9.1	28.0 ± 8.2
Median	25.6	25.5	24.8	25.1
Range	20.2 - 48	17.2 - 58.8	20.1 - 59.8	17.2 - 59.8
Baseline PASI, n(%)				
≤20	0 (0.0)	1 (2.5)	0 (0.0)	1 (0.8)
>20	40 (100.0)	39 (97.5)	41 (100.0)	120 (99.2)
Baseline total BSA				
Mean ± SD	37.6 ± 13.9	40.3 ± 17.6	43.1 ± 19.6	40.4 ± 17.2
Median	36.7	36.8	37.7	36.8
Range	12 - 72.5	16 - 94	13.1 - 90.5	12 - 94
Baseline IGA mod 2011 score, n(%)				
3 = Moderate disease	0 (0.0)	1 (2.5)	0 (0.0)	1 (0.8)
4 = Severe disease	40 (100.0)	39 (97.5)	41 (100.0)	120 (99.2)

1.6 Subgroups (FAS)

	Treatment Groups			
Subgroups	**SEC low (N=40)**	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Subgroup Age, n (%)				
< 12 years	8 (20.0)	9 (22.5)	10 (24.4)	27 (22.3)
≥ 12 years	32 (80.0)	31 (77.5)	31 (75.6)	94 (77.7)
Subgroup Gender, n (%)				
Male	13 (32.5)	17 (42.5)	16 (39.0)	46 (38.0)
Female	27 (67.5)	23 (57.5)	25 (61.0)	75 (62.0)
Subgroup Disease Severity, n (%)				
Baseline PASI ≤ median	20 (50.0)	20 (50.0)	22 (53.7)	62 (51.2)
Baseline PASI > median	20 (50.0)	20 (50.0)	19 (46.3)	59 (48.8)
Subgroup Region, n (%)				
Africa	1 (2.5)	1 (2.5)	4 (9.8)	6 (5.0)
America	4 (10.0)	5 (12.5)	8 (19.5)	17 (14.0)
Asia	7 (17.5)	2 (5.0)	5 (12.2)	14 (11.6)
Europe	28 (70.0)	32 (80.0)	24 (58.5)	84 (69.4)
Subgroup Region - Europe vs. Others, n (%)				
Europe	28 (70.0)	32 (80.0)	24 (58.5)	84 (69.4)
Others	12 (30.0)	8 (20.0)	17 (41.5)	37 (30.6)
Subgroup Weight, n (%)				
< 25 kg	2 (5.0)	3 (7.5)	4 (9.8)	9 (7.4)
≥ 25 kg - < 50 kg	17 (42.5)	15 (37.5)	16 (39.0)	48 (39.7)
≥ 50 kg	21 (52.5)	22 (55.0)	21 (51.2)	64 (52.9)
Subgroup Weight - < 50kg vs. ≥ 50 kg, n (%)				
< 50 kg	19 (47.5)	18 (45.0)	20 (48.8)	57 (47.1)
≥ 50 kg	21 (52.5)	22 (55.0)	21 (51.2)	64 (52.9)
Subgroup Previous Systemic Therapy, n (%)				
No	14 (35.0)	19 (47.5)	22 (53.7)	55 (45.5)
Yes	26 (65.0)	21 (52.5)	19 (46.3)	66 (54.5)

Efficacy and safety subgroup analysis is displayed for all subgrouping factors with at least 10 patients in each subgroup.

Efficacy Analysis

2.1 All-Cause Mortality (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
All-cause Mortality						
N'	**40**	**40**	**41**			
n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

3.0 BSA (Percent), Return Rates (FAS)

	Treatment Groups			
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Number of patients with valid data n (%)				
Baseline Returns	40 (100.0)	40 (100.0)	41 (100.0)	121 (100.0)
Week 1 Returns	38 (95.0)	37 (92.5)	41 (100.0)	116 (95.9)
Week 2 Returns	37 (92.5)	37 (92.5)	39 (95.1)	113 (93.4)
Week 3 Returns	39 (97.5)	35 (87.5)	41 (100.0)	115 (95.0)
Week 4 Returns	38 (95.0)	38 (95.0)	38 (92.7)	114 (94.2)
Week 8 Returns	39 (97.5)	38 (95.0)	41 (100.0)	118 (97.5)
Week 12 Returns	32 (80.0)	36 (90.0)	35 (85.4)	103 (85.1)
Week 13 Returns	31 (77.5)	34 (85.0)	31 (75.6)	96 (79.3)
Week 14 Returns	35 (87.5)	36 (90.0)	34 (82.9)	105 (86.8)
Week 15 Returns	37 (92.5)	35 (87.5)	34 (82.9)	106 (87.6)
Week 16 Returns	39 (97.5)	37 (92.5)	36 (87.8)	112 (92.6)
Week 20 Returns	39 (97.5)	38 (95.0)	38 (92.7)	115 (95.0)
Week 24 Returns	39 (97.5)	38 (95.0)	37 (90.2)	114 (94.2)
Week 28 Returns	38 (95.0)	37 (92.5)	36 (87.8)	111 (91.7)
Week 32 Returns	39 (97.5)	38 (95.0)	36 (87.8)	113 (93.4)
Week 36 Returns	38 (95.0)	38 (95.0)	35 (85.4)	111 (91.7)
Week 40 Returns	38 (95.0)	38 (95.0)	35 (85.4)	111 (91.7)
Week 44 Returns	39 (97.5)	38 (95.0)	33 (80.5)	110 (90.9)
Week 48 Returns	38 (95.0)	36 (90.0)	34 (82.9)	108 (89.3)
Week 52 Returns	39 (97.5)	38 (95.0)	34 (82.9)	111 (91.7)

3.1 BSA (Percent), Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
N'	39	39	41		
Baseline Mean (SD)	37.59 (13.86)	40.26 (17.56)	43.13 (19.56)		
Week 52 Adjusted Mean Change (SE)	-35.27 (2.13)	-35.19 (2.14)	-31.57 (2.17)	-3.69 [-9.68; 2.29] 0.226	-3.62 [-9.59; 2.36] 0.236

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

3.2 BSA (Percent), Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.131					
Age < 12 years, N	**8**	**9**	**10**		
N'	8	9	10		
Baseline Mean (SD)	35.85 (15.87)	43.98 (16.06)	51.31 (18.96)		
Week 52 Adjusted Mean Change (SE)	-35.08 (4.65)	-33.42 (4.56)	-35.41 (4.31)	0.33 [-12.15; 12.80] 0.959	1.98 [-10.27; 14.23] 0.751
Age ≥ 12 years, N	**32**	**31**	**31**		
N'	31	30	31		
Baseline Mean (SD)	38.03 (13.56)	39.18 (18.08)	40.49 (19.30)		
Week 52 Adjusted Mean Change (SE)	-35.29 (2.36)	-35.70 (2.40)	-30.32 (2.48)	-4.96 [-11.69; 1.76] 0.148	-5.37 [-12.15; 1.40] 0.120

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.3 BSA (Percent), Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.496					
Male, N	**13**	**17**	**16**		
N'	13	17	16		
Baseline Mean (SD)	39.82 (17.49)	39.54 (17.58)	41.99 (18.95)		
Week 52 Adjusted Mean Change (SE)	-34.67 (3.68)	-38.39 (3.22)	-31.58 (3.56)	-3.09 [-13.14; 6.96] 0.546	-6.81 [-16.23; 2.61] 0.156
Female, N	**27**	**23**	**25**		
N'	26	22	25		
Baseline Mean (SD)	36.52 (11.97)	40.80 (17.92)	43.86 (20.29)		
Week 52 Adjusted Mean Change (SE)	-35.58 (2.62)	-32.62 (2.88)	-31.46 (2.75)	-4.11 [-11.59; 3.36] 0.281	-1.15 [-8.95; 6.65] 0.772

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.4 BSA (Percent), Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.637					
Baseline PASI ≤ Median, N	**20**	**20**	**22**		
N'	20	19	22		
Baseline Mean (SD)	29.13 (9.50)	34.50 (14.57)	33.30 (13.05)		
Week 52 Adjusted Mean Change (SE)	-31.59 (3.00)	-31.49 (3.03)	-30.10 (2.91)	-1.49 [-9.55; 6.57] 0.717	-1.39 [-9.54; 6.76] 0.737
Baseline PASI > Median, N	**20**	**20**	**19**		
N'	19	20	19		
Baseline Mean (SD)	46.05 (12.39)	46.03 (18.72)	54.52 (19.91)		
Week 52 Adjusted Mean Change (SE)	-38.91 (3.02)	-38.98 (3.00)	-33.73 (3.31)	-5.18 [-13.82; 3.47] 0.240	-5.25 [-13.83; 3.33] 0.230

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.5 BSA (Percent), Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.076					
Europe, N	**28**	**32**	**24**		
N'	28	32	24		
Baseline Mean (SD)	37.41 (13.62)	39.18 (17.50)	36.53 (16.13)		
Week 52 Adjusted Mean Change (SE)	-36.10 (2.45)	-36.64 (2.32)	-35.32 (2.74)	-0.79 [-7.99; 6.42] 0.831	-1.32 [-8.35; 5.72] 0.714
Others, N	**12**	**8**	**17**		
N'	11	7	17		
Baseline Mean (SD)	38.01 (15.01)	44.61 (18.28)	52.45 (20.60)		
Week 52 Adjusted Mean Change (SE)	-33.65 (3.92)	-28.73 (4.90)	-25.91 (3.44)	-7.74 [-18.04; 2.56] 0.141	-2.82 [-14.54; 8.89] 0.637

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.6 BSA (Percent), Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.572					
Weight < 50 kg, N	**19**	**18**	**20**		
N'	19	17	20		
Baseline Mean (SD)	34.92 (12.28)	42.21 (19.87)	47.16 (17.88)		
Week 52 Adjusted Mean Change (SE)	-33.84 (3.00)	-30.95 (3.22)	-30.92 (3.06)	-2.91 [-11.35; 5.53] 0.499	-0.03 [-8.72; 8.66] 0.995
Weight ≥ 50 kg, N	**21**	**22**	**21**		
N'	20	22	21		
Baseline Mean (SD)	40.01 (15.03)	38.67 (15.72)	39.30 (20.73)		
Week 52 Adjusted Mean Change (SE)	-36.66 (2.91)	-38.28 (2.77)	-32.12 (2.99)	-4.55 [-12.73; 3.63] 0.276	-6.17 [-14.16; 1.83] 0.131

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.7 BSA (Percent), Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.721					
No previous systemic therapy, N	**14**	**19**	**22**		
N'	13	18	22		
Baseline Mean (SD)	38.06 (17.39)	35.25 (13.61)	43.07 (17.26)		
Week 52 Adjusted Mean Change (SE)	-36.74 (3.68)	-35.62 (3.20)	-34.06 (2.93)	-2.68 [-11.91; 6.56] 0.570	-1.56 [-10.09; 6.97] 0.720
Previous systemic therapy, N	**26**	**21**	**19**		
N'	26	21	19		
Baseline Mean (SD)	37.34 (11.93)	44.80 (19.72)	43.21 (22.41)		
Week 52 Adjusted Mean Change (SE)	-34.57 (2.60)	-34.76 (2.90)	-28.49 (3.22)	-6.07 [-14.20; 2.05] 0.143	-6.27 [-14.75; 2.21] 0.147

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

4.1 BSA 0% (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Total BSA Involvement 0% Week 52						
N'	**39**	**38**	**34**			
n (%)	16.25 (40.63)	19.59 (48.98)	9.07 (22.12)			
SEC low vs. ETA				2.38 [0.90; 6.29] 0.080	1.84 [0.92; 3.66] 0.084	0.19 [-0.01; 0.38] 0.069
SEC high vs. ETA				3.33 [1.27; 8.75] 0.015	2.21 [1.14; 4.29] 0.018	0.27 [0.07; 0.47] 0.009

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.2 BSA 0% by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.094**					
Age < 12 years, N / N'	**8 / 8**	**9 / 8**	**10 / 9**			
n (%)	6.00 (75.00)	3.37 (37.44)	4.01 (40.10)			
SEC low vs. ETA				4.10 [0.57; 29.43] 0.161	1.87 [0.79; 4.41] 0.153	0.35 [-0.08; 0.78] 0.109
SEC high vs. ETA				0.89 [0.14; 5.74] 0.906	0.92 [0.28; 3.01] 0.897	-0.03 [-0.48; 0.42] 0.908
Age ≥ 12 years, N / N'	**32 / 31**	**31 / 30**	**31 / 25**			
n (%)	10.25 (32.03)	16.22 (52.32)	5.06 (16.32)			
SEC low vs. ETA				2.38 [0.71; 7.98] 0.159	1.96 [0.76; 5.08] 0.165	0.16 [-0.05; 0.37] 0.142
SEC high vs. ETA				5.46 [1.68; 17.83] 0.005	3.21 [1.34; 7.67] 0.009	0.36 [0.14; 0.58] 0.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.3 BSA 0% by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.569**					
Male, N / N'	**13 / 13**	**17 / 17**	**16 / 12**			
n (%)	3.00 (23.08)	8.00 (47.06)	3.01 (18.81)			
SEC low vs. ETA				1.28 [0.22; 7.53] 0.782	1.23 [0.30; 5.09] 0.778	0.04 [-0.26; 0.34] 0.780
SEC high vs. ETA				3.68 [0.78; 17.33] 0.099	2.50 [0.80; 7.81] 0.114	0.28 [-0.02; 0.59] 0.070
Female, N / N'	**27 / 26**	**23 / 21**	**25 / 22**			
n (%)	13.25 (49.07)	11.59 (50.39)	6.06 (24.24)			
SEC low vs. ETA				2.95 [0.90; 9.63] 0.073	2.02 [0.91; 4.50] 0.083	0.25 [-0.01; 0.50] 0.056
SEC high vs. ETA				3.10 [0.90; 10.63] 0.072	2.08 [0.92; 4.68] 0.078	0.26 [-0.01; 0.53] 0.058

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.4 BSA 0% by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.481**					
Baseline PASI ≤ Median, N / N'	**20 / 20**	**20 / 19**	**22 / 19**			
n (%)	7.00 (35.00)	10.22 (51.10)	3.06 (13.91)			
SEC low vs. ETA				3.24 [0.72; 14.67] 0.126	2.52 [0.75; 8.45] 0.134	0.21 [-0.04; 0.47] 0.105
SEC high vs. ETA				6.18 [1.39; 27.36] 0.016	3.68 [1.18; 11.48] 0.025	0.37 [0.11; 0.64] 0.006
Baseline PASI > Median, N / N'	**20 / 19**	**20 / 19**	**19 / 15**			
n (%)	9.25 (46.25)	9.37 (46.85)	6.01 (31.63)			
SEC low vs. ETA				1.83 [0.50; 6.73] 0.363	1.46 [0.64; 3.31] 0.364	0.15 [-0.16; 0.45] 0.348
SEC high vs. ETA				1.87 [0.51; 6.90] 0.346	1.48 [0.65; 3.35] 0.348	0.15 [-0.15; 0.46] 0.330

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.5 BSA 0% by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Total BSA Involvement 0% Week 52						
Interaction Test	**N.E.**					
Europe, N / N'	**28 / 28**	**32 / 31**	**24 / 21**			
n (%)	14.00 (50.00)	19.37 (60.53)	7.05 (29.37)			
SEC low vs. ETA				2.36 [0.76; 7.39] 0.139	1.70 [0.82; 3.52] 0.150	0.21 [-0.05; 0.47] 0.121
SEC high vs. ETA				3.60 [1.17; 11.10] 0.026	2.06 [1.04; 4.09] 0.038	0.31 [0.06; 0.56] 0.015
Others, N / N'	**12 / 11**	**8 / 7**	**17 / 13**			
n (%)	2.25 (18.75)	0.22 (2.75)	2.02 (11.88)			
SEC low vs. ETA				1.66 [0.21; 13.39] 0.636	1.56 [0.26; 9.47] 0.632	0.07 [-0.21; 0.35] 0.629
SEC high vs. ETA				0.89 [N.E.; N.E.] N.E.	0.49 [0.03; 8.97] 0.632	-0.09 [-0.31; 0.12] 0.402

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.6 BSA 0% by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.011**					
Weight < 50 kg, N / N'	**19 / 19**	**18 / 16**	**20 / 17**			
n (%)	11.00 (57.89)	5.59 (31.06)	6.02 (30.10)			
SEC low vs. ETA				3.09 [0.84; 11.37] 0.089	1.92 [0.89; 4.16] 0.096	0.28 [-0.02; 0.58] 0.069
SEC high vs. ETA				1.04 [0.26; 4.23] 0.956	1.03 [0.38; 2.76] 0.960	0.01 [-0.29; 0.31] 0.950
Weight ≥ 50 kg, N / N'	**21 / 20**	**22 / 22**	**21 / 17**			
n (%)	5.25 (25.00)	14.00 (63.64)	3.05 (14.52)			
SEC low vs. ETA				1.93 [0.40; 9.26] 0.412	1.72 [0.47; 6.26] 0.411	0.10 [-0.14; 0.35] 0.397
SEC high vs. ETA				9.68 [2.21; 42.35] 0.003	4.39 [1.47; 13.11] 0.008	0.49 [0.24; 0.74] <.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.7 BSA 0% by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.384**					
No previous systemic therapy, N / N'	**14 / 13**	**19 / 17**	**22 / 19**			
n (%)	8.25 (58.93)	10.59 (55.74)	8.01 (36.41)			
SEC low vs. ETA				2.44 [0.62; 9.70] 0.204	1.62 [0.79; 3.30] 0.187	0.23 [-0.11; 0.56] 0.184
SEC high vs. ETA				2.16 [0.61; 7.65] 0.233	1.53 [0.76; 3.06] 0.230	0.19 [-0.11; 0.50] 0.217
Previous systemic therapy, N / N'	**26 / 26**	**21 / 21**	**19 / 15**			
n (%)	8.00 (30.77)	9.00 (42.86)	1.06 (5.58)			
SEC low vs. ETA				7.36 [0.84; 64.22] 0.071	5.61 [0.77; 41.05] 0.090	0.25 [0.05; 0.46] 0.017
SEC high vs. ETA				12.16 [1.38; 106.77] 0.024	7.81 [1.09; 55.92] 0.041	0.37 [0.14; 0.61] 0.002

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

5.0 PASI, Return Rates (FAS)

	Treatment Groups			
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Number of patients with valid data n (%)				
Baseline Returns	40 (100.0)	40 (100.0)	41 (100.0)	121 (100.0)
Week 1 Returns	38 (95.0)	37 (92.5)	41 (100.0)	116 (95.9)
Week 2 Returns	37 (92.5)	37 (92.5)	39 (95.1)	113 (93.4)
Week 3 Returns	39 (97.5)	35 (87.5)	41 (100.0)	115 (95.0)
Week 4 Returns	38 (95.0)	38 (95.0)	38 (92.7)	114 (94.2)
Week 8 Returns	39 (97.5)	38 (95.0)	41 (100.0)	118 (97.5)
Week 12 Returns	32 (80.0)	36 (90.0)	35 (85.4)	103 (85.1)
Week 13 Returns	31 (77.5)	34 (85.0)	31 (75.6)	96 (79.3)
Week 14 Returns	35 (87.5)	36 (90.0)	34 (82.9)	105 (86.8)
Week 15 Returns	37 (92.5)	35 (87.5)	34 (82.9)	106 (87.6)
Week 16 Returns	39 (97.5)	37 (92.5)	36 (87.8)	112 (92.6)
Week 20 Returns	39 (97.5)	38 (95.0)	38 (92.7)	115 (95.0)
Week 24 Returns	39 (97.5)	38 (95.0)	37 (90.2)	114 (94.2)
Week 28 Returns	38 (95.0)	37 (92.5)	36 (87.8)	111 (91.7)
Week 32 Returns	39 (97.5)	38 (95.0)	36 (87.8)	113 (93.4)
Week 36 Returns	38 (95.0)	38 (95.0)	35 (85.4)	111 (91.7)
Week 40 Returns	38 (95.0)	38 (95.0)	35 (85.4)	111 (91.7)
Week 44 Returns	39 (97.5)	38 (95.0)	33 (80.5)	110 (90.9)
Week 48 Returns	38 (95.0)	36 (90.0)	34 (82.9)	108 (89.3)
Week 52 Returns	39 (97.5)	38 (95.0)	34 (82.9)	111 (91.7)

5.1 PASI, Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
N'	39	39	41		
Baseline Mean (SD)	27.56 (6.89)	27.96 (8.67)	28.40 (9.05)		
Week 52 Adjusted Mean Change (SE)	-25.59 (1.24)	-26.02 (1.25)	-22.02 (1.27)	-3.57 [-7.05; -0.08] 0.045	-4.00 [-7.49; -0.50] 0.025

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

5.2 PASI, Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.613					
Age < 12 years, N	**8**	**9**	**10**		
N'	8	9	10		
Baseline Mean (SD)	29.13 (9.72)	27.88 (6.63)	29.88 (9.00)		
Week 52 Adjusted Mean Change (SE)	-27.09 (2.71)	-23.46 (2.66)	-21.58 (2.49)	-5.51 [-12.71; 1.70] 0.134	-1.89 [-9.03; 5.25] 0.604
Age ≥ 12 years, N	**32**	**31**	**31**		
N'	31	30	31		
Baseline Mean (SD)	27.17 (6.13)	27.98 (9.27)	27.93 (9.17)		
Week 52 Adjusted Mean Change (SE)	-25.21 (1.38)	-26.72 (1.40)	-22.16 (1.45)	-3.04 [-6.96; 0.88] 0.128	-4.56 [-8.51; -0.61] 0.024

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.3 PASI, Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.732					
Male, N	**13**	**17**	**16**		
N'	13	17	16		
Baseline Mean (SD)	27.86 (7.73)	28.46 (8.87)	28.79 (9.26)		
Week 52 Adjusted Mean Change (SE)	-24.40 (2.16)	-27.01 (1.89)	-22.65 (2.10)	-1.75 [-7.66; 4.16] 0.561	-4.36 [-9.90; 1.18] 0.123
Female, N	**27**	**23**	**25**		
N'	26	22	25		
Baseline Mean (SD)	27.41 (6.60)	27.59 (8.70)	28.16 (9.11)		
Week 52 Adjusted Mean Change (SE)	-26.18 (1.53)	-25.25 (1.69)	-21.69 (1.61)	-4.49 [-8.85; -0.14] 0.043	-3.56 [-8.13; 1.02] 0.128

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.4 PASI, Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.174					
Baseline PASI ≤ Median, N	**20**	**20**	**22**		
N'	20	19	22		
Baseline Mean (SD)	22.51 (1.66)	22.56 (1.97)	22.63 (1.55)		
Week 52 Adjusted Mean Change (SE)	-23.69 (1.77)	-23.47 (1.81)	-22.10 (1.75)	-1.59 [-6.29; 3.11] 0.508	-1.37 [-6.13; 3.39] 0.572
Baseline PASI > Median, N	**20**	**20**	**19**		
N'	19	20	19		
Baseline Mean (SD)	32.61 (6.41)	33.37 (9.43)	35.09 (9.57)		
Week 52 Adjusted Mean Change (SE)	-27.49 (1.80)	-28.63 (1.80)	-22.03 (1.96)	-5.47 [-10.49; -0.45] 0.033	-6.61 [-11.59; -1.62] 0.009

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.5 PASI, Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.046					
Europe, N	**28**	**32**	**24**		
N'	28	32	24		
Baseline Mean (SD)	27.89 (7.38)	28.60 (9.38)	27.26 (8.92)		
Week 52 Adjusted Mean Change (SE)	-25.75 (1.43)	-27.03 (1.36)	-25.03 (1.60)	-0.72 [-4.94; 3.50] 0.738	-2.00 [-6.12; 2.13] 0.342
Others, N	**12**	**8**	**17**		
N'	11	7	17		
Baseline Mean (SD)	26.79 (5.80)	25.40 (4.48)	30.02 (9.26)		
Week 52 Adjusted Mean Change (SE)	-25.20 (2.29)	-21.58 (2.87)	-17.48 (1.98)	-7.72 [-13.67; -1.77] 0.011	-4.10 [-10.95; 2.74] 0.240

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.6 PASI, Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.737					
Weight < 50 kg, N	**19**	**18**	**20**		
N'	19	17	20		
Baseline Mean (SD)	27.46 (7.66)	27.43 (9.65)	29.29 (8.79)		
Week 52 Adjusted Mean Change (SE)	-25.91 (1.74)	-23.84 (1.88)	-20.38 (1.77)	-5.53 [-10.40; -0.66] 0.026	-3.46 [-8.52; 1.61] 0.181
Weight ≥ 50 kg, N	**21**	**22**	**21**		
N'	20	22	21		
Baseline Mean (SD)	27.65 (6.29)	28.40 (7.99)	27.56 (9.44)		
Week 52 Adjusted Mean Change (SE)	-25.29 (1.70)	-27.64 (1.62)	-23.58 (1.75)	-1.71 [-6.49; 3.07] 0.483	-4.06 [-8.73; 0.61] 0.088

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.7 PASI, Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.567					
No previous systemic therapy, N	**14**	**19**	**22**		
N'	13	18	22		
Baseline Mean (SD)	25.91 (5.05)	25.46 (5.03)	27.70 (6.81)		
Week 52 Adjusted Mean Change (SE)	-26.02 (2.15)	-26.52 (1.87)	-23.81 (1.71)	-2.21 [-7.59; 3.18] 0.422	-2.70 [-7.67; 2.26] 0.285
Previous systemic therapy, N	**26**	**21**	**19**		
N'	26	21	19		
Baseline Mean (SD)	28.45 (7.64)	30.22 (10.61)	29.23 (11.26)		
Week 52 Adjusted Mean Change (SE)	-25.39 (1.52)	-25.57 (1.69)	-19.82 (1.89)	-5.57 [-10.31; -0.82] 0.022	-5.74 [-10.71; -0.78] 0.023

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

6.1 PASI Response (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI50 Response Week 52						
N'	**39**	**38**	**34**			
n (%)	40.00 (100.00)	38.86 (97.15)	35.96 (87.71)			
SEC low vs. ETA				7.06 [N.E.; N.E.] N.E.	1.14 [1.00; 1.30] 0.047	0.12 [0.01; 0.24] 0.033
SEC high vs. ETA				4.76 [0.51; 44.91] 0.173	1.11 [0.96; 1.28] 0.154	0.09 [-0.03; 0.22] 0.140
PASI75 Response Week 52						
N'	**39**	**38**	**34**			
n (%)	35.91 (89.78)	36.49 (91.23)	29.96 (73.07)			
SEC low vs. ETA				3.18 [0.89; 11.33] 0.074	1.23 [0.98; 1.54] 0.074	0.17 [-0.01; 0.34] 0.060
SEC high vs. ETA				3.82 [0.95; 15.36] 0.060	1.25 [1.00; 1.57] 0.054	0.18 [0.01; 0.36] 0.041
PASI90 Response Week 52						
N'	**39**	**38**	**34**			
n (%)	30.61 (76.53)	33.02 (82.55)	21.94 (53.51)			
SEC low vs. ETA				2.80 [1.06; 7.39] 0.038	1.43 [1.02; 2.02] 0.041	0.23 [0.02; 0.44] 0.029
SEC high vs. ETA				4.05 [1.41; 11.61] 0.009	1.54 [1.11; 2.15] 0.010	0.29 [0.09; 0.49] 0.004
PASI100 Response Week 52						
N'	**39**	**38**	**34**			
n (%)	16.29 (40.73)	19.76 (49.40)	9.52 (23.22)			
SEC low vs. ETA				2.25 [0.85; 5.97] 0.103	1.76 [0.88; 3.49] 0.108	0.18 [-0.03; 0.38] 0.092

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
SEC high vs. ETA				3.19 [1.21; 8.40] 0.019	2.13 [1.11; 4.10] 0.024	0.26 [0.06; 0.47] 0.013
PASI Rebound Week 52						
N'	**39**	**38**	**34**			
n (%)	0.00 (0.00)	0.00 (0.00)	2.08 (5.07)			
SEC low vs. ETA				0.40 [N.E.; N.E.] N.E.	0.20 [0.01; 4.04] 0.293	-0.05 [-0.12; 0.02] 0.148
SEC high vs. ETA				0.40 [N.E.; N.E.] N.E.	0.20 [0.01; 4.04] 0.293	-0.05 [-0.12; 0.02] 0.148

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.2 PASI Response by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI50 Response Week 52						
Interaction Test	**N.E.**					
Age < 12 years, N / N'	**8 / 8**	**9 / 8**	**10 / 9**			
n (%)	8.00 (100.00)	7.94 (88.22)	8.53 (85.30)			
SEC low vs. ETA				1.25 [N.E.; N.E.] N.E.	1.17 [0.88; 1.56] 0.269	0.15 [-0.09; 0.39] 0.227
SEC high vs. ETA				1.22 [0.07; 20.42] 0.888	1.04 [0.71; 1.51] 0.856	0.03 [-0.29; 0.35] 0.859
Age ≥ 12 years, N / N'	**32 / 31**	**31 / 30**	**31 / 25**			
n (%)	32.00 (100.00)	30.92 (99.74)	27.43 (88.48)			
SEC low vs. ETA				4.98 [N.E.; N.E.] N.E.	1.13 [0.98; 1.30] 0.092	0.12 [-0.01; 0.24] 0.072
SEC high vs. ETA				4.73 [N.E.; N.E.] N.E.	1.13 [0.97; 1.31] 0.107	0.11 [-0.02; 0.24] 0.087
PASI75 Response Week 52						
Interaction Test	**p=0.192**					
Age < 12 years, N / N'	**8 / 8**	**9 / 8**	**10 / 9**			
n (%)	7.00 (87.50)	6.69 (74.33)	8.31 (83.10)			
SEC low vs. ETA				1.34 [0.09; 20.59] 0.834	1.05 [0.71; 1.57] 0.795	0.04 [-0.29; 0.38] 0.798
SEC high vs. ETA				0.59 [0.05; 6.52] 0.666	0.89 [0.53; 1.49] 0.668	-0.09 [-0.48; 0.30] 0.661
Age ≥ 12 years, N / N'	**32 / 31**	**31 / 30**	**31 / 25**			
n (%)	28.91 (90.34)	29.80 (96.13)	21.65 (69.84)			
SEC low vs. ETA				3.95 [0.93; 16.75] 0.063	1.29 [0.98; 1.71] 0.066	0.21 [0.00; 0.41] 0.048
SEC high vs. ETA				10.78 [1.26; 92.06] 0.030	1.38 [1.06; 1.79] 0.017	0.26 [0.07; 0.45] 0.006

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI90 Response Week 52						
Interaction Test	**p=0.263**					
Age < 12 years, N / N'	**8 / 8**	**9 / 8**	**10 / 9**			
n (%)	7.00 (87.50)	6.39 (71.00)	7.14 (71.40)			
SEC low vs. ETA				2.63 [0.22; 31.19] 0.442	1.23 [0.76; 1.99] 0.405	0.16 [-0.21; 0.53] 0.391
SEC high vs. ETA				0.99 [0.13; 7.77] 0.992	0.99 [0.54; 1.82] 0.981	-0.00 [-0.43; 0.42] 0.985
Age ≥ 12 years, N / N'	**32 / 31**	**31 / 30**	**31 / 25**			
n (%)	23.61 (73.78)	26.63 (85.90)	14.80 (47.74)			
SEC low vs. ETA				3.03 [1.03; 8.91] 0.044	1.55 [1.00; 2.40] 0.051	0.26 [0.02; 0.50] 0.033
SEC high vs. ETA				6.49 [1.83; 22.96] 0.004	1.80 [1.20; 2.71] 0.005	0.38 [0.16; 0.60] <.001
PASI100 Response Week 52						
Interaction Test	**p=0.078**					
Age < 12 years, N / N'	**8 / 8**	**9 / 8**	**10 / 9**			
n (%)	6.00 (75.00)	3.21 (35.67)	4.07 (40.70)			
SEC low vs. ETA				4.01 [0.55; 28.98] 0.169	1.85 [0.78; 4.35] 0.161	0.34 [-0.09; 0.77] 0.118
SEC high vs. ETA				0.81 [0.13; 5.20] 0.828	0.87 [0.27; 2.86] 0.820	-0.05 [-0.50; 0.40] 0.825
Age ≥ 12 years, N / N'	**32 / 31**	**31 / 30**	**31 / 25**			
n (%)	10.29 (32.16)	16.55 (53.39)	5.45 (17.58)			
SEC low vs. ETA				2.20 [0.65; 7.42] 0.202	1.84 [0.71; 4.73] 0.208	0.15 [-0.07; 0.36] 0.185
SEC high vs. ETA				5.24 [1.60; 17.15] 0.006	3.05 [1.29; 7.21] 0.011	0.36 [0.13; 0.58] 0.002

	Treatment Groups			Comparison		
	SEC low (N=40)	SEC high (N=40)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.3 PASI Response by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI50 Response Week 52						
Interaction Test	**N.E.**					
Male, N / N'	**13 / 13**	**17 / 17**	**16 / 12**			
n (%)	13.00 (100.00)	17.00 (100.00)	13.36 (83.50)			
SEC low vs. ETA				2.81 [N.E.; N.E.] N.E.	1.20 [0.94; 1.53] 0.147	0.17 [-0.04; 0.37] 0.109
SEC high vs. ETA				3.69 [N.E.; N.E.] N.E.	1.20 [0.94; 1.53] 0.147	0.17 [-0.04; 0.37] 0.109
Female, N / N'	**27 / 26**	**23 / 21**	**25 / 22**			
n (%)	27.00 (100.00)	21.86 (95.04)	22.60 (90.40)			
SEC low vs. ETA				3.13 [N.E.; N.E.] N.E.	1.11 [0.96; 1.28] 0.167	0.10 [-0.03; 0.22] 0.144
SEC high vs. ETA				1.97 [0.16; 24.88] 0.599	1.05 [0.88; 1.25] 0.572	0.05 [-0.11; 0.21] 0.568
PASI75 Response Week 52						
Interaction Test	**p=0.645**					
Male, N / N'	**13 / 13**	**17 / 17**	**16 / 12**			
n (%)	11.00 (84.62)	16.00 (94.12)	12.18 (76.13)			
SEC low vs. ETA				1.65 [0.23; 11.94] 0.620	1.11 [0.76; 1.64] 0.585	0.08 [-0.22; 0.39] 0.586
SEC high vs. ETA				4.67 [0.43; 50.97] 0.207	1.24 [0.89; 1.73] 0.207	0.18 [-0.08; 0.44] 0.174
Female, N / N'	**27 / 26**	**23 / 21**	**25 / 22**			
n (%)	24.91 (92.26)	20.49 (89.09)	17.78 (71.12)			
SEC low vs. ETA				4.72 [0.87; 25.44] 0.071	1.30 [0.98; 1.72] 0.071	0.21 [0.00; 0.42] 0.050
SEC high vs. ETA				3.33 [0.60; 18.32] 0.167	1.25 [0.92; 1.70] 0.150	0.18 [-0.05; 0.41] 0.131

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI90 Response Week 52						
Interaction Test	**p=0.125**					
Male, N / N'	**13 / 13**	**17 / 17**	**16 / 12**			
n (%)	8.00 (61.54)	15.00 (88.24)	10.52 (65.75)			
SEC low vs. ETA				0.83 [0.18; 3.88] 0.818	0.94 [0.53; 1.66] 0.824	-0.04 [-0.40; 0.32] 0.819
SEC high vs. ETA				3.73 [0.61; 22.76] 0.154	1.34 [0.89; 2.03] 0.159	0.22 [-0.06; 0.51] 0.126
Female, N / N'	**27 / 26**	**23 / 21**	**25 / 22**			
n (%)	22.61 (83.74)	18.02 (78.35)	11.42 (45.68)			
SEC low vs. ETA				5.93 [1.59; 22.08] 0.008	1.83 [1.15; 2.94] 0.012	0.38 [0.13; 0.63] 0.002
SEC high vs. ETA				4.20 [1.14; 15.55] 0.031	1.72 [1.05; 2.81] 0.032	0.33 [0.06; 0.59] 0.016
PASI100 Response Week 52						
Interaction Test	**p=0.574**					
Male, N / N'	**13 / 13**	**17 / 17**	**16 / 12**			
n (%)	3.00 (23.08)	8.00 (47.06)	3.28 (20.50)			
SEC low vs. ETA				1.17 [0.20; 6.90] 0.865	1.14 [0.28; 4.68] 0.860	0.03 [-0.28; 0.33] 0.870
SEC high vs. ETA				3.34 [0.70; 15.89] 0.129	2.32 [0.75; 7.17] 0.145	0.27 [-0.05; 0.58] 0.097
Female, N / N'	**27 / 26**	**23 / 21**	**25 / 22**			
n (%)	13.29 (49.22)	11.76 (51.13)	6.24 (24.96)			
SEC low vs. ETA				2.86 [0.87; 9.37] 0.083	1.98 [0.89; 4.38] 0.094	0.24 [-0.02; 0.50] 0.065
SEC high vs. ETA				3.07 [0.89; 10.61] 0.076	2.05 [0.91; 4.60] 0.082	0.26 [-0.01; 0.53] 0.060

	Treatment Groups			Comparison		
	SEC low (N=40)	SEC high (N=40)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.4 PASI Response by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI50 Response Week 52						
Interaction Test	**N.E.**					
Baseline PASI ≤ Median, N / N'	**20 / 20**	**20 / 19**	**22 / 19**			
n (%)	20.00 (100.00)	18.92 (94.60)	20.20 (91.82)			
SEC low vs. ETA				1.75 [N.E.; N.E.] N.E.	1.09 [0.94; 1.26] 0.248	0.08 [-0.05; 0.21] 0.225
SEC high vs. ETA				1.45 [0.09; 22.48] 0.791	1.03 [0.86; 1.24] 0.745	0.03 [-0.14; 0.20] 0.746
Baseline PASI > Median, N / N'	**20 / 19**	**20 / 19**	**19 / 15**			
n (%)	20.00 (100.00)	19.94 (99.70)	15.76 (82.95)			
SEC low vs. ETA				4.74 [N.E.; N.E.] N.E.	1.21 [0.96; 1.51] 0.101	0.17 [-0.01; 0.35] 0.070
SEC high vs. ETA				4.67 [N.E.; N.E.] N.E.	1.20 [0.96; 1.51] 0.108	0.17 [-0.02; 0.35] 0.077
PASI75 Response Week 52						
Interaction Test	**p=0.910**					
Baseline PASI ≤ Median, N / N'	**20 / 20**	**20 / 19**	**22 / 19**			
n (%)	19.00 (95.00)	18.80 (94.00)	17.29 (78.59)			
SEC low vs. ETA				4.93 [0.50; 48.28] 0.171	1.21 [0.93; 1.57] 0.148	0.16 [-0.04; 0.37] 0.123
SEC high vs. ETA				4.26 [0.43; 41.89] 0.214	1.20 [0.92; 1.57] 0.188	0.15 [-0.06; 0.37] 0.166
Baseline PASI > Median, N / N'	**20 / 19**	**20 / 19**	**19 / 15**			
n (%)	16.91 (84.55)	17.69 (88.45)	12.67 (66.68)			

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
SEC low vs. ETA				2.66 [0.55; 12.82] 0.223	1.27 [0.86; 1.87] 0.226	0.18 [-0.10; 0.45] 0.203
SEC high vs. ETA				3.75 [0.65; 21.50] 0.139	1.33 [0.91; 1.93] 0.138	0.22 [-0.05; 0.48] 0.110
PASI90 Response Week 52						
Interaction Test	**p=0.974**					
Baseline PASI ≤ Median, N / N'	**20 / 20**	**20 / 19**	**22 / 19**			
n (%)	15.00 (75.00)	16.63 (83.15)	11.76 (53.45)			
SEC low vs. ETA				2.55 [0.68; 9.59] 0.166	1.41 [0.87; 2.28] 0.166	0.22 [-0.07; 0.50] 0.144
SEC high vs. ETA				4.18 [0.94; 18.54] 0.060	1.56 [0.98; 2.46] 0.058	0.30 [0.02; 0.57] 0.036
Baseline PASI > Median, N / N'	**20 / 19**	**20 / 19**	**19 / 15**			
n (%)	15.61 (78.05)	16.39 (81.95)	10.18 (53.58)			
SEC low vs. ETA				3.00 [0.73; 12.30] 0.126	1.46 [0.89; 2.38] 0.131	0.24 [-0.05; 0.54] 0.104
SEC high vs. ETA				3.82 [0.86; 16.93] 0.077	1.53 [0.95; 2.47] 0.081	0.28 [-0.00; 0.57] 0.053
PASI100 Response Week 52						
Interaction Test	**p=0.473**					
Baseline PASI ≤ Median, N / N'	**20 / 20**	**20 / 19**	**22 / 19**			
n (%)	7.00 (35.00)	10.55 (52.75)	3.45 (15.68)			
SEC low vs. ETA				2.86 [0.63; 12.89] 0.172	2.26 [0.69; 7.45] 0.180	0.19 [-0.07; 0.46] 0.150
SEC high vs. ETA				5.80 [1.31; 25.73] 0.021	3.40 [1.12; 10.38] 0.031	0.37 [0.10; 0.65] 0.008
Baseline PASI > Median, N / N'	**20 / 19**	**20 / 19**	**19 / 15**			

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
n (%)	9.29 (46.45)	9.21 (46.05)	6.07 (31.95)			
SEC low vs. ETA				1.82 [0.49; 6.70] 0.368	1.45 [0.64; 3.29] 0.370	0.15 [-0.16; 0.45] 0.354
SEC high vs. ETA				1.79 [0.49; 6.58] 0.380	1.44 [0.64; 3.27] 0.381	0.14 [-0.16; 0.45] 0.366

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.5 PASI Response by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI50 Response Week 52						
Interaction Test	**N.E.**					
Europe, N / N'	**28 / 28**	**32 / 31**	**24 / 21**			
n (%)	28.00 (100.00)	31.94 (99.81)	21.63 (90.13)			
SEC low vs. ETA				3.29 [N.E.; N.E.] N.E.	1.11 [0.95; 1.29] 0.179	0.10 [-0.04; 0.23] 0.155
SEC high vs. ETA				3.71 [N.E.; N.E.] N.E.	1.11 [0.95; 1.29] 0.188	0.10 [-0.04; 0.23] 0.165
Others, N / N'	**12 / 11**	**8 / 7**	**17 / 13**			
n (%)	12.00 (100.00)	6.92 (86.50)	14.33 (84.29)			
SEC low vs. ETA				2.48 [N.E.; N.E.] N.E.	1.19 [0.95; 1.49] 0.134	0.16 [-0.03; 0.34] 0.100
SEC high vs. ETA				1.18 [0.10; 14.55] 0.898	1.03 [0.71; 1.48] 0.890	0.02 [-0.29; 0.33] 0.889
PASI75 Response Week 52						
Interaction Test	**p=0.386**					
Europe, N / N'	**28 / 28**	**32 / 31**	**24 / 21**			
n (%)	25.00 (89.29)	30.69 (95.91)	19.89 (82.87)			
SEC low vs. ETA				1.67 [0.32; 8.85] 0.545	1.08 [0.85; 1.37] 0.532	0.06 [-0.14; 0.26] 0.529
SEC high vs. ETA				4.88 [0.50; 47.61] 0.173	1.16 [0.94; 1.43] 0.179	0.13 [-0.05; 0.31] 0.156
Others, N / N'	**12 / 11**	**8 / 7**	**17 / 13**			
n (%)	10.91 (90.92)	5.80 (72.50)	10.07 (59.24)			
SEC low vs. ETA				6.61 [0.68; 64.00] 0.103	1.54 [0.97; 2.45] 0.069	0.32 [0.02; 0.62] 0.039
SEC high vs. ETA				1.79 [0.27; 11.94] 0.549	1.22 [0.66; 2.28] 0.524	0.13 [-0.28; 0.54] 0.524

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI90 Response Week 52						
Interaction Test	**p=0.199**					
Europe, N / N'	**28 / 28**	**32 / 31**	**24 / 21**			
n (%)	20.00 (71.43)	27.39 (85.59)	15.47 (64.46)			
SEC low vs. ETA				1.37 [0.42; 4.46] 0.604	1.11 [0.75; 1.63] 0.600	0.07 [-0.19; 0.33] 0.598
SEC high vs. ETA				3.21 [0.85; 12.12] 0.084	1.33 [0.94; 1.87] 0.102	0.21 [-0.02; 0.45] 0.077
Others, N / N'	**12 / 11**	**8 / 7**	**17 / 13**			
n (%)	10.61 (88.42)	5.63 (70.38)	6.47 (38.06)			
SEC low vs. ETA				11.98 [1.32; 108.66] 0.027	2.33 [1.19; 4.57] 0.014	0.50 [0.19; 0.81] 0.001
SEC high vs. ETA				3.72 [0.57; 24.23] 0.170	1.85 [0.83; 4.10] 0.130	0.32 [-0.09; 0.73] 0.123
PASI100 Response Week 52						
Interaction Test	**N.E.**					
Europe, N / N'	**28 / 28**	**32 / 31**	**24 / 21**			
n (%)	14.00 (50.00)	19.21 (60.03)	7.28 (30.33)			
SEC low vs. ETA				2.26 [0.72; 7.12] 0.162	1.65 [0.80; 3.40] 0.173	0.20 [-0.07; 0.46] 0.144
SEC high vs. ETA				3.38 [1.09; 10.46] 0.035	1.98 [1.00; 3.93] 0.050	0.30 [0.04; 0.55] 0.022
Others, N / N'	**12 / 11**	**8 / 7**	**17 / 13**			
n (%)	2.29 (19.08)	0.55 (6.88)	2.24 (13.18)			
SEC low vs. ETA				1.53 [0.19; 12.26] 0.689	1.45 [0.24; 8.63] 0.685	0.06 [-0.23; 0.35] 0.686
SEC high vs. ETA				0.86 [N.E.; N.E.] N.E.	0.63 [0.04; 9.74] 0.738	-0.06 [-0.33; 0.21] 0.647

	Treatment Groups			Comparison		
	SEC low (N=40)	SEC high (N=40)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.6 PASI Response by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI50 Response Week 52						
Interaction Test	**N.E.**					
Weight < 50 kg, N / N'	**19 / 19**	**18 / 16**	**20 / 17**			
n (%)	19.00 (100.00)	16.86 (93.67)	17.37 (86.85)			
SEC low vs. ETA				3.26 [N.E.; N.E.] N.E.	1.15 [0.96; 1.39] 0.132	0.13 [-0.03; 0.29] 0.105
SEC high vs. ETA				2.22 [0.19; 25.61] 0.523	1.08 [0.86; 1.35] 0.510	0.07 [-0.13; 0.27] 0.502
Weight ≥ 50 kg, N / N'	**21 / 20**	**22 / 22**	**21 / 17**			
n (%)	21.00 (100.00)	22.00 (100.00)	18.59 (88.52)			
SEC low vs. ETA				2.87 [N.E.; N.E.] N.E.	1.13 [0.94; 1.36] 0.185	0.11 [-0.04; 0.27] 0.155
SEC high vs. ETA				3.01 [N.E.; N.E.] N.E.	1.13 [0.94; 1.36] 0.185	0.11 [-0.04; 0.27] 0.155
PASI75 Response Week 52						
Interaction Test	**N.E.**					
Weight < 50 kg, N / N'	**19 / 19**	**18 / 16**	**20 / 17**			
n (%)	17.00 (89.47)	14.49 (80.50)	13.76 (68.80)			
SEC low vs. ETA				3.71 [0.64; 21.36] 0.142	1.30 [0.92; 1.84] 0.136	0.21 [-0.05; 0.46] 0.110
SEC high vs. ETA				1.86 [0.38; 9.11] 0.443	1.17 [0.79; 1.74] 0.439	0.12 [-0.17; 0.41] 0.429
Weight ≥ 50 kg, N / N'	**21 / 20**	**22 / 22**	**21 / 17**			
n (%)	18.91 (90.05)	22.00 (100.00)	16.20 (77.14)			
SEC low vs. ETA				2.58 [0.40; 16.74] 0.319	1.17 [0.86; 1.58] 0.311	0.13 [-0.11; 0.37] 0.295
SEC high vs. ETA				7.83 [N.E.; N.E.] N.E.	1.30 [1.00; 1.69] 0.051	0.23 [0.03; 0.43] 0.026

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI90 Response Week 52						
Interaction Test	**p=0.117**					
Weight < 50 kg, N / N'	**19 / 19**	**18 / 16**	**20 / 17**			
n (%)	15.00 (78.95)	12.02 (66.78)	11.43 (57.15)			
SEC low vs. ETA				2.73 [0.67; 11.23] 0.163	1.38 [0.88; 2.18] 0.163	0.22 [-0.07; 0.51] 0.139
SEC high vs. ETA				1.50 [0.38; 5.84] 0.562	1.17 [0.69; 1.97] 0.559	0.10 [-0.22; 0.42] 0.554
Weight ≥ 50 kg, N / N'	**21 / 20**	**22 / 22**	**21 / 17**			
n (%)	15.61 (74.33)	21.00 (95.45)	10.51 (50.05)			
SEC low vs. ETA				2.82 [0.75; 10.70] 0.126	1.49 [0.89; 2.49] 0.132	0.24 [-0.05; 0.54] 0.106
SEC high vs. ETA				19.50 [2.22; 171.39] 0.007	1.91 [1.21; 3.01] 0.005	0.45 [0.22; 0.69] <.001
PASI100 Response Week 52						
Interaction Test	**p=0.014**					
Weight < 50 kg, N / N'	**19 / 19**	**18 / 16**	**20 / 17**			
n (%)	11.00 (57.89)	5.76 (32.00)	6.24 (31.20)			
SEC low vs. ETA				2.95 [0.80; 10.92] 0.106	1.86 [0.86; 4.01] 0.114	0.27 [-0.04; 0.57] 0.085
SEC high vs. ETA				1.03 [0.25; 4.21] 0.963	1.02 [0.39; 2.71] 0.965	0.01 [-0.30; 0.31] 0.959
Weight ≥ 50 kg, N / N'	**21 / 20**	**22 / 22**	**21 / 17**			
n (%)	5.29 (25.19)	14.00 (63.64)	3.28 (15.62)			
SEC low vs. ETA				1.80 [0.37; 8.78] 0.465	1.62 [0.44; 5.92] 0.464	0.10 [-0.16; 0.35] 0.455
SEC high vs. ETA				8.97 [2.05; 39.34] 0.004	4.11 [1.39; 12.18] 0.011	0.48 [0.22; 0.74] <.001

	Treatment Groups			Comparison		
	SEC low (N=40)	SEC high (N=40)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.7 PASI Response by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI50 Response Week 52						
Interaction Test	**N.E.**					
No previous systemic therapy, N / N'	**14 / 13**	**19 / 17**	**22 / 19**			
n (%)	14.00 (100.00)	18.86 (99.26)	20.05 (91.14)			
SEC low vs. ETA				1.42 [N.E.; N.E.] N.E.	1.10 [0.95; 1.27] 0.202	0.09 [-0.04; 0.22] 0.180
SEC high vs. ETA				1.88 [N.E.; N.E.] N.E.	1.09 [0.93; 1.27] 0.277	0.08 [-0.06; 0.22] 0.257
Previous systemic therapy, N / N'	**26 / 26**	**21 / 21**	**19 / 15**			
n (%)	26.00 (100.00)	20.00 (95.24)	15.91 (83.74)			
SEC low vs. ETA				5.69 [N.E.; N.E.] N.E.	1.20 [0.95; 1.51] 0.130	0.16 [-0.03; 0.35] 0.094
SEC high vs. ETA				3.61 [0.31; 41.66] 0.304	1.14 [0.89; 1.46] 0.308	0.12 [-0.10; 0.33] 0.285
PASI75 Response Week 52						
Interaction Test	**N.E.**					
No previous systemic therapy, N / N'	**14 / 13**	**19 / 17**	**22 / 19**			
n (%)	13.91 (99.36)	18.49 (97.32)	16.81 (76.41)			
SEC low vs. ETA				5.13 [N.E.; N.E.] N.E.	1.30 [1.01; 1.68] 0.043	0.23 [0.03; 0.43] 0.022
SEC high vs. ETA				5.90 [N.E.; N.E.] N.E.	1.27 [0.97; 1.66] 0.076	0.21 [-0.00; 0.42] 0.052
Previous systemic therapy, N / N'	**26 / 26**	**21 / 21**	**19 / 15**			
n (%)	22.00 (84.62)	18.00 (85.71)	13.15 (69.21)			

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
SEC low vs. ETA				2.37 [0.53; 10.62] 0.258	1.23 [0.85; 1.77] 0.280	0.15 [-0.11; 0.42] 0.256
SEC high vs. ETA				2.58 [0.52; 12.89] 0.249	1.24 [0.85; 1.80] 0.257	0.17 [-0.11; 0.44] 0.234
PASI90 Response Week 52						
Interaction Test	**p=0.946**					
No previous systemic therapy, N / N'	**14 / 13**	**19 / 17**	**22 / 19**			
n (%)	12.61 (90.07)	17.02 (89.58)	14.33 (65.14)			
SEC low vs. ETA				4.94 [0.57; 42.89] 0.148	1.38 [0.96; 2.00] 0.084	0.25 [-0.02; 0.52] 0.066
SEC high vs. ETA				4.73 [0.67; 33.38] 0.119	1.37 [0.96; 1.96] 0.079	0.24 [-0.01; 0.50] 0.058
Previous systemic therapy, N / N'	**26 / 26**	**21 / 21**	**19 / 15**			
n (%)	18.00 (69.23)	16.00 (76.19)	7.61 (40.05)			
SEC low vs. ETA				3.28 [0.93; 11.54] 0.064	1.74 [0.92; 3.27] 0.089	0.29 [0.00; 0.58] 0.050
SEC high vs. ETA				4.60 [1.17; 18.09] 0.029	1.91 [1.02; 3.58] 0.043	0.36 [0.07; 0.66] 0.016
PASI100 Response Week 52						
Interaction Test	**p=0.463**					
No previous systemic therapy, N / N'	**14 / 13**	**19 / 17**	**22 / 19**			
n (%)	8.29 (59.21)	10.76 (56.63)	8.17 (37.14)			
SEC low vs. ETA				2.40 [0.60; 9.58] 0.215	1.59 [0.78; 3.24] 0.198	0.22 [-0.11; 0.55] 0.195
SEC high vs. ETA				2.17 [0.61; 7.76] 0.233	1.52 [0.77; 3.03] 0.230	0.19 [-0.11; 0.50] 0.217
Previous systemic therapy, N / N'	**26 / 26**	**21 / 21**	**19 / 15**			

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
n (%)	8.00 (30.77)	9.00 (42.86)	1.35 (7.11)			
SEC low vs. ETA				5.98 [0.70; 50.70] 0.101	4.61 [0.66; 32.28] 0.123	0.24 [0.02; 0.45] 0.033
SEC high vs. ETA				9.88 [1.16; 84.34] 0.036	6.43 [0.94; 43.94] 0.058	0.36 [0.11; 0.60] 0.005

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.1 IGA mod 2011 Response (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
IGA mod 2011 Response Week 52						
N'	**39**	**38**	**34**			
n (%)	29.79 (74.48)	31.22 (78.05)	23.85 (58.17)			
SEC low vs. ETA				2.08 [0.80; 5.41] 0.134	1.28 [0.93; 1.77] 0.135	0.16 [-0.04; 0.37] 0.123
SEC high vs. ETA				2.53 [0.93; 6.90] 0.069	1.34 [0.98; 1.85] 0.070	0.20 [-0.01; 0.40] 0.058

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.2 IGA mod 2011 Response by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.569**					
Age < 12 years, N / N'	**8 / 8**	**9 / 8**	**10 / 9**			
n (%)	7.00 (87.50)	6.56 (72.89)	5.18 (51.80)			
SEC low vs. ETA				5.86 [0.54; 63.75] 0.146	1.69 [0.87; 3.31] 0.123	0.36 [-0.03; 0.75] 0.074
SEC high vs. ETA				2.42 [0.33; 17.72] 0.385	1.41 [0.66; 3.00] 0.377	0.21 [-0.24; 0.66] 0.354
Age ≥ 12 years, N / N'	**32 / 31**	**31 / 30**	**31 / 25**			
n (%)	22.79 (71.22)	24.66 (79.55)	18.67 (60.23)			
SEC low vs. ETA				1.62 [0.56; 4.69] 0.372	1.18 [0.82; 1.71] 0.372	0.11 [-0.13; 0.35] 0.364
SEC high vs. ETA				2.53 [0.80; 8.00] 0.113	1.32 [0.93; 1.87] 0.115	0.19 [-0.04; 0.42] 0.098

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.3 IGA mod 2011 Response by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.161**					
Male, N / N'	**13 / 13**	**17 / 17**	**16 / 12**			
n (%)	8.00 (61.54)	15.00 (88.24)	10.62 (66.38)			
SEC low vs. ETA				0.81 [0.17; 3.86] 0.791	0.93 [0.52; 1.65] 0.801	-0.05 [-0.41; 0.31] 0.794
SEC high vs. ETA				3.62 [0.58; 22.56] 0.169	1.33 [0.88; 2.02] 0.174	0.22 [-0.07; 0.51] 0.142
Female, N / N'	**27 / 26**	**23 / 21**	**25 / 22**			
n (%)	21.79 (80.70)	16.22 (70.52)	13.23 (52.92)			
SEC low vs. ETA				3.63 [1.05; 12.59] 0.042	1.53 [1.00; 2.32] 0.048	0.28 [0.03; 0.53] 0.029
SEC high vs. ETA				2.10 [0.62; 7.13] 0.233	1.33 [0.83; 2.13] 0.229	0.18 [-0.10; 0.45] 0.215

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.4 IGA mod 2011 Response by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.776**					
Baseline PASI ≤ Median, N / N'	**20 / 20**	**20 / 19**	**22 / 19**			
n (%)	14.00 (70.00)	15.66 (78.30)	13.35 (60.68)			
SEC low vs. ETA				1.50 [0.42; 5.39] 0.538	1.15 [0.74; 1.81] 0.530	0.09 [-0.20; 0.38] 0.528
SEC high vs. ETA				2.30 [0.58; 9.17] 0.238	1.29 [0.85; 1.96] 0.231	0.18 [-0.10; 0.45] 0.215
Baseline PASI > Median, N / N'	**20 / 19**	**20 / 19**	**19 / 15**			
n (%)	15.79 (78.95)	15.56 (77.80)	10.50 (55.26)			
SEC low vs. ETA				2.96 [0.71; 12.38] 0.138	1.43 [0.88; 2.32] 0.146	0.24 [-0.06; 0.53] 0.117
SEC high vs. ETA				2.77 [0.66; 11.58] 0.162	1.41 [0.86; 2.30] 0.169	0.23 [-0.07; 0.53] 0.141

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.5 IGA mod 2011 Response by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.083**					
Europe, N / N'	**28 / 28**	**32 / 31**	**24 / 21**			
n (%)	19.00 (67.86)	26.56 (83.00)	17.13 (71.37)			
SEC low vs. ETA				0.85 [0.26; 2.78] 0.786	0.95 [0.66; 1.37] 0.785	-0.04 [-0.29; 0.22] 0.784
SEC high vs. ETA				1.94 [0.53; 7.10] 0.317	1.16 [0.86; 1.58] 0.330	0.12 [-0.11; 0.34] 0.315
Others, N / N'	**12 / 11**	**8 / 7**	**17 / 13**			
n (%)	10.79 (89.92)	4.66 (58.25)	6.72 (39.53)			
SEC low vs. ETA				12.98 [1.37; 122.78] 0.025	2.29 [1.18; 4.44] 0.015	0.50 [0.20; 0.81] 0.001
SEC high vs. ETA				2.08 [0.35; 12.41] 0.420	1.47 [0.60; 3.61] 0.395	0.19 [-0.25; 0.62] 0.402

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.6 IGA mod 2011 Response by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.291**					
Weight < 50 kg, N / N'	**19 / 19**	**18 / 16**	**20 / 17**			
n (%)	15.00 (78.95)	12.22 (67.89)	9.44 (47.20)			
SEC low vs. ETA				4.04 [0.99; 16.52] 0.052	1.68 [0.98; 2.86] 0.059	0.32 [0.03; 0.61] 0.033
SEC high vs. ETA				2.32 [0.59; 9.17] 0.229	1.44 [0.80; 2.59] 0.226	0.21 [-0.11; 0.53] 0.208
Weight ≥ 50 kg, N / N'	**21 / 20**	**22 / 22**	**21 / 17**			
n (%)	14.79 (70.43)	19.00 (86.36)	14.41 (68.62)			
SEC low vs. ETA				1.09 [0.29; 4.11] 0.904	1.03 [0.68; 1.55] 0.900	0.02 [-0.27; 0.30] 0.901
SEC high vs. ETA				2.82 [0.61; 13.01] 0.185	1.26 [0.89; 1.77] 0.186	0.18 [-0.07; 0.43] 0.164

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.7 IGA mod 2011 Response by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.541**					
No previous systemic therapy, N / N'	**14 / 13**	**19 / 17**	**22 / 19**			
n (%)	12.79 (91.36)	15.22 (80.11)	14.50 (65.91)			
SEC low vs. ETA				5.47 [0.61; 49.14] 0.129	1.39 [0.97; 1.98] 0.071	0.25 [-0.00; 0.51] 0.052
SEC high vs. ETA				2.07 [0.46; 9.43] 0.346	1.22 [0.82; 1.81] 0.335	0.14 [-0.14; 0.42] 0.324
Previous systemic therapy, N / N'	**26 / 26**	**21 / 21**	**19 / 15**			
n (%)	17.00 (65.38)	16.00 (76.19)	9.35 (49.21)			
SEC low vs. ETA				1.92 [0.57; 6.49] 0.294	1.33 [0.77; 2.31] 0.308	0.16 [-0.13; 0.46] 0.283
SEC high vs. ETA				3.20 [0.83; 12.34] 0.091	1.55 [0.91; 2.63] 0.105	0.27 [-0.03; 0.56] 0.073

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

8.0 CDLQI, Return Rates (FAS)

	Treatment Groups			
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**Total (N=121)**
Number of patients with valid data n (%)				
Baseline Returns	40 (100.0)	40 (100.0)	41 (100.0)	121 (100.0)
Week 4 Returns	37 (92.5)	36 (90.0)	40 (97.6)	113 (93.4)
Week 8 Returns	37 (92.5)	37 (92.5)	40 (97.6)	114 (94.2)
Week 12 Returns	31 (77.5)	35 (87.5)	34 (82.9)	100 (82.6)
Week 24 Returns	38 (95.0)	37 (92.5)	39 (95.1)	114 (94.2)
Week 36 Returns	39 (97.5)	37 (92.5)	33 (80.5)	109 (90.1)
Week 52 Returns	37 (92.5)	37 (92.5)	35 (85.4)	109 (90.1)

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.1 CDLQI, Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
N'	39	38	41		
Baseline Mean (SD)	12.18 (7.25)	10.85 (7.62)	10.34 (7.67)		
Week 4 Adjusted Mean Change (SE)	-6.19 (0.74)	-5.88 (0.75)	-5.23 (0.71)		
Week 8 Adjusted Mean Change (SE)	-7.49 (0.74)	-8.03 (0.74)	-6.00 (0.71)		
Week 12 Adjusted Mean Change (SE)	-8.41 (0.77)	-7.75 (0.75)	-7.61 (0.75)		
Week 24 Adjusted Mean Change (SE)	-8.87 (0.73)	-8.18 (0.74)	-6.92 (0.72)		
Week 36 Adjusted Mean Change (SE)	-8.32 (0.73)	-8.10 (0.74)	-7.09 (0.75)		
Week 52 Adjusted Mean Change (SE)	-9.05 (0.74)	-8.56 (0.74)	-8.12 (0.74)	-0.93 [-2.99; 1.12] 0.372	-0.44 [-2.50; 1.61] 0.671

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.2 CDLQI, Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.179					
Age < 12 years, N	**8**	**9**	**10**		
N'	8	8	10		
Baseline Mean (SD)	10.25 (6.34)	12.56 (7.91)	13.80 (3.74)		
Week 4 Adjusted Mean Change (SE)	-5.45 (1.63)	-3.28 (1.64)	-2.52 (1.42)		
Week 8 Adjusted Mean Change (SE)	-6.60 (1.58)	-8.52 (1.63)	-0.72 (1.45)		
Week 12 Adjusted Mean Change (SE)	-7.10 (1.79)	-8.64 (1.70)	-3.45 (1.55)		
Week 24 Adjusted Mean Change (SE)	-9.10 (1.58)	-9.38 (1.64)	-5.42 (1.42)		
Week 36 Adjusted Mean Change (SE)	-9.48 (1.58)	-8.10 (1.58)	-5.33 (1.45)		
Week 52 Adjusted Mean Change (SE)	-9.98 (1.58)	-7.97 (1.58)	-8.33 (1.45)	-1.65 [-5.87; 2.58] 0.444	0.36 [-3.85; 4.57] 0.867
Age ≥ 12 years, N	**32**	**31**	**31**		
N'	31	30	31		
Baseline Mean (SD)	12.66 (7.47)	10.35 (7.59)	9.23 (8.30)		
Week 4 Adjusted Mean Change (SE)	-6.34 (0.81)	-6.51 (0.82)	-6.13 (0.81)		
Week 8 Adjusted Mean Change (SE)	-7.71 (0.82)	-7.92 (0.82)	-7.61 (0.81)		
Week 12 Adjusted Mean Change (SE)	-8.63 (0.84)	-7.58 (0.82)	-8.83 (0.84)		
Week 24 Adjusted Mean Change (SE)	-8.79 (0.81)	-7.92 (0.82)	-7.41 (0.82)		
Week 36 Adjusted Mean Change (SE)	-8.00 (0.81)	-8.10 (0.82)	-7.67 (0.86)		

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-8.77 (0.82)	-8.73 (0.82)	-8.01 (0.84)	-0.76 [-3.08; 1.56] 0.521	-0.72 [-3.03; 1.59] 0.543

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.3 CDLQI, Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.054					
Male, N	**13**	**17**	**16**		
N'	13	17	16		
Baseline Mean (SD)	11.54 (7.66)	10.59 (6.01)	8.81 (7.79)		
Week 4 Adjusted Mean Change (SE)	-5.29 (1.27)	-6.62 (1.13)	-5.85 (1.13)		
Week 8 Adjusted Mean Change (SE)	-5.44 (1.25)	-8.60 (1.11)	-7.32 (1.15)		
Week 12 Adjusted Mean Change (SE)	-6.83 (1.38)	-8.52 (1.13)	-9.09 (1.19)		
Week 24 Adjusted Mean Change (SE)	-7.29 (1.25)	-9.58 (1.09)	-6.58 (1.17)		
Week 36 Adjusted Mean Change (SE)	-7.14 (1.25)	-9.77 (1.11)	-7.37 (1.22)		
Week 52 Adjusted Mean Change (SE)	-7.32 (1.27)	-9.39 (1.11)	-7.93 (1.19)	0.61 [-2.82; 4.04] 0.728	-1.47 [-4.66; 1.73] 0.368
Female, N	**27**	**23**	**25**		
N'	26	21	25		
Baseline Mean (SD)	12.48 (7.18)	11.04 (8.75)	11.32 (7.58)		
Week 4 Adjusted Mean Change (SE)	-6.65 (0.89)	-5.26 (0.98)	-4.82 (0.91)		
Week 8 Adjusted Mean Change (SE)	-8.54 (0.90)	-7.55 (0.98)	-5.19 (0.90)		
Week 12 Adjusted Mean Change (SE)	-9.17 (0.92)	-7.12 (1.00)	-6.70 (0.94)		
Week 24 Adjusted Mean Change (SE)	-9.67 (0.89)	-7.02 (1.00)	-7.07 (0.90)		
Week 36 Adjusted Mean Change (SE)	-8.91 (0.89)	-6.79 (0.98)	-6.89 (0.94)		

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-9.90 (0.89)	-7.88 (0.98)	-8.19 (0.93)	-1.71 [-4.25; 0.82] 0.185	0.31 [-2.35; 2.97] 0.821

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.4 CDLQI, Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.873					
Baseline PASI ≤ Median, N	**20**	**20**	**22**		
N'	20	19	22		
Baseline Mean (SD)	10.80 (6.69)	10.05 (6.05)	9.59 (7.33)		
Week 4 Adjusted Mean Change (SE)	-5.87 (1.05)	-6.68 (1.05)	-6.07 (0.98)		
Week 8 Adjusted Mean Change (SE)	-7.28 (1.03)	-7.32 (1.06)	-6.00 (0.99)		
Week 12 Adjusted Mean Change (SE)	-8.73 (1.05)	-6.80 (1.06)	-7.51 (0.99)		
Week 24 Adjusted Mean Change (SE)	-8.65 (1.02)	-8.14 (1.06)	-7.11 (0.99)		
Week 36 Adjusted Mean Change (SE)	-8.60 (1.02)	-7.41 (1.05)	-6.94 (1.00)		
Week 52 Adjusted Mean Change (SE)	-8.99 (1.03)	-7.92 (1.06)	-7.73 (1.01)	-1.26 [-4.11; 1.58] 0.383	-0.19 [-3.07; 2.69] 0.899
Baseline PASI > Median, N	**20**	**20**	**19**		
N'	19	19	19		
Baseline Mean (SD)	13.55 (7.69)	11.65 (9.01)	11.21 (8.16)		
Week 4 Adjusted Mean Change (SE)	-6.50 (1.06)	-4.93 (1.08)	-4.20 (1.06)		
Week 8 Adjusted Mean Change (SE)	-7.71 (1.07)	-8.71 (1.05)	-6.00 (1.05)		
Week 12 Adjusted Mean Change (SE)	-7.93 (1.16)	-8.74 (1.08)	-7.81 (1.16)		
Week 24 Adjusted Mean Change (SE)	-9.12 (1.07)	-8.24 (1.05)	-6.71 (1.06)		
Week 36 Adjusted Mean Change (SE)	-8.02 (1.06)	-8.81 (1.06)	-7.38 (1.16)		

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-9.11 (1.07)	-9.18 (1.05)	-8.58 (1.10)	-0.53 [-3.54; 2.48] 0.729	-0.60 [-3.58; 2.38] 0.690

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.5 CDLQI, Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.670					
Europe, N	**28**	**32**	**24**		
N'	28	31	24		
Baseline Mean (SD)	12.39 (7.22)	10.38 (7.51)	9.38 (8.00)		
Week 4 Adjusted Mean Change (SE)	-6.17 (0.88)	-5.90 (0.82)	-5.26 (0.93)		
Week 8 Adjusted Mean Change (SE)	-7.40 (0.88)	-8.12 (0.82)	-7.09 (0.94)		
Week 12 Adjusted Mean Change (SE)	-8.60 (0.89)	-7.70 (0.83)	-8.03 (0.96)		
Week 24 Adjusted Mean Change (SE)	-8.86 (0.86)	-8.24 (0.82)	-8.02 (0.94)		
Week 36 Adjusted Mean Change (SE)	-8.75 (0.86)	-8.58 (0.82)	-8.31 (0.96)		
Week 52 Adjusted Mean Change (SE)	-9.00 (0.86)	-8.75 (0.82)	-8.83 (0.96)	-0.17 [-2.71; 2.38] 0.897	0.08 [-2.40; 2.57] 0.948
Others, N	**12**	**8**	**17**		
N'	11	7	17		
Baseline Mean (SD)	11.67 (7.62)	12.75 (8.28)	11.71 (7.17)		
Week 4 Adjusted Mean Change (SE)	-6.20 (1.37)	-5.91 (1.79)	-5.29 (1.12)		
Week 8 Adjusted Mean Change (SE)	-7.65 (1.37)	-7.61 (1.72)	-4.51 (1.10)		
Week 12 Adjusted Mean Change (SE)	-7.74 (1.55)	-8.07 (1.79)	-7.10 (1.18)		
Week 24 Adjusted Mean Change (SE)	-8.91 (1.40)	-7.90 (1.72)	-5.37 (1.12)		
Week 36 Adjusted Mean Change (SE)	-7.20 (1.37)	-6.04 (1.72)	-5.16 (1.21)		

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-9.24 (1.44)	-7.75 (1.72)	-7.10 (1.16)	-2.14 [-5.78; 1.49] 0.247	-0.66 [-4.73; 3.42] 0.752

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.6 CDLQI, Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.187					
Weight < 50 kg, N	**19**	**18**	**20**		
N'	19	16	20		
Baseline Mean (SD)	12.32 (6.92)	12.11 (7.82)	11.15 (5.30)		
Week 4 Adjusted Mean Change (SE)	-6.19 (1.05)	-5.11 (1.15)	-3.69 (1.01)		
Week 8 Adjusted Mean Change (SE)	-6.90 (1.05)	-8.28 (1.15)	-3.92 (1.02)		
Week 12 Adjusted Mean Change (SE)	-7.99 (1.14)	-7.58 (1.17)	-6.21 (1.09)		
Week 24 Adjusted Mean Change (SE)	-9.05 (1.05)	-8.46 (1.15)	-5.50 (1.02)		
Week 36 Adjusted Mean Change (SE)	-8.27 (1.03)	-7.84 (1.13)	-5.19 (1.07)		
Week 52 Adjusted Mean Change (SE)	-9.49 (1.05)	-8.59 (1.13)	-7.91 (1.05)	-1.59 [-4.50; 1.33] 0.285	-0.68 [-3.71; 2.35] 0.660
Weight ≥ 50 kg, N	**21**	**22**	**21**		
N'	20	22	21		
Baseline Mean (SD)	12.05 (7.70)	9.82 (7.47)	9.57 (9.46)		
Week 4 Adjusted Mean Change (SE)	-6.17 (1.02)	-6.43 (0.97)	-6.72 (1.00)		
Week 8 Adjusted Mean Change (SE)	-8.02 (1.02)	-7.86 (0.96)	-7.95 (0.99)		
Week 12 Adjusted Mean Change (SE)	-8.70 (1.03)	-7.87 (0.97)	-8.93 (1.01)		
Week 24 Adjusted Mean Change (SE)	-8.70 (1.01)	-8.00 (0.96)	-8.28 (1.00)		
Week 36 Adjusted Mean Change (SE)	-8.35 (1.01)	-8.30 (0.97)	-8.91 (1.04)		

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-8.62 (1.02)	-8.54 (0.97)	-8.34 (1.03)	-0.28 [-3.13; 2.57] 0.846	-0.20 [-2.97; 2.57] 0.886

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.7 CDLQI, Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.995					
No previous systemic therapy, N	**14**	**19**	**22**		
N'	13	17	22		
Baseline Mean (SD)	9.93 (7.88)	9.11 (7.23)	9.68 (7.14)		
Week 4 Adjusted Mean Change (SE)	-7.46 (1.29)	-6.64 (1.10)	-5.83 (0.98)		
Week 8 Adjusted Mean Change (SE)	-8.80 (1.28)	-8.47 (1.10)	-6.30 (0.98)		
Week 12 Adjusted Mean Change (SE)	-8.85 (1.31)	-8.23 (1.10)	-7.54 (1.06)		
Week 24 Adjusted Mean Change (SE)	-9.15 (1.26)	-8.82 (1.10)	-7.40 (0.99)		
Week 36 Adjusted Mean Change (SE)	-9.53 (1.26)	-9.53 (1.10)	-8.78 (1.02)		
Week 52 Adjusted Mean Change (SE)	-9.69 (1.26)	-8.82 (1.10)	-8.89 (1.00)	-0.80 [-3.95; 2.35] 0.619	0.07 [-2.85; 2.98] 0.964
Previous systemic therapy, N	**26**	**21**	**19**		
N'	26	21	19		
Baseline Mean (SD)	13.38 (6.74)	12.43 (7.78)	11.11 (8.37)		
Week 4 Adjusted Mean Change (SE)	-5.54 (0.90)	-5.25 (1.02)	-4.55 (1.04)		
Week 8 Adjusted Mean Change (SE)	-6.82 (0.90)	-7.68 (1.00)	-5.66 (1.04)		
Week 12 Adjusted Mean Change (SE)	-8.19 (0.96)	-7.38 (1.03)	-7.58 (1.06)		
Week 24 Adjusted Mean Change (SE)	-8.73 (0.90)	-7.67 (1.00)	-6.39 (1.04)		
Week 36 Adjusted Mean Change (SE)	-7.69 (0.90)	-6.90 (1.00)	-5.09 (1.11)		

	Treatment Groups			Comparisons	
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-8.72 (0.91)	-8.37 (1.00)	-7.18 (1.11)	-1.54 [-4.36; 1.28] 0.284	-1.19 [-4.13; 1.75] 0.426

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

9.0 CDLQI (Age ≤ 16), Return Rates (FAS)

	Treatment Groups			
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**Total (N=103)**
Number of patients with valid data n (%)				
Baseline Returns	34 (100.0)	35 (100.0)	34 (100.0)	103 (100.0)
Week 4 Returns	32 (94.1)	31 (88.6)	33 (97.1)	96 (93.2)
Week 8 Returns	31 (91.2)	32 (91.4)	33 (97.1)	96 (93.2)
Week 12 Returns	25 (73.5)	30 (85.7)	28 (82.4)	83 (80.6)
Week 24 Returns	28 (82.4)	29 (82.9)	28 (82.4)	85 (82.5)
Week 36 Returns	25 (73.5)	26 (74.3)	23 (67.6)	74 (71.8)
Week 52 Returns	24 (70.6)	26 (74.3)	24 (70.6)	74 (71.8)

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.1 CDLQI (Age ≤ 16), Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
N'	33	33	34		
Baseline Mean (SD)	11.35 (7.37)	10.77 (8.00)	9.76 (6.49)		
Week 4 Adjusted Mean Change (SE)	-6.18 (0.76)	-5.17 (0.76)	-4.41 (0.74)		
Week 8 Adjusted Mean Change (SE)	-7.30 (0.76)	-7.58 (0.75)	-4.89 (0.74)		
Week 12 Adjusted Mean Change (SE)	-8.38 (0.81)	-7.13 (0.77)	-6.69 (0.78)		
Week 24 Adjusted Mean Change (SE)	-8.82 (0.79)	-7.79 (0.78)	-6.10 (0.78)		
Week 36 Adjusted Mean Change (SE)	-8.19 (0.82)	-7.63 (0.81)	-6.29 (0.83)		
Week 52 Adjusted Mean Change (SE)	-9.24 (0.83)	-7.78 (0.81)	-8.02 (0.82)	-1.22 [-3.52; 1.07] 0.295	0.23 [-2.03; 2.50] 0.839

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.2 CDLQI (Age ≤ 16), Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.227					
Age < 12 years, N	**8**	**9**	**10**		
N'	8	8	10		
Baseline Mean (SD)	10.25 (6.34)	12.56 (7.91)	13.80 (3.74)		
Week 4 Adjusted Mean Change (SE)	-5.01 (1.55)	-2.86 (1.55)	-2.12 (1.34)		
Week 8 Adjusted Mean Change (SE)	-6.18 (1.49)	-8.09 (1.55)	-0.31 (1.38)		
Week 12 Adjusted Mean Change (SE)	-6.64 (1.72)	-8.22 (1.63)	-3.06 (1.49)		
Week 24 Adjusted Mean Change (SE)	-8.68 (1.49)	-8.98 (1.55)	-5.02 (1.34)		
Week 36 Adjusted Mean Change (SE)	-9.05 (1.49)	-7.70 (1.49)	-4.92 (1.38)		
Week 52 Adjusted Mean Change (SE)	-9.55 (1.49)	-7.57 (1.49)	-7.92 (1.38)	-1.64 [-5.63; 2.35] 0.420	0.35 [-3.63; 4.33] 0.864
Age ≥ 12 years, N	**26**	**26**	**24**		
N'	25	25	24		
Baseline Mean (SD)	11.69 (7.74)	10.15 (8.09)	8.08 (6.70)		
Week 4 Adjusted Mean Change (SE)	-6.49 (0.84)	-5.84 (0.85)	-5.41 (0.88)		
Week 8 Adjusted Mean Change (SE)	-7.66 (0.86)	-7.43 (0.84)	-6.69 (0.87)		
Week 12 Adjusted Mean Change (SE)	-8.81 (0.90)	-6.85 (0.85)	-8.07 (0.90)		
Week 24 Adjusted Mean Change (SE)	-8.81 (0.90)	-7.41 (0.88)	-6.40 (0.95)		
Week 36 Adjusted Mean Change (SE)	-7.65 (0.95)	-7.59 (0.93)	-6.71 (1.03)		

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-8.94 (0.97)	-7.87 (0.93)	-7.69 (1.01)	-1.25 [-4.01; 1.50] 0.372	-0.18 [-2.88; 2.51] 0.893

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.3 CDLQI (Age ≤ 16), Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.469					
Male, N	**9**	**14**	**13**		
N'	9	14	13		
Baseline Mean (SD)	8.78 (7.24)	10.29 (6.49)	7.38 (5.99)		
Week 4 Adjusted Mean Change (SE)	-6.05 (1.45)	-5.70 (1.21)	-4.26 (1.21)		
Week 8 Adjusted Mean Change (SE)	-5.72 (1.45)	-7.93 (1.18)	-6.05 (1.24)		
Week 12 Adjusted Mean Change (SE)	-8.01 (1.75)	-7.85 (1.21)	-7.89 (1.31)		
Week 24 Adjusted Mean Change (SE)	-8.28 (1.57)	-8.97 (1.18)	-4.65 (1.36)		
Week 36 Adjusted Mean Change (SE)	-7.54 (1.65)	-9.19 (1.33)	-6.07 (1.56)		
Week 52 Adjusted Mean Change (SE)	-8.71 (1.65)	-8.16 (1.33)	-7.92 (1.48)	-0.78 [-5.12; 3.56] 0.724	-0.24 [-4.15; 3.67] 0.904
Female, N	**25**	**21**	**21**		
N'	24	19	21		
Baseline Mean (SD)	12.28 (7.34)	11.10 (9.01)	11.24 (6.48)		
Week 4 Adjusted Mean Change (SE)	-6.21 (0.90)	-4.78 (0.99)	-4.52 (0.96)		
Week 8 Adjusted Mean Change (SE)	-7.93 (0.91)	-7.30 (0.99)	-4.24 (0.94)		
Week 12 Adjusted Mean Change (SE)	-8.54 (0.93)	-6.62 (1.01)	-6.02 (0.99)		
Week 24 Adjusted Mean Change (SE)	-9.03 (0.92)	-6.87 (1.05)	-6.73 (0.97)		
Week 36 Adjusted Mean Change (SE)	-8.44 (0.95)	-6.69 (1.03)	-6.27 (1.01)		

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-9.45 (0.97)	-7.45 (1.03)	-7.98 (1.01)	-1.47 [-4.21; 1.28] 0.294	0.53 [-2.30; 3.36] 0.714

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.4 CDLQI (Age ≤ 16), Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.865					
Baseline PASI ≤ Median, N	**16**	**17**	**17**		
N'	16	16	17		
Baseline Mean (SD)	9.38 (6.68)	9.71 (6.41)	9.71 (5.79)		
Week 4 Adjusted Mean Change (SE)	-5.24 (1.10)	-6.30 (1.08)	-4.81 (1.05)		
Week 8 Adjusted Mean Change (SE)	-6.32 (1.10)	-6.93 (1.10)	-4.62 (1.07)		
Week 12 Adjusted Mean Change (SE)	-8.16 (1.12)	-6.18 (1.10)	-6.43 (1.07)		
Week 24 Adjusted Mean Change (SE)	-7.85 (1.15)	-7.61 (1.12)	-5.73 (1.14)		
Week 36 Adjusted Mean Change (SE)	-8.34 (1.18)	-7.30 (1.10)	-5.81 (1.17)		
Week 52 Adjusted Mean Change (SE)	-8.42 (1.18)	-7.24 (1.12)	-7.91 (1.20)	-0.51 [-3.83; 2.80] 0.760	0.67 [-2.57; 3.90] 0.686
Baseline PASI > Median, N	**18**	**18**	**17**		
N'	17	17	17		
Baseline Mean (SD)	13.11 (7.69)	11.78 (9.33)	9.82 (7.31)		
Week 4 Adjusted Mean Change (SE)	-7.04 (1.05)	-3.93 (1.09)	-3.96 (1.07)		
Week 8 Adjusted Mean Change (SE)	-8.23 (1.07)	-8.17 (1.05)	-5.13 (1.05)		
Week 12 Adjusted Mean Change (SE)	-8.47 (1.21)	-8.07 (1.09)	-6.97 (1.17)		
Week 24 Adjusted Mean Change (SE)	-9.71 (1.10)	-7.98 (1.09)	-6.42 (1.09)		
Week 36 Adjusted Mean Change (SE)	-8.06 (1.14)	-8.03 (1.20)	-6.78 (1.20)		

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-10.02 (1.17)	-8.38 (1.17)	-8.10 (1.14)	-1.92 [-5.14; 1.29] 0.240	-0.29 [-3.50; 2.93] 0.860

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.5 CDLQI (Age ≤ 16), Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.439					
Europe, N	**23**	**27**	**18**		
N'	23	26	18		
Baseline Mean (SD)	11.35 (7.28)	10.19 (7.98)	8.94 (6.96)		
Week 4 Adjusted Mean Change (SE)	-6.55 (0.90)	-5.12 (0.85)	-4.66 (1.01)		
Week 8 Adjusted Mean Change (SE)	-7.36 (0.92)	-7.68 (0.85)	-6.23 (1.03)		
Week 12 Adjusted Mean Change (SE)	-8.76 (0.95)	-7.02 (0.86)	-7.25 (1.05)		
Week 24 Adjusted Mean Change (SE)	-8.91 (0.95)	-7.72 (0.87)	-7.98 (1.09)		
Week 36 Adjusted Mean Change (SE)	-9.09 (1.00)	-7.91 (0.91)	-8.27 (1.12)		
Week 52 Adjusted Mean Change (SE)	-9.46 (1.00)	-8.06 (0.91)	-9.39 (1.15)	-0.08 [-3.08; 2.92] 0.960	1.33 [-1.56; 4.21] 0.366
Others, N	**11**	**8**	**16**		
N'	10	7	16		
Baseline Mean (SD)	11.36 (7.92)	12.75 (8.28)	10.69 (6.01)		
Week 4 Adjusted Mean Change (SE)	-5.30 (1.35)	-5.46 (1.70)	-4.23 (1.09)		
Week 8 Adjusted Mean Change (SE)	-7.10 (1.35)	-7.22 (1.62)	-3.41 (1.07)		
Week 12 Adjusted Mean Change (SE)	-7.36 (1.59)	-7.63 (1.70)	-6.14 (1.17)		
Week 24 Adjusted Mean Change (SE)	-8.60 (1.40)	-8.01 (1.70)	-4.18 (1.11)		
Week 36 Adjusted Mean Change (SE)	-6.48 (1.40)	-6.68 (1.70)	-3.91 (1.24)		

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-8.75 (1.45)	-6.84 (1.70)	-6.59 (1.17)	-2.16 [-5.82; 1.50] 0.246	-0.26 [-4.32; 3.80] 0.900

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.6 CDLQI (Age ≤ 16), Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.187					
Weight < 50 kg, N	**19**	**18**	**20**		
N'	19	16	20		
Baseline Mean (SD)	12.32 (6.92)	12.11 (7.82)	11.15 (5.30)		
Week 4 Adjusted Mean Change (SE)	-5.78 (1.00)	-4.69 (1.09)	-3.28 (0.96)		
Week 8 Adjusted Mean Change (SE)	-6.50 (1.00)	-7.85 (1.09)	-3.50 (0.97)		
Week 12 Adjusted Mean Change (SE)	-7.56 (1.11)	-7.15 (1.12)	-5.78 (1.04)		
Week 24 Adjusted Mean Change (SE)	-8.64 (1.00)	-8.30 (1.12)	-5.08 (0.97)		
Week 36 Adjusted Mean Change (SE)	-7.76 (1.02)	-7.96 (1.09)	-4.76 (1.02)		
Week 52 Adjusted Mean Change (SE)	-9.22 (1.04)	-8.03 (1.09)	-7.48 (1.00)	-1.74 [-4.57; 1.10] 0.229	-0.55 [-3.47; 2.37] 0.711
Weight ≥ 50 kg, N	**15**	**17**	**14**		
N'	14	17	14		
Baseline Mean (SD)	10.13 (7.98)	9.35 (8.17)	7.79 (7.66)		
Week 4 Adjusted Mean Change (SE)	-6.69 (1.14)	-5.62 (1.06)	-6.09 (1.17)		
Week 8 Adjusted Mean Change (SE)	-8.37 (1.17)	-7.33 (1.04)	-6.87 (1.15)		
Week 12 Adjusted Mean Change (SE)	-9.31 (1.20)	-7.09 (1.06)	-8.01 (1.17)		
Week 24 Adjusted Mean Change (SE)	-8.92 (1.28)	-7.29 (1.08)	-7.68 (1.33)		
Week 36 Adjusted Mean Change (SE)	-8.72 (1.38)	-7.19 (1.19)	-9.05 (1.45)		

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-8.97 (1.38)	-7.46 (1.19)	-8.43 (1.45)	-0.54 [-4.47; 3.40] 0.789	0.97 [-2.72; 4.66] 0.606

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.7 CDLQI (Age ≤ 16), Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Interaction test: p=0.896					
No previous systemic therapy, N	**12**	**15**	**19**		
N'	11	13	19		
Baseline Mean (SD)	8.92 (8.05)	8.40 (7.66)	8.63 (5.62)		
Week 4 Adjusted Mean Change (SE)	-7.40 (1.29)	-5.92 (1.19)	-4.58 (1.00)		
Week 8 Adjusted Mean Change (SE)	-8.45 (1.33)	-8.07 (1.19)	-5.13 (1.00)		
Week 12 Adjusted Mean Change (SE)	-8.50 (1.37)	-7.38 (1.19)	-6.65 (1.08)		
Week 24 Adjusted Mean Change (SE)	-8.92 (1.33)	-8.52 (1.22)	-7.16 (1.04)		
Week 36 Adjusted Mean Change (SE)	-8.94 (1.38)	-9.37 (1.25)	-8.36 (1.08)		
Week 52 Adjusted Mean Change (SE)	-9.61 (1.38)	-8.46 (1.25)	-8.71 (1.04)	-0.89 [-4.28; 2.49] 0.603	0.25 [-2.94; 3.44] 0.877
Previous systemic therapy, N	**22**	**20**	**15**		
N'	22	20	15		
Baseline Mean (SD)	12.68 (6.80)	12.55 (7.96)	11.20 (7.40)		
Week 4 Adjusted Mean Change (SE)	-5.52 (0.93)	-4.67 (0.99)	-4.19 (1.11)		
Week 8 Adjusted Mean Change (SE)	-6.72 (0.93)	-7.26 (0.98)	-4.59 (1.11)		
Week 12 Adjusted Mean Change (SE)	-8.34 (1.01)	-7.01 (1.01)	-6.64 (1.13)		
Week 24 Adjusted Mean Change (SE)	-8.80 (0.98)	-7.31 (1.01)	-4.72 (1.19)		
Week 36 Adjusted Mean Change (SE)	-7.79 (1.01)	-6.37 (1.05)	-3.16 (1.30)		

	Treatment Groups			Comparisons	
	SEC low (N=34)	**SEC high (N=35)**	**ETA (N=34)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
Week 52 Adjusted Mean Change (SE)	-9.06 (1.04)	-7.31 (1.05)	-6.93 (1.36)	-2.14 [-5.49; 1.22] 0.211	-0.39 [-3.76; 2.98] 0.821

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 1 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

10.1 CDLQI Response (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response Week 52						
N'	**37**	**37**	**35**			
n (%)	21.83 (54.58)	26.82 (67.05)	21.84 (53.27)			
SEC low vs. ETA				1.05 [0.43; 2.56] 0.909	1.02 [0.68; 1.55] 0.908	0.01 [-0.21; 0.24] 0.908
SEC high vs. ETA				1.77 [0.70; 4.51] 0.228	1.26 [0.87; 1.83] 0.228	0.14 [-0.08; 0.36] 0.218

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.2 CDLQI Response by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response Week 52						
Interaction Test	**p=0.477**					
Age < 12 years, N / N'	**8 / 8**	**9 / 8**	**10 / 9**			
n (%)	5.00 (62.50)	4.48 (49.78)	4.21 (42.10)			
SEC low vs. ETA				2.19 [0.34; 14.26] 0.412	1.49 [0.59; 3.76] 0.398	0.20 [-0.26; 0.66] 0.385
SEC high vs. ETA				1.34 [0.21; 8.57] 0.755	1.18 [0.42; 3.31] 0.753	0.08 [-0.39; 0.54] 0.748
Age ≥ 12 years, N / N'	**32 / 29**	**31 / 29**	**31 / 26**			
n (%)	16.83 (52.59)	22.34 (72.06)	17.63 (56.87)			
SEC low vs. ETA				0.84 [0.31; 2.32] 0.741	0.92 [0.58; 1.47] 0.740	-0.04 [-0.29; 0.21] 0.739
SEC high vs. ETA				1.94 [0.65; 5.76] 0.234	1.27 [0.86; 1.87] 0.235	0.15 [-0.09; 0.40] 0.222

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.3 CDLQI Response by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response Week 52						
Interaction Test	**p=0.124**					
Male, N / N'	**13 / 12**	**17 / 16**	**16 / 13**			
n (%)	5.20 (40.00)	13.88 (81.65)	9.36 (58.50)			
SEC low vs. ETA				0.48 [0.11; 2.18] 0.344	0.68 [0.31; 1.53] 0.353	-0.19 [-0.55; 0.18] 0.325
SEC high vs. ETA				3.05 [0.61; 15.18] 0.173	1.40 [0.86; 2.28] 0.179	0.23 [-0.08; 0.55] 0.148
Female, N / N'	**27 / 25**	**23 / 21**	**25 / 22**			
n (%)	16.63 (61.59)	12.94 (56.26)	12.48 (49.92)			
SEC low vs. ETA				1.60 [0.52; 4.87] 0.412	1.23 [0.75; 2.05] 0.413	0.12 [-0.16; 0.39] 0.404
SEC high vs. ETA				1.28 [0.40; 4.15] 0.675	1.13 [0.65; 1.96] 0.675	0.06 [-0.23; 0.36] 0.672

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.4 CDLQI Response by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response Week 52						
Interaction Test	**p=0.522**					
Baseline PASI ≤ Median, N / N'	**20 / 19**	**20 / 18**	**22 / 19**			
n (%)	8.20 (41.00)	12.34 (61.70)	11.58 (52.64)			
SEC low vs. ETA				0.63 [0.18; 2.18] 0.468	0.78 [0.40; 1.53] 0.469	-0.12 [-0.42; 0.19] 0.458
SEC high vs. ETA				1.44 [0.40; 5.16] 0.576	1.17 [0.67; 2.04] 0.573	0.09 [-0.22; 0.40] 0.569
Baseline PASI > Median, N / N'	**20 / 18**	**20 / 19**	**19 / 16**			
n (%)	13.63 (68.15)	14.48 (72.40)	10.26 (54.00)			
SEC low vs. ETA				1.80 [0.48; 6.80] 0.387	1.26 [0.74; 2.14] 0.388	0.14 [-0.17; 0.45] 0.375
SEC high vs. ETA				2.19 [0.56; 8.54] 0.257	1.34 [0.80; 2.24] 0.260	0.18 [-0.12; 0.49] 0.240

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.5 CDLQI Response by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response Week 52						
Interaction Test	**p=0.141**					
Europe, N / N'	**28 / 28**	**32 / 30**	**24 / 21**			
n (%)	14.00 (50.00)	22.36 (69.88)	16.12 (67.17)			
SEC low vs. ETA				0.49 [0.16; 1.54] 0.224	0.74 [0.47; 1.19] 0.218	-0.17 [-0.44; 0.10] 0.208
SEC high vs. ETA				1.13 [0.35; 3.61] 0.835	1.04 [0.72; 1.51] 0.834	0.03 [-0.23; 0.28] 0.833
Others, N / N'	**12 / 9**	**8 / 7**	**17 / 14**			
n (%)	7.83 (65.25)	4.46 (55.75)	5.72 (33.65)			
SEC low vs. ETA				3.57 [0.70; 18.19] 0.125	1.94 [0.84; 4.47] 0.118	0.32 [-0.06; 0.69] 0.095
SEC high vs. ETA				2.41 [0.40; 14.37] 0.335	1.66 [0.63; 4.36] 0.308	0.22 [-0.21; 0.65] 0.317

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.6 CDLQI Response by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response Week 52						
Interaction Test	**p=0.684**					
Weight < 50 kg, N / N'	**19 / 18**	**18 / 16**	**20 / 17**			
n (%)	11.01 (57.95)	10.94 (60.78)	9.72 (48.60)			
SEC low vs. ETA				1.44 [0.41; 5.14] 0.571	1.19 [0.65; 2.19] 0.565	0.09 [-0.22; 0.41] 0.564
SEC high vs. ETA				1.62 [0.42; 6.21] 0.479	1.25 [0.68; 2.31] 0.477	0.12 [-0.21; 0.45] 0.469
Weight ≥ 50 kg, N / N'	**21 / 19**	**22 / 21**	**21 / 18**			
n (%)	10.82 (51.52)	15.88 (72.18)	12.12 (57.71)			
SEC low vs. ETA				0.78 [0.23; 2.70] 0.699	0.89 [0.50; 1.58] 0.695	-0.06 [-0.37; 0.25] 0.695
SEC high vs. ETA				1.87 [0.52; 6.73] 0.336	1.25 [0.79; 1.98] 0.337	0.14 [-0.14; 0.43] 0.324

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.7 CDLQI Response by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response Week 52						
Interaction Test	**p=0.697**					
No previous systemic therapy, N / N'	**14 / 13**	**19 / 17**	**22 / 20**			
n (%)	7.62 (54.43)	12.94 (68.11)	13.56 (61.64)			
SEC low vs. ETA				0.75 [0.19; 2.98] 0.682	0.88 [0.48; 1.61] 0.682	-0.07 [-0.41; 0.27] 0.678
SEC high vs. ETA				1.33 [0.35; 5.09] 0.681	1.10 [0.69; 1.77] 0.682	0.06 [-0.24; 0.37] 0.678
Previous systemic therapy, N / N'	**26 / 24**	**21 / 20**	**19 / 15**			
n (%)	14.21 (54.65)	13.88 (66.10)	8.28 (43.58)			
SEC low vs. ETA				1.55 [0.46; 5.18] 0.480	1.26 [0.66; 2.38] 0.483	0.11 [-0.19; 0.41] 0.471
SEC high vs. ETA				2.47 [0.68; 9.01] 0.172	1.52 [0.82; 2.82] 0.183	0.23 [-0.08; 0.53] 0.153

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

11.1 CDLQI Response (Age ≤ 16) (FAS)

	Treatment Groups			Comparison		
	SEC low (N=25)	**SEC high (N=29)**	**ETA (N=28)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response (Age ≤ 16) Week 52						
N'	**24**	**26**	**24**			
n (%)	17.14 (68.56)	17.78 (61.31)	14.29 (51.04)			
SEC low vs. ETA				2.06 [0.65; 6.52] 0.217	1.35 [0.84; 2.15] 0.215	0.18 [-0.09; 0.44] 0.201
SEC high vs. ETA				1.51 [0.50; 4.53] 0.461	1.20 [0.74; 1.96] 0.461	0.10 [-0.17; 0.37] 0.454

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.2 CDLQI Response (Age ≤ 16) by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=25)	**SEC high (N=29)**	**ETA (N=28)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.962**					
Age < 12 years, N / N'	**8 / 8**	**9 / 8**	**10 / 9**			
n (%)	5.00 (62.50)	4.41 (49.00)	4.28 (42.80)			
SEC low vs. ETA				2.13 [0.33; 13.95] 0.430	1.47 [0.58; 3.69] 0.415	0.20 [-0.27; 0.66] 0.404
SEC high vs. ETA				1.27 [0.20; 8.02] 0.800	1.14 [0.41; 3.20] 0.798	0.06 [-0.40; 0.53] 0.794
Age ≥ 12 years, N / N'	**17 / 16**	**20 / 18**	**18 / 15**			
n (%)	12.14 (71.41)	13.37 (66.85)	10.01 (55.61)			
SEC low vs. ETA				1.96 [0.47; 8.22] 0.360	1.29 [0.75; 2.20] 0.355	0.16 [-0.17; 0.48] 0.342
SEC high vs. ETA				1.59 [0.41; 6.24] 0.505	1.20 [0.70; 2.07] 0.504	0.11 [-0.21; 0.44] 0.496

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.3 CDLQI Response (Age ≤ 16) by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=25)	**SEC high (N=29)**	**ETA (N=28)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.892**					
Male, N / N'	**6 / 6**	**10 / 9**	**10 / 7**			
n (%)	4.00 (66.67)	6.91 (69.10)	5.60 (56.00)			
SEC low vs. ETA				1.52 [0.18; 12.49] 0.697	1.20 [0.53; 2.73] 0.667	0.11 [-0.39; 0.61] 0.677
SEC high vs. ETA				1.70 [0.26; 11.17] 0.579	1.24 [0.60; 2.59] 0.565	0.13 [-0.31; 0.57] 0.560
Female, N / N'	**19 / 18**	**19 / 17**	**18 / 17**			
n (%)	13.14 (69.16)	10.87 (57.21)	8.69 (48.28)			
SEC low vs. ETA				2.35 [0.61; 9.08] 0.216	1.43 [0.80; 2.56] 0.223	0.21 [-0.11; 0.53] 0.197
SEC high vs. ETA				1.42 [0.38; 5.37] 0.604	1.18 [0.62; 2.25] 0.605	0.09 [-0.24; 0.42] 0.598

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.4 CDLQI Response (Age ≤ 16) by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=25)	**SEC high (N=29)**	**ETA (N=28)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.986**					
Baseline PASI ≤ Median, N / N'	**12 / 12**	**16 / 14**	**13 / 11**			
n (%)	8.00 (66.67)	9.37 (58.56)	6.00 (46.15)			
SEC low vs. ETA				2.26 [0.44; 11.66] 0.331	1.45 [0.68; 3.09] 0.330	0.21 [-0.19; 0.60] 0.307
SEC high vs. ETA				1.63 [0.35; 7.62] 0.537	1.27 [0.59; 2.76] 0.538	0.12 [-0.26; 0.51] 0.527
Baseline PASI > Median, N / N'	**13 / 12**	**13 / 12**	**15 / 13**			
n (%)	9.14 (70.31)	8.41 (64.69)	8.29 (55.27)			
SEC low vs. ETA				1.88 [0.38; 9.18] 0.437	1.27 [0.70; 2.31] 0.426	0.15 [-0.21; 0.51] 0.417
SEC high vs. ETA				1.47 [0.31; 6.94] 0.629	1.17 [0.62; 2.20] 0.624	0.09 [-0.28; 0.47] 0.621

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.5 CDLQI Response (Age ≤ 16) by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=25)	**SEC high (N=29)**	**ETA (N=28)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.435**					
Europe, N / N'	**16 / 16**	**22 / 20**	**13 / 12**			
n (%)	11.00 (68.75)	14.32 (65.09)	9.31 (71.62)			
SEC low vs. ETA				0.87 [0.17; 4.39] 0.866	0.96 [0.59; 1.56] 0.873	-0.03 [-0.37; 0.31] 0.869
SEC high vs. ETA				0.74 [0.16; 3.45] 0.703	0.91 [0.56; 1.47] 0.697	-0.07 [-0.39; 0.26] 0.696
Others, N / N'	**9 / 8**	**7 / 6**	**15 / 12**			
n (%)	6.14 (68.22)	3.46 (49.43)	4.98 (33.20)			
SEC low vs. ETA				4.10 [0.66; 25.59] 0.131	2.07 [0.83; 5.19] 0.119	0.35 [-0.06; 0.76] 0.092
SEC high vs. ETA				1.92 [0.28; 13.00] 0.505	1.49 [0.48; 4.59] 0.488	0.16 [-0.30; 0.63] 0.495

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.6 CDLQI Response (Age ≤ 16) by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=25)	**SEC high (N=29)**	**ETA (N=28)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.619**					
Weight < 50 kg, N / N'	**17 / 16**	**17 / 15**	**20 / 17**			
n (%)	10.14 (59.65)	9.87 (58.06)	9.98 (49.90)			
SEC low vs. ETA				1.47 [0.39; 5.60] 0.573	1.20 [0.65; 2.21] 0.564	0.10 [-0.23; 0.43] 0.564
SEC high vs. ETA				1.38 [0.36; 5.36] 0.641	1.16 [0.62; 2.19] 0.638	0.08 [-0.26; 0.42] 0.635
Weight ≥ 50 kg, N / N'	**8 / 8**	**12 / 11**	**8 / 7**			
n (%)	7.00 (87.50)	7.91 (65.92)	4.31 (53.88)			
SEC low vs. ETA				5.32 [0.45; 63.01] 0.185	1.63 [0.79; 3.38] 0.187	0.34 [-0.09; 0.76] 0.124
SEC high vs. ETA				1.61 [0.25; 10.32] 0.615	1.23 [0.55; 2.73] 0.611	0.12 [-0.33; 0.57] 0.602

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.7 CDLQI Response (Age ≤ 16) by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=25)	**SEC high (N=29)**	**ETA (N=28)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.821**					
No previous systemic therapy, N / N'	**9 / 9**	**13 / 11**	**17 / 16**			
n (%)	7.00 (77.78)	8.87 (68.23)	10.69 (62.88)			
SEC low vs. ETA				2.01 [0.32; 12.58] 0.456	1.24 [0.74; 2.07] 0.415	0.15 [-0.21; 0.51] 0.417
SEC high vs. ETA				1.27 [0.26; 6.32] 0.770	1.08 [0.62; 1.88] 0.778	0.05 [-0.31; 0.41] 0.771
Previous systemic therapy, N / N'	**16 / 15**	**16 / 15**	**11 / 8**			
n (%)	10.14 (63.38)	8.91 (55.69)	3.60 (32.73)			
SEC low vs. ETA				3.42 [0.64; 18.38] 0.151	1.96 [0.72; 5.36] 0.188	0.31 [-0.08; 0.69] 0.117
SEC high vs. ETA				2.52 [0.48; 13.25] 0.276	1.73 [0.62; 4.83] 0.299	0.23 [-0.16; 0.62] 0.244

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

Safety Analysis

S.1.1 Adverse Events, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
Any AE, n (%)	34 (85.0)	34 (85.0)	34 (82.9)			
SEC low vs. ETA				1.16 [0.30; 4.67] 1.000	1.03 [0.85; 1.24] 1.000	0.02 [-0.14; 0.18] 0.799
SEC high vs. ETA				1.16 [0.30; 4.67] 1.000	1.03 [0.85; 1.24] 1.000	0.02 [-0.14; 0.18] 0.799
Any AE, disease specific events excluded, n (%)	34 (85.0)	34 (85.0)	34 (82.9)			
SEC low vs. ETA				1.16 [0.30; 4.67] 1.000	1.03 [0.85; 1.24] 1.000	0.02 [-0.14; 0.18] 0.799
SEC high vs. ETA				1.16 [0.30; 4.67] 1.000	1.03 [0.85; 1.24] 1.000	0.02 [-0.14; 0.18] 0.799
Any SAE, n (%)	3 (7.5)	4 (10.0)	5 (12.2)			
SEC low vs. ETA				0.59 [0.08; 3.28] 0.740	0.62 [0.16; 2.40] 0.712	-0.05 [-0.18; 0.08] 0.476
SEC high vs. ETA				0.80 [0.15; 4.07] 1.000	0.82 [0.24; 2.84] 1.000	-0.02 [-0.16; 0.11] 0.753
Any SAE, disease specific events excluded, n (%)	3 (7.5)	4 (10.0)	5 (12.2)			
SEC low vs. ETA				0.59 [0.08; 3.28] 0.740	0.62 [0.16; 2.40] 0.712	-0.05 [-0.18; 0.08] 0.476
SEC high vs. ETA				0.80 [0.15; 4.07] 1.000	0.82 [0.24; 2.84] 1.000	-0.02 [-0.16; 0.11] 0.753
Any severe AE, n (%)	1 (2.5)	3 (7.5)	4 (9.8)			
SEC low vs. ETA				0.24 [<0.01; 2.58] 0.375	0.26 [0.03; 2.19] 0.359	-0.07 [-0.18; 0.03] 0.167
SEC high vs. ETA				0.75 [0.10; 4.79] 1.000	0.77 [0.18; 3.22] 1.000	-0.02 [-0.14; 0.10] 0.717

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE, disease specific events excluded, n (%)	1 (2.5)	3 (7.5)	4 (9.8)			
SEC low vs. ETA				0.24 [<0.01; 2.58] 0.375	0.26 [0.03; 2.19] 0.359	-0.07 [-0.18; 0.03] 0.167
SEC high vs. ETA				0.75 [0.10; 4.79] 1.000	0.77 [0.18; 3.22] 1.000	-0.02 [-0.14; 0.10] 0.717
Any AE leading to study discontinuation, n (%)	0 (0.0)	1 (2.5)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
Any AE leading to study drug discontinuation, n (%)	1 (2.5)	1 (2.5)	1 (2.4)			
SEC low vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
SEC high vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

List of Excluded Disease-Specific SOC/Preferred Terms

Preferred Terms (grouped by disease-specific event category)
General disorders and administration site conditions
Fatigue
Malaise
Musculoskeletal and connective tissue disorders
Arthralgia
Back pain
Joint swelling
Pain in extremity
Skin and subcutaneous tissue disorders
Dry skin
Erythema
Pruritus
Pruritus generalised
Psoriasis
Skin fissures
Skin irritation

S.1.2 Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
Any adverse event, n (%)	34 (85.0)	34 (85.0)	34 (82.9)			
SEC low vs. ETA				1.16 [0.30; 4.67] 1.000	1.03 [0.85; 1.24] 1.000	0.02 [-0.14; 0.18] 0.799
SEC high vs. ETA				1.16 [0.30; 4.67] 1.000	1.03 [0.85; 1.24] 1.000	0.02 [-0.14; 0.18] 0.799
Mild, n (%)	33 (82.5)	32 (80.0)	32 (78.0)			
SEC low vs. ETA				1.32 [0.38; 4.72] 0.824	1.06 [0.85; 1.31] 0.781	0.04 [-0.13; 0.22] 0.614
SEC high vs. ETA				1.12 [0.34; 3.82] 1.000	1.03 [0.82; 1.28] 1.000	0.02 [-0.16; 0.20] 0.829
Moderate, n (%)	15 (37.5)	16 (40.0)	19 (46.3)			
SEC low vs. ETA				0.70 [0.26; 1.84] 0.562	0.81 [0.48; 1.36] 0.502	-0.09 [-0.30; 0.13] 0.418
SEC high vs. ETA				0.77 [0.29; 2.04] 0.725	0.86 [0.52; 1.43] 0.656	-0.06 [-0.28; 0.15] 0.564
Severe, n (%)	1 (2.5)	3 (7.5)	4 (9.8)			
SEC low vs. ETA				0.24 [<0.01; 2.58] 0.375	0.26 [0.03; 2.19] 0.359	-0.07 [-0.18; 0.03] 0.167
SEC high vs. ETA				0.75 [0.10; 4.79] 1.000	0.77 [0.18; 3.22] 1.000	-0.02 [-0.14; 0.10] 0.717
Infections and infestations, n (%)	30 (75.0)	27 (67.5)	27 (65.9)			
SEC low vs. ETA				1.55 [0.54; 4.61] 0.511	1.14 [0.86; 1.51] 0.467	0.09 [-0.11; 0.29] 0.364
SEC high vs. ETA				1.08 [0.39; 3.01] 1.000	1.03 [0.75; 1.39] 1.000	0.02 [-0.19; 0.22] 0.875

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Mild, n (%)	27 (67.5)	26 (65.0)	25 (61.0)			
SEC low vs. ETA				1.32 [0.49; 3.67] 0.704	1.11 [0.80; 1.53] 0.645	0.07 [-0.14; 0.27] 0.539
SEC high vs. ETA				1.19 [0.44; 3.24] 0.885	1.07 [0.76; 1.49] 0.819	0.04 [-0.17; 0.25] 0.707
Moderate, n (%)	10 (25.0)	11 (27.5)	10 (24.4)			
SEC low vs. ETA				1.03 [0.33; 3.21] 1.000	1.03 [0.48; 2.19] 1.000	0.01 [-0.18; 0.19] 0.949
SEC high vs. ETA				1.17 [0.39; 3.60] 0.947	1.13 [0.54; 2.36] 0.804	0.03 [-0.16; 0.22] 0.749
Severe, n (%)	1 (2.5)	3 (7.5)	1 (2.4)			
SEC low vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
SEC high vs. ETA				3.20 [0.24; 174.44] 0.597	3.08 [0.33; 28.34] 0.359	0.05 [-0.04; 0.14] 0.293
Nasopharyngitis, n (%)	12 (30.0)	16 (40.0)	11 (26.8)			
SEC low vs. ETA				1.17 [0.40; 3.45] 0.944	1.12 [0.56; 2.24] 0.809	0.03 [-0.16; 0.23] 0.752
SEC high vs. ETA				1.80 [0.65; 5.19] 0.307	1.49 [0.79; 2.81] 0.244	0.13 [-0.07; 0.34] 0.205
Mild, n (%)	11 (27.5)	15 (37.5)	10 (24.4)			
SEC low vs. ETA				1.17 [0.39; 3.60] 0.947	1.13 [0.54; 2.36] 0.804	0.03 [-0.16; 0.22] 0.749
SEC high vs. ETA				1.85 [0.65; 5.47] 0.300	1.54 [0.79; 3.01] 0.235	0.13 [-0.07; 0.33] 0.198
Moderate, n (%)	2 (5.0)	3 (7.5)	2 (4.9)			
SEC low vs. ETA				1.03 [0.07; 14.82] 1.000	1.03 [0.15; 6.93] 1.000	0.00 [-0.09; 0.10] 0.980
SEC high vs. ETA				1.57 [0.17; 19.82] 0.976	1.54 [0.27; 8.72] 0.675	0.03 [-0.08; 0.13] 0.624

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Gastroenteritis, n (%)	5 (12.5)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				5.61 [0.59; 276.88] 0.190	5.13 [0.63; 41.95] 0.109	0.10 [-0.01; 0.21] 0.081
SEC high vs. ETA				1.03 [<0.01; 39.97] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Mild, n (%)	4 (10.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Moderate, n (%)	1 (2.5)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Pharyngitis, n (%)	4 (10.0)	4 (10.0)	3 (7.3)			
SEC low vs. ETA				1.40 [0.22; 10.24] 0.972	1.37 [0.33; 5.72] 0.712	0.03 [-0.10; 0.15] 0.668
SEC high vs. ETA				1.40 [0.22; 10.24] 0.972	1.37 [0.33; 5.72] 0.712	0.03 [-0.10; 0.15] 0.668
Mild, n (%)	3 (7.5)	4 (10.0)	1 (2.4)			
SEC low vs. ETA				3.20 [0.24; 174.44] 0.597	3.08 [0.33; 28.34] 0.359	0.05 [-0.04; 0.14] 0.293
SEC high vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	1 (2.5)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Tonsillitis, n (%)	4 (10.0)	3 (7.5)	1 (2.4)			
SEC low vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
SEC high vs. ETA				3.20 [0.24; 174.44] 0.597	3.08 [0.33; 28.34] 0.359	0.05 [-0.04; 0.14] 0.293
Mild, n (%)	2 (5.0)	2 (5.0)	1 (2.4)			
SEC low vs. ETA				2.09 [0.10; 127.26] 0.981	2.05 [0.19; 21.73] 0.616	0.03 [-0.06; 0.11] 0.542
SEC high vs. ETA				2.09 [0.10; 127.26] 0.981	2.05 [0.19; 21.73] 0.616	0.03 [-0.06; 0.11] 0.542
Moderate, n (%)	3 (7.5)	1 (2.5)	0 (0.0)			
SEC low vs. ETA				4.11 [0.43; >999.99] 0.232	7.17 [0.38; 134.54] 0.116	0.08 [-0.01; 0.16] 0.072
SEC high vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Gastrointestinal disorders, n (%)	12 (30.0)	13 (32.5)	14 (34.1)			
SEC low vs. ETA				0.83 [0.29; 2.33] 0.872	0.88 [0.47; 1.66] 0.813	-0.04 [-0.24; 0.16] 0.689
SEC high vs. ETA				0.93 [0.33; 2.59] 1.000	0.95 [0.51; 1.76] 1.000	-0.02 [-0.22; 0.19] 0.875
Mild, n (%)	12 (30.0)	13 (32.5)	8 (19.5)			
SEC low vs. ETA				1.76 [0.57; 5.72] 0.403	1.54 [0.70; 3.36] 0.312	0.10 [-0.08; 0.29] 0.271
SEC high vs. ETA				1.97 [0.64; 6.36] 0.280	1.67 [0.77; 3.58] 0.212	0.13 [-0.06; 0.32] 0.178
Moderate, n (%)	2 (5.0)	2 (5.0)	6 (14.6)			
SEC low vs. ETA				0.31 [0.03; 1.89] 0.280	0.34 [0.07; 1.59] 0.264	-0.10 [-0.22; 0.03] 0.139
SEC high vs. ETA				0.31 [0.03; 1.89] 0.280	0.34 [0.07; 1.59] 0.264	-0.10 [-0.22; 0.03] 0.139
Severe, n (%)	0 (0.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Abdominal pain, n (%)	3 (7.5)	4 (10.0)	5 (12.2)			
SEC low vs. ETA				0.59 [0.08; 3.28] 0.740	0.62 [0.16; 2.40] 0.712	-0.05 [-0.18; 0.08] 0.476
SEC high vs. ETA				0.80 [0.15; 4.07] 1.000	0.82 [0.24; 2.84] 1.000	-0.02 [-0.16; 0.11] 0.753
Mild, n (%)	2 (5.0)	4 (10.0)	3 (7.3)			
SEC low vs. ETA				0.67 [0.05; 6.20] 1.000	0.68 [0.12; 3.88] 1.000	-0.02 [-0.13; 0.08] 0.664
SEC high vs. ETA				1.40 [0.22; 10.24] 0.972	1.37 [0.33; 5.72] 0.712	0.03 [-0.10; 0.15] 0.668

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	1 (2.5)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Abdominal pain upper, n (%)	4 (10.0)	3 (7.5)	4 (9.8)			
SEC low vs. ETA				1.03 [0.18; 5.96] 1.000	1.03 [0.27; 3.82] 1.000	0.00 [-0.13; 0.13] 0.971
SEC high vs. ETA				0.75 [0.10; 4.79] 1.000	0.77 [0.18; 3.22] 1.000	-0.02 [-0.14; 0.10] 0.717
Mild, n (%)	4 (10.0)	2 (5.0)	3 (7.3)			
SEC low vs. ETA				1.40 [0.22; 10.24] 0.972	1.37 [0.33; 5.72] 0.712	0.03 [-0.10; 0.15] 0.668
SEC high vs. ETA				0.67 [0.05; 6.20] 1.000	0.68 [0.12; 3.88] 1.000	-0.02 [-0.13; 0.08] 0.664
Moderate, n (%)	0 (0.0)	1 (2.5)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Diarrhoea, n (%)	4 (10.0)	4 (10.0)	1 (2.4)			
SEC low vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
SEC high vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
Mild, n (%)	4 (10.0)	4 (10.0)	1 (2.4)			
SEC low vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
SEC high vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vomiting, n (%)	1 (2.5)	4 (10.0)	1 (2.4)			
SEC low vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
SEC high vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
Mild, n (%)	1 (2.5)	4 (10.0)	0 (0.0)			
SEC low vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
SEC high vs. ETA				5.79 [0.70; >999.99] 0.110	9.22 [0.51; 165.88] 0.055	0.10 [0.01; 0.19] 0.035
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Skin and subcutaneous tissue disorders, n (%)	12 (30.0)	12 (30.0)	10 (24.4)			
SEC low vs. ETA				1.32 [0.44; 4.01] 0.751	1.23 [0.60; 2.52] 0.624	0.06 [-0.14; 0.25] 0.570
SEC high vs. ETA				1.32 [0.44; 4.01] 0.751	1.23 [0.60; 2.52] 0.624	0.06 [-0.14; 0.25] 0.570
Mild, n (%)	11 (27.5)	9 (22.5)	7 (17.1)			
SEC low vs. ETA				1.83 [0.56; 6.35] 0.390	1.61 [0.69; 3.74] 0.295	0.10 [-0.08; 0.28] 0.256
SEC high vs. ETA				1.40 [0.41; 5.02] 0.739	1.32 [0.54; 3.20] 0.587	0.05 [-0.12; 0.23] 0.539
Moderate, n (%)	3 (7.5)	4 (10.0)	2 (4.9)			
SEC low vs. ETA				1.57 [0.17; 19.82] 0.976	1.54 [0.27; 8.72] 0.675	0.03 [-0.08; 0.13] 0.624
SEC high vs. ETA				2.15 [0.29; 25.08] 0.652	2.05 [0.40; 10.57] 0.432	0.05 [-0.06; 0.17] 0.378
Severe, n (%)	0 (0.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Eczema, n (%)	1 (2.5)	4 (10.0)	1 (2.4)			
SEC low vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
SEC high vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Mild, n (%)	1 (2.5)	3 (7.5)	1 (2.4)			
SEC low vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
SEC high vs. ETA				3.20 [0.24; 174.44] 0.597	3.08 [0.33; 28.34] 0.359	0.05 [-0.04; 0.14] 0.293
Moderate, n (%)	0 (0.0)	1 (2.5)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Respiratory, thoracic and mediastinal disorders, n (%)	6 (15.0)	10 (25.0)	4 (9.8)			
SEC low vs. ETA				1.62 [0.35; 8.52] 0.705	1.54 [0.47; 5.04] 0.519	0.05 [-0.09; 0.20] 0.473
SEC high vs. ETA				3.04 [0.78; 14.65] 0.127	2.56 [0.87; 7.51] 0.084	0.15 [-0.01; 0.31] 0.065
Mild, n (%)	6 (15.0)	9 (22.5)	4 (9.8)			
SEC low vs. ETA				1.62 [0.35; 8.52] 0.705	1.54 [0.47; 5.04] 0.519	0.05 [-0.09; 0.20] 0.473
SEC high vs. ETA				2.65 [0.66; 12.96] 0.207	2.31 [0.77; 6.89] 0.140	0.13 [-0.03; 0.29] 0.114
Moderate, n (%)	0 (0.0)	1 (2.5)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Cough, n (%)	2 (5.0)	4 (10.0)	2 (4.9)			
SEC low vs. ETA				1.03 [0.07; 14.82] 1.000	1.03 [0.15; 6.93] 1.000	0.00 [-0.09; 0.10] 0.980
SEC high vs. ETA				2.15 [0.29; 25.08] 0.652	2.05 [0.40; 10.57] 0.432	0.05 [-0.06; 0.17] 0.378
Mild, n (%)	2 (5.0)	3 (7.5)	2 (4.9)			
SEC low vs. ETA				1.03 [0.07; 14.82] 1.000	1.03 [0.15; 6.93] 1.000	0.00 [-0.09; 0.10] 0.980
SEC high vs. ETA				1.57 [0.17; 19.82] 0.976	1.54 [0.27; 8.72] 0.675	0.03 [-0.08; 0.13] 0.624
Moderate, n (%)	0 (0.0)	1 (2.5)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Oropharyngeal pain, n (%)	2 (5.0)	4 (10.0)	1 (2.4)			
SEC low vs. ETA				2.09 [0.10; 127.26] 0.981	2.05 [0.19; 21.73] 0.616	0.03 [-0.06; 0.11] 0.542
SEC high vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
Mild, n (%)	2 (5.0)	4 (10.0)	1 (2.4)			
SEC low vs. ETA				2.09 [0.10; 127.26] 0.981	2.05 [0.19; 21.73] 0.616	0.03 [-0.06; 0.11] 0.542
SEC high vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
General disorders and administration site conditions, n (%)	9 (22.5)	9 (22.5)	8 (19.5)			
SEC low vs. ETA				1.19 [0.36; 4.06] 0.954	1.15 [0.49; 2.69] 0.790	0.03 [-0.15; 0.21] 0.741
SEC high vs. ETA				1.19 [0.36; 4.06] 0.954	1.15 [0.49; 2.69] 0.790	0.03 [-0.15; 0.21] 0.741
Mild, n (%)	9 (22.5)	8 (20.0)	7 (17.1)			
SEC low vs. ETA				1.40 [0.41; 5.02] 0.739	1.32 [0.54; 3.20] 0.587	0.05 [-0.12; 0.23] 0.539
SEC high vs. ETA				1.21 [0.34; 4.42] 0.957	1.17 [0.47; 2.93] 0.781	0.03 [-0.14; 0.20] 0.735
Moderate, n (%)	0 (0.0)	1 (2.5)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Blood and lymphatic system disorders, n (%)	6 (15.0)	2 (5.0)	2 (4.9)			
SEC low vs. ETA				3.39 [0.56; 36.53] 0.248	3.08 [0.66; 14.34] 0.155	0.10 [-0.03; 0.23] 0.124
SEC high vs. ETA				1.03 [0.07; 14.82] 1.000	1.03 [0.15; 6.93] 1.000	0.00 [-0.09; 0.10] 0.980
Mild, n (%)	4 (10.0)	2 (5.0)	1 (2.4)			
SEC low vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
SEC high vs. ETA				2.09 [0.10; 127.26] 0.981	2.05 [0.19; 21.73] 0.616	0.03 [-0.06; 0.11] 0.542

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	2 (5.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				2.09 [0.10; 127.26] 0.981	2.05 [0.19; 21.73] 0.616	0.03 [-0.06; 0.11] 0.542
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Severe, n (%)	0 (0.0)	1 (2.5)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
Investigations, n (%)	5 (12.5)	2 (5.0)	6 (14.6)			
SEC low vs. ETA				0.84 [0.18; 3.63] 1.000	0.85 [0.28; 2.58] 1.000	-0.02 [-0.17; 0.13] 0.779
SEC high vs. ETA				0.31 [0.03; 1.89] 0.280	0.34 [0.07; 1.59] 0.264	-0.10 [-0.22; 0.03] 0.139
Mild, n (%)	5 (12.5)	1 (2.5)	3 (7.3)			
SEC low vs. ETA				1.80 [0.32; 12.42] 0.684	1.71 [0.44; 6.68] 0.482	0.05 [-0.08; 0.18] 0.434
SEC high vs. ETA				0.33 [<0.01; 4.30] 0.634	0.34 [0.04; 3.15] 0.616	-0.05 [-0.14; 0.05] 0.311
Moderate, n (%)	2 (5.0)	1 (2.5)	4 (9.8)			
SEC low vs. ETA				0.49 [0.04; 3.66] 0.699	0.51 [0.10; 2.64] 0.675	-0.05 [-0.16; 0.07] 0.410
SEC high vs. ETA				0.24 [<0.01; 2.58] 0.375	0.26 [0.03; 2.19] 0.359	-0.07 [-0.18; 0.03] 0.167
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Nervous system disorders, n (%)	6 (15.0)	6 (15.0)	4 (9.8)			
SEC low vs. ETA				1.62 [0.35; 8.52] 0.705	1.54 [0.47; 5.04] 0.519	0.05 [-0.09; 0.20] 0.473
SEC high vs. ETA				1.62 [0.35; 8.52] 0.705	1.54 [0.47; 5.04] 0.519	0.05 [-0.09; 0.20] 0.473

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Mild, n (%)	6 (15.0)	5 (12.5)	3 (7.3)			
SEC low vs. ETA				2.21 [0.43; 14.74] 0.457	2.05 [0.55; 7.64] 0.312	0.08 [-0.06; 0.21] 0.270
SEC high vs. ETA				1.80 [0.32; 12.42] 0.684	1.71 [0.44; 6.68] 0.482	0.05 [-0.08; 0.18] 0.434
Moderate, n (%)	0 (0.0)	1 (2.5)	2 (4.9)			
SEC low vs. ETA				0.42 [<0.01; 5.44] 0.506	0.20 [0.01; 4.14] 0.494	-0.05 [-0.11; 0.02] 0.147
SEC high vs. ETA				0.50 [<0.01; 10.06] 1.000	0.51 [0.05; 5.43] 1.000	-0.02 [-0.11; 0.06] 0.569
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Headache, n (%)	5 (12.5)	6 (15.0)	4 (9.8)			
SEC low vs. ETA				1.32 [0.26; 7.21] 0.968	1.28 [0.37; 4.43] 0.737	0.03 [-0.11; 0.16] 0.695
SEC high vs. ETA				1.62 [0.35; 8.52] 0.705	1.54 [0.47; 5.04] 0.519	0.05 [-0.09; 0.20] 0.473
Mild, n (%)	5 (12.5)	5 (12.5)	3 (7.3)			
SEC low vs. ETA				1.80 [0.32; 12.42] 0.684	1.71 [0.44; 6.68] 0.482	0.05 [-0.08; 0.18] 0.434
SEC high vs. ETA				1.80 [0.32; 12.42] 0.684	1.71 [0.44; 6.68] 0.482	0.05 [-0.08; 0.18] 0.434
Moderate, n (%)	0 (0.0)	1 (2.5)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Musculoskeletal and connective tissue disorders, n (%)	1 (2.5)	3 (7.5)	5 (12.2)			
SEC low vs. ETA				0.19 [<0.01; 1.80] 0.212	0.21 [0.03; 1.68] 0.201	-0.10 [-0.21; 0.01] 0.088
SEC high vs. ETA				0.59 [0.08; 3.28] 0.740	0.62 [0.16; 2.40] 0.712	-0.05 [-0.18; 0.08] 0.476
Mild, n (%)	1 (2.5)	1 (2.5)	4 (9.8)			
SEC low vs. ETA				0.24 [<0.01; 2.58] 0.375	0.26 [0.03; 2.19] 0.359	-0.07 [-0.18; 0.03] 0.167
SEC high vs. ETA				0.24 [<0.01; 2.58] 0.375	0.26 [0.03; 2.19] 0.359	-0.07 [-0.18; 0.03] 0.167
Moderate, n (%)	0 (0.0)	2 (5.0)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				2.09 [0.10; 127.26] 0.981	2.05 [0.19; 21.73] 0.616	0.03 [-0.06; 0.11] 0.542
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Reproductive system and breast disorders, n (%)	3 (7.5)	5 (12.5)	3 (7.3)			
SEC low vs. ETA				1.03 [0.13; 8.17] 1.000	1.03 [0.22; 4.78] 1.000	0.00 [-0.11; 0.12] 0.975
SEC high vs. ETA				1.80 [0.32; 12.42] 0.684	1.71 [0.44; 6.68] 0.482	0.05 [-0.08; 0.18] 0.434
Mild, n (%)	3 (7.5)	5 (12.5)	3 (7.3)			
SEC low vs. ETA				1.03 [0.13; 8.17] 1.000	1.03 [0.22; 4.78] 1.000	0.00 [-0.11; 0.12] 0.975
SEC high vs. ETA				1.80 [0.32; 12.42] 0.684	1.71 [0.44; 6.68] 0.482	0.05 [-0.08; 0.18] 0.434
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Dysmenorrhoea, n (%)	1 (2.5)	4 (10.0)	2 (4.9)			
SEC low vs. ETA				0.50 [<0.01; 10.06] 1.000	0.51 [0.05; 5.43] 1.000	-0.02 [-0.11; 0.06] 0.569
SEC high vs. ETA				2.15 [0.29; 25.08] 0.652	2.05 [0.40; 10.57] 0.432	0.05 [-0.06; 0.17] 0.378
Mild, n (%)	1 (2.5)	4 (10.0)	2 (4.9)			
SEC low vs. ETA				0.50 [<0.01; 10.06] 1.000	0.51 [0.05; 5.43] 1.000	-0.02 [-0.11; 0.06] 0.569
SEC high vs. ETA				2.15 [0.29; 25.08] 0.652	2.05 [0.40; 10.57] 0.432	0.05 [-0.06; 0.17] 0.378
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Eye disorders, n (%)	2 (5.0)	4 (10.0)	3 (7.3)			
SEC low vs. ETA				0.67 [0.05; 6.20] 1.000	0.68 [0.12; 3.88] 1.000	-0.02 [-0.13; 0.08] 0.664
SEC high vs. ETA				1.40 [0.22; 10.24] 0.972	1.37 [0.33; 5.72] 0.712	0.03 [-0.10; 0.15] 0.668
Mild, n (%)	2 (5.0)	4 (10.0)	3 (7.3)			
SEC low vs. ETA				0.67 [0.05; 6.20] 1.000	0.68 [0.12; 3.88] 1.000	-0.02 [-0.13; 0.08] 0.664
SEC high vs. ETA				1.40 [0.22; 10.24] 0.972	1.37 [0.33; 5.72] 0.712	0.03 [-0.10; 0.15] 0.668

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	0 (0.0)	1 (2.5)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Injury, poisoning and procedural complications, n (%)	4 (10.0)	4 (10.0)	1 (2.4)			
SEC low vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
SEC high vs. ETA				4.37 [0.41; 224.23] 0.344	4.10 [0.48; 35.11] 0.201	0.08 [-0.03; 0.18] 0.155
Mild, n (%)	4 (10.0)	3 (7.5)	0 (0.0)			
SEC low vs. ETA				5.79 [0.70; >999.99] 0.110	9.22 [0.51; 165.88] 0.055	0.10 [0.01; 0.19] 0.035
SEC high vs. ETA				4.11 [0.43; >999.99] 0.232	7.17 [0.38; 134.54] 0.116	0.08 [-0.01; 0.16] 0.072
Moderate, n (%)	0 (0.0)	2 (5.0)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				2.09 [0.10; 127.26] 0.981	2.05 [0.19; 21.73] 0.616	0.03 [-0.06; 0.11] 0.542

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S.1.3 Serious Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
Any SAE, n (%)	3 (7.5)	4 (10.0)	5 (12.2)			
SEC low vs. ETA				0.59 [0.08; 3.28] 0.740	0.62 [0.16; 2.40] 0.712	-0.05 [-0.18; 0.08] 0.476
SEC high vs. ETA				0.80 [0.15; 4.07] 1.000	0.82 [0.24; 2.84] 1.000	-0.02 [-0.16; 0.11] 0.753
Mild, n (%)	1 (2.5)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	1 (2.5)	1 (2.5)	3 (7.3)			
SEC low vs. ETA				0.33 [<0.01; 4.30] 0.634	0.34 [0.04; 3.15] 0.616	-0.05 [-0.14; 0.05] 0.311
SEC high vs. ETA				0.33 [<0.01; 4.30] 0.634	0.34 [0.04; 3.15] 0.616	-0.05 [-0.14; 0.05] 0.311
Severe, n (%)	1 (2.5)	3 (7.5)	3 (7.3)			
SEC low vs. ETA				0.33 [<0.01; 4.30] 0.634	0.34 [0.04; 3.15] 0.616	-0.05 [-0.14; 0.05] 0.311
SEC high vs. ETA				1.03 [0.13; 8.17] 1.000	1.03 [0.22; 4.78] 1.000	0.00 [-0.11; 0.12] 0.975
Gastrointestinal disorders, n (%)	0 (0.0)	0 (0.0)	3 (7.3)			
SEC low vs. ETA				0.26 [<0.01; 2.44] 0.250	0.15 [0.01; 2.75] 0.241	-0.07 [-0.15; 0.01] 0.072
SEC high vs. ETA				0.26 [<0.01; 2.44] 0.250	0.15 [0.01; 2.75] 0.241	-0.07 [-0.15; 0.01] 0.072
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	0 (0.0)	0 (0.0)	2 (4.9)			
SEC low vs. ETA				0.42 [<0.01; 5.44] 0.506	0.20 [0.01; 4.14] 0.494	-0.05 [-0.11; 0.02] 0.147
SEC high vs. ETA				0.42 [<0.01; 5.44] 0.506	0.20 [0.01; 4.14] 0.494	-0.05 [-0.11; 0.02] 0.147
Severe, n (%)	0 (0.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Infections and infestations, n (%)	1 (2.5)	2 (5.0)	0 (0.0)			
SEC low vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
SEC high vs. ETA				2.52 [0.19; >999.99] 0.481	5.12 [0.25; 103.47] 0.241	0.05 [-0.02; 0.12] 0.147
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	1 (2.5)	2 (5.0)	0 (0.0)			
SEC low vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
SEC high vs. ETA				2.52 [0.19; >999.99] 0.481	5.12 [0.25; 103.47] 0.241	0.05 [-0.02; 0.12] 0.147

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S1.4 Any AE Leading to Study Discontinuation

Patient ID	Actual Treat-ment	Reported term/ Preferred term/ System organ class	Start Date/Day End Date/Day Date/Day of study discontinuation	Serious	Severity/ Causality/ Action taken[1]
1500005	SEC high	TOXIC SHOCK SYNDROME/ Toxic shock syndrome/ Infections and infestations	2018-06-21 / 16 2018-07-18 / 43 2018-11-28 / 176	Y	SEV/ NO/ withdrawn
		right calf abcess/ Abscess limb/ Infections and infestations	2018-07-06 / 31 2018-07-18 / 43 2018-11-28 / 176	N	MILD/ NO/ na

[1] not changed = DOSE NOT CHANGED, withdrawn = DRUG WITHDRAWN, na = NOT APPLICABLE

S1.5 Any AE Leading to Study Drug Discontinuation by SOC and PT, Frequencies (SAF)

	Treatment Groups		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**
N'	40	40	41
Infections and infestations, n (%)	0 (0.0)	1 (2.5)	0 (0.0)
Toxic shock syndrome, n (%)	0 (0.0)	1 (2.5)	0 (0.0)
Investigations, n (%)	0 (0.0)	0 (0.0)	1 (2.4)
Hepatic enzyme increased, n (%)	0 (0.0)	0 (0.0)	1 (2.4)
Psychiatric disorders, n (%)	1 (2.5)	0 (0.0)	0 (0.0)
Behaviour disorder, n (%)	1 (2.5)	0 (0.0)	0 (0.0)
Major depression, n (%)	1 (2.5)	0 (0.0)	0 (0.0)
Mental disorder, n (%)	1 (2.5)	0 (0.0)	0 (0.0)
Suicidal ideation, n (%)	1 (2.5)	0 (0.0)	0 (0.0)

N': Number of patients in the analysis
n (%): Number and percentage of patients with event

S.1.6 Adverse Events of Special Interest by Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
Infections and infestations (SOC), n (%)	30 (75.0)	28 (70.0)	27 (65.9)			
SEC low vs. ETA				1.55 [0.54; 4.61] 0.511	1.14 [0.86; 1.51] 0.467	0.09 [-0.11; 0.29] 0.364
SEC high vs. ETA				1.21 [0.43; 3.43] 0.872	1.06 [0.79; 1.43] 0.813	0.04 [-0.16; 0.24] 0.689
Mild, n (%)	27 (67.5)	27 (67.5)	25 (61.0)			
SEC low vs. ETA				1.32 [0.49; 3.67] 0.704	1.11 [0.80; 1.53] 0.645	0.07 [-0.14; 0.27] 0.539
SEC high vs. ETA				1.32 [0.49; 3.67] 0.704	1.11 [0.80; 1.53] 0.645	0.07 [-0.14; 0.27] 0.539
Moderate, n (%)	10 (25.0)	11 (27.5)	10 (24.4)			
SEC low vs. ETA				1.03 [0.33; 3.21] 1.000	1.03 [0.48; 2.19] 1.000	0.01 [-0.18; 0.19] 0.949
SEC high vs. ETA				1.17 [0.39; 3.60] 0.947	1.13 [0.54; 2.36] 0.804	0.03 [-0.16; 0.22] 0.749
Severe, n (%)	1 (2.5)	3 (7.5)	1 (2.4)			
SEC low vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
SEC high vs. ETA				3.20 [0.24; 174.44] 0.597	3.08 [0.33; 28.34] 0.359	0.05 [-0.04; 0.14] 0.293
Serious, n (%)	1 (2.5)	2 (5.0)	0 (0.0)			
SEC low vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
SEC high vs. ETA				2.52 [0.19; >999.99] 0.481	5.12 [0.25; 103.47] 0.241	0.05 [-0.02; 0.12] 0.147

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Hypersensitivity (SMQ) (narrow), n (%)	3 (7.5)	9 (22.5)	5 (12.2)			
SEC low vs. ETA				0.59 [0.08; 3.28] 0.740	0.62 [0.16; 2.40] 0.712	-0.05 [-0.18; 0.08] 0.476
SEC high vs. ETA				2.07 [0.55; 8.74] 0.352	1.85 [0.68; 5.03] 0.253	0.10 [-0.06; 0.27] 0.217
Mild, n (%)	3 (7.5)	6 (15.0)	5 (12.2)			
SEC low vs. ETA				0.59 [0.08; 3.28] 0.740	0.62 [0.16; 2.40] 0.712	-0.05 [-0.18; 0.08] 0.476
SEC high vs. ETA				1.27 [0.29; 5.77] 0.964	1.23 [0.41; 3.71] 0.756	0.03 [-0.12; 0.18] 0.713
Moderate, n (%)	0 (0.0)	4 (10.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				5.79 [0.70; >999.99] 0.110	9.22 [0.51; 165.88] 0.055	0.10 [0.01; 0.19] 0.035
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Neutropenia (NMQ) (narrow), n (%)	2 (5.0)	1 (2.5)	1 (2.4)			
SEC low vs. ETA				2.09 [0.10; 127.26] 0.981	2.05 [0.19; 21.73] 0.616	0.03 [-0.06; 0.11] 0.542
SEC high vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
Mild, n (%)	1 (2.5)	1 (2.5)	0 (0.0)			
SEC low vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311
SEC high vs. ETA				1.03 [0.03; >999.99] 0.988	3.07 [0.13; 73.28] 0.494	0.03 [-0.02; 0.07] 0.311

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	1 (2.5)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				1.03 [0.01; 82.50] 1.000	1.03 [0.07; 15.83] 1.000	0.00 [-0.07; 0.07] 0.986
SEC high vs. ETA				1.03 [<0.01; 39.98] 1.000	0.34 [0.01; 8.14] 1.000	-0.02 [-0.07; 0.02] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Drug specific antibody present (PT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

Die Diskrepanz in der Häufigkeit der Ereignisse in der SOC Infections and Investigations im Vergleich zu S.1.2 erklärt sich folgendermaßen: In S.1.2. (UE nach SOC und PT) wird die Primary SOC verwendet wird, während in S.1.6. auch Events zur SOC Infections and infestations zugeordnet werden, die zwar auch zu dieser SOC gehören, aber primär einer anderen SOC zugeordnet sind. Konkret handelt es sich dabei um das AE ‚Virus warts' in der Gruppe SEC high (PT: Skin papilloma, Primary SOC: Neoplasms benign, malignant and unspecified, Secondary SOCs: Skin and subcutaneous tissue disorders / Infections and infestations).

S.1.7 Tanner Stage, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
N'	**40**	**40**	**40**			
n (%)	36 (90.0)	31 (77.5)	35 (87.5)			
SEC low vs. ETA				1.28 [0.25; 7.02] 1.000	1.03 [0.88; 1.20] 1.000	0.03 [-0.11; 0.16] 0.723
SEC high vs. ETA				0.50 [0.12; 1.86] 0.378	0.89 [0.72; 1.09] 0.378	-0.10 [-0.27; 0.07] 0.235
Pubertal at Week 52						
N'	**38**	**36**	**36**			
n (%)	35 (92.1)	30 (83.3)	34 (94.4)			
SEC low vs. ETA				0.69 [0.05; 6.42] 1.000	0.98 [0.86; 1.10] 1.000	-0.02 [-0.14; 0.09] 0.687
SEC high vs. ETA				0.30 [0.03; 1.84] 0.260	0.88 [0.75; 1.04] 0.260	-0.11 [-0.25; 0.03] 0.128

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S.2.1 Adverse Events, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' Age < 12 years	8	9	10			
N' Age ≥ 12 years	32	31	31			
Any AE						
Interaction test:	p=0.798					
Age < 12 years, n (%)	7 (87.5)	7 (77.8)	7 (70.0)			
SEC low vs. ETA				2.83 [0.17; 179.59] 0.765	1.25 [0.77; 2.03] 0.588	0.18 [-0.19; 0.54] 0.347
SEC high vs. ETA				1.47 [0.12; 22.87] 1.000	1.11 [0.65; 1.90] 1.000	0.08 [-0.32; 0.47] 0.698
Age ≥ 12 years, n (%)	27 (84.4)	27 (87.1)	27 (87.1)			
SEC low vs. ETA				0.80 [0.14; 4.19] 1.000	0.97 [0.79; 1.18] 1.000	-0.03 [-0.20; 0.15] 0.757
SEC high vs. ETA				1.00 [0.17; 5.96] 1.000	1.00 [0.83; 1.21] 1.000	0.00 [-0.17; 0.17] 1.000
Any SAE						
Interaction test:	p=0.354					
Age < 12 years, n (%)	0 (0.0)	2 (22.2)	1 (10.0)			
SEC low vs. ETA				1.25 [<0.01; 48.75] 1.000	0.41 [0.02; 8.84] 1.000	-0.10 [-0.29; 0.09] 0.292
SEC high vs. ETA				2.45 [0.11; 168.26] 0.916	2.22 [0.24; 20.57] 0.582	0.12 [-0.21; 0.45] 0.467
Age ≥ 12 years, n (%)	3 (9.4)	2 (6.5)	4 (12.9)			
SEC low vs. ETA				0.70 [0.09; 4.57] 0.963	0.73 [0.18; 2.99] 0.708	-0.04 [-0.19; 0.12] 0.656
SEC high vs. ETA				0.47 [0.04; 3.60] 0.671	0.50 [0.10; 2.53] 0.671	-0.06 [-0.21; 0.08] 0.387

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=0.630					
Age < 12 years, n (%)	0 (0.0)	2 (22.2)	1 (10.0)			
SEC low vs. ETA				1.25 [<0.01; 48.75] 1.000	0.41 [0.02; 8.84] 1.000	-0.10 [-0.29; 0.09] 0.292
SEC high vs. ETA				2.45 [0.11; 168.26] 0.916	2.22 [0.24; 20.57] 0.582	0.12 [-0.21; 0.45] 0.467
Age ≥ 12 years, n (%)	1 (3.1)	1 (3.2)	3 (9.7)			
SEC low vs. ETA				0.31 [<0.01; 4.07] 0.589	0.32 [0.04; 2.94] 0.355	-0.07 [-0.19; 0.05] 0.286
SEC high vs. ETA				0.32 [<0.01; 4.21] 0.612	0.33 [0.04; 3.03] 0.612	-0.06 [-0.19; 0.06] 0.297
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	1 (11.1)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.11 [0.03; >999.99] 0.947	3.30 [0.15; 72.09] 0.474	0.11 [-0.09; 0.32] 0.289
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.626					
Age < 12 years, n (%)	0 (0.0)	1 (11.1)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.11 [0.03; >999.99] 0.947	3.30 [0.15; 72.09] 0.474	0.11 [-0.09; 0.32] 0.289

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Age ≥ 12 years, n (%)	1 (3.1)	0 (0.0)	1 (3.2)			
SEC low vs. ETA				0.97 [0.01; 78.47] 1.000	0.97 [0.06; 14.82] 1.000	-0.00 [-0.09; 0.09] 0.982
SEC high vs. ETA				1.00 [<0.01; 39.00] 1.000	0.33 [0.01; 7.88] 1.000	-0.03 [-0.09; 0.03] 0.309

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.2.2 Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.3 Serious Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.4 Severe Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.5 Adverse Events of Special Interest, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' Age < 12 years	8	9	10			
N' Age ≥ 12 years	32	31	31			
Infections and infestations (SOC)						
Interaction test:	p=0.857					
Age < 12 years, n (%)	5 (62.5)	6 (66.7)	5 (50.0)			
SEC low vs. ETA				1.62 [0.18; 16.83] 0.960	1.25 [0.55; 2.84] 0.664	0.13 [-0.33; 0.58] 0.592
SEC high vs. ETA				1.93 [0.23; 19.39] 0.790	1.33 [0.62; 2.89] 0.650	0.17 [-0.27; 0.60] 0.455
Age ≥ 12 years, n (%)	25 (78.1)	22 (71.0)	22 (71.0)			
SEC low vs. ETA				1.45 [0.40; 5.44] 0.717	1.10 [0.82; 1.47] 0.572	0.07 [-0.14; 0.29] 0.513
SEC high vs. ETA				1.00 [0.29; 3.46] 1.000	1.00 [0.73; 1.37] 1.000	0.00 [-0.23; 0.23] 1.000
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.243					
Age < 12 years, n (%)	0 (0.0)	2 (22.2)	3 (30.0)			
SEC low vs. ETA				0.27 [<0.01; 2.87] 0.294	0.17 [0.01; 2.96] 0.216	-0.30 [-0.58; -0.02] 0.038
SEC high vs. ETA				0.68 [0.04; 8.05] 1.000	0.74 [0.16; 3.48] 1.000	-0.08 [-0.47; 0.32] 0.698
Age ≥ 12 years, n (%)	3 (9.4)	7 (22.6)	2 (6.5)			
SEC low vs. ETA				1.49 [0.16; 19.08] 1.000	1.45 [0.26; 8.11] 1.000	0.03 [-0.10; 0.16] 0.667
SEC high vs. ETA				4.14 [0.70; 44.45] 0.147	3.50 [0.79; 15.54] 0.147	0.16 [-0.01; 0.33] 0.064

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.198					
Age < 12 years, n (%)	2 (25.0)	1 (11.1)	0 (0.0)			
SEC low vs. ETA				3.34 [0.24; >999.99] 0.366	6.11 [0.33; 111.71] 0.183	0.25 [-0.05; 0.55] 0.102
SEC high vs. ETA				1.11 [0.03; >999.99] 0.947	3.30 [0.15; 72.09] 0.474	0.11 [-0.09; 0.32] 0.289
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	1 (3.2)			
SEC low vs. ETA				0.97 [<0.01; 37.78] 0.984	0.32 [0.01; 7.65] 0.492	-0.03 [-0.09; 0.03] 0.309
SEC high vs. ETA				1.00 [<0.01; 39.00] 1.000	0.33 [0.01; 7.88] 1.000	-0.03 [-0.09; 0.03] 0.309
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.2.6 Tanner Stage, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=0.720**					
Age < 12 years, N / N'	**8 / 8**	**9 / 9**	**10 / 10**			
n (%)	4 (50.0)	2 (22.2)	6 (60.0)			
SEC low vs. ETA				0.68 [0.07; 6.23] 1.000	0.83 [0.35; 1.97] 1.000	-0.10 [-0.56; 0.36] 0.671
SEC high vs. ETA				0.21 [0.01; 1.94] 0.230	0.37 [0.10; 1.39] 0.170	-0.38 [-0.79; 0.03] 0.069
Age ≥ 12 years, N / N'	**32 / 32**	**31 / 31**	**31 / 30**			
n (%)	32 (100.0)	29 (93.5)	29 (96.7)			
SEC low vs. ETA				1.07 [0.03; N.E.] 0.968	1.03 [0.97; 1.11] 0.484	0.03 [-0.03; 0.10] 0.309
SEC high vs. ETA				0.51 [<0.01; 10.21] 1.000	0.97 [0.86; 1.08] 1.000	-0.03 [-0.14; 0.08] 0.570
Pubertal at Week 52						
Interaction Test	**p=1.000**					
Age < 12 years, N / N'	**8 / 8**	**9 / 8**	**10 / 7**			
n (%)	5 (62.5)	3 (37.5)	5 (71.4)			
SEC low vs. ETA				0.68 [0.04; 9.11] 1.000	0.88 [0.43; 1.78] 1.000	-0.09 [-0.56; 0.38] 0.712
SEC high vs. ETA				0.27 [0.02; 3.07] 0.429	0.53 [0.19; 1.44] 0.315	-0.34 [-0.81; 0.13] 0.161
Age ≥ 12 years, N / N'	**32 / 30**	**31 / 28**	**31 / 29**			
n (%)	30 (100.0)	27 (96.4)	29 (100.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.97 [N.E.; 37.66] 0.982	0.96 [0.90; 1.04] 0.491	-0.04 [-0.10; 0.03] 0.309

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.1 Adverse Events, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' Male	13	17	16			
N' Female	27	23	25			
Any AE						
Interaction test:	p=0.020					
Male, n (%)	13 (100.0)	12 (70.6)	13 (81.3)			
SEC low vs. ETA				3.47 [0.35; >999.99] 0.307	1.23 [0.97; 1.56] 0.232	0.19 [-0.00; 0.38] 0.055
SEC high vs. ETA				0.56 [0.07; 3.66] 0.761	0.87 [0.59; 1.28] 0.688	-0.11 [-0.40; 0.18] 0.470
Female, n (%)	21 (77.8)	22 (95.7)	21 (84.0)			
SEC low vs. ETA				0.67 [0.12; 3.32] 0.832	0.93 [0.71; 1.21] 0.729	-0.06 [-0.27; 0.15] 0.566
SEC high vs. ETA				4.08 [0.36; 215.56] 0.402	1.14 [0.94; 1.38] 0.350	0.12 [-0.05; 0.28] 0.169
Any SAE						
Interaction test:	p=0.566					
Male, n (%)	0 (0.0)	1 (5.9)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.94 [0.02; >999.99] 1.000	2.83 [0.12; 64.89] 1.000	0.06 [-0.05; 0.17] 0.303
Female, n (%)	3 (11.1)	3 (13.0)	5 (20.0)			
SEC low vs. ETA				0.51 [0.07; 2.98] 0.616	0.56 [0.15; 2.09] 0.458	-0.09 [-0.29; 0.11] 0.375
SEC high vs. ETA				0.61 [0.08; 3.61] 0.801	0.65 [0.18; 2.43] 0.703	-0.07 [-0.28; 0.14] 0.513

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=1.000					
Male, n (%)	0 (0.0)	0 (0.0)	1 (6.3)			
SEC low vs. ETA				1.23 [<0.01; 48.00] 1.000	0.40 [0.02; 9.18] 1.000	-0.06 [-0.18; 0.06] 0.302
SEC high vs. ETA				0.94 [<0.01; 36.71] 0.970	0.31 [0.01; 7.21] 0.485	-0.06 [-0.18; 0.06] 0.302
Female, n (%)	1 (3.7)	3 (13.0)	3 (12.0)			
SEC low vs. ETA				0.29 [<0.01; 3.89] 0.552	0.31 [0.03; 2.78] 0.341	-0.08 [-0.23; 0.06] 0.265
SEC high vs. ETA				1.10 [0.13; 9.17] 1.000	1.09 [0.24; 4.86] 1.000	0.01 [-0.18; 0.20] 0.913
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	1 (4.3)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.09 [0.03; >999.99] 0.958	3.25 [0.14; 76.01] 0.479	0.04 [-0.04; 0.13] 0.307
Any AE leading to study drug discontinuation						
Interaction test:	p=0.603					
Male, n (%)	0 (0.0)	0 (0.0)	1 (6.3)			
SEC low vs. ETA				1.23 [<0.01; 48.00] 1.000	0.40 [0.02; 9.18] 1.000	-0.06 [-0.18; 0.06] 0.302
SEC high vs. ETA				0.94 [<0.01; 36.71] 0.970	0.31 [0.01; 7.21] 0.485	-0.06 [-0.18; 0.06] 0.302

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Female, n (%)	1 (3.7)	1 (4.3)	0 (0.0)			
SEC low vs. ETA				0.93 [0.02; >999.99] 1.000	2.79 [0.12; 65.39] 1.000	0.04 [-0.03; 0.11] 0.308
SEC high vs. ETA				1.09 [0.03; >999.99] 0.958	3.25 [0.14; 76.01] 0.479	0.04 [-0.04; 0.13] 0.307

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.2 Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.3 Serious Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.4 Severe Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.5 Adverse Events of Special Interest, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' Male	13	17	16			
N' Female	27	23	25			
Infections and infestations (SOC)						
Interaction test:	p=0.067					
Male, n (%)	12 (92.3)	10 (58.8)	12 (75.0)			
SEC low vs. ETA				3.83 [0.32; 213.09] 0.472	1.23 [0.89; 1.70] 0.343	0.17 [-0.08; 0.43] 0.187
SEC high vs. ETA				0.49 [0.08; 2.61] 0.540	0.78 [0.48; 1.28] 0.465	-0.16 [-0.48; 0.15] 0.315
Female, n (%)	18 (66.7)	18 (78.3)	15 (60.0)			
SEC low vs. ETA				1.33 [0.37; 4.81] 0.833	1.11 [0.73; 1.69] 0.774	0.07 [-0.20; 0.33] 0.618
SEC high vs. ETA				2.36 [0.58; 10.86] 0.293	1.30 [0.89; 1.92] 0.221	0.18 [-0.07; 0.44] 0.161
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.796					
Male, n (%)	0 (0.0)	3 (17.6)	1 (6.3)			
SEC low vs. ETA				1.23 [<0.01; 48.00] 1.000	0.40 [0.02; 9.18] 1.000	-0.06 [-0.18; 0.06] 0.302
SEC high vs. ETA				3.11 [0.22; 179.78] 0.648	2.82 [0.33; 24.43] 0.601	0.11 [-0.10; 0.33] 0.302
Female, n (%)	3 (11.1)	6 (26.1)	4 (16.0)			
SEC low vs. ETA				0.66 [0.09; 4.41] 0.911	0.69 [0.17; 2.80] 0.698	-0.05 [-0.24; 0.14] 0.607
SEC high vs. ETA				1.83 [0.36; 10.34] 0.614	1.63 [0.53; 5.05] 0.487	0.10 [-0.13; 0.33] 0.390
Neutropenia (NMQ) (narrow)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Female, n (%)	2 (7.4)	1 (4.3)	1 (4.0)			
SEC low vs. ETA				1.90 [0.09; 117.92] 1.000	1.85 [0.18; 19.19] 1.000	0.03 [-0.09; 0.16] 0.594
SEC high vs. ETA				1.09 [0.01; 89.16] 1.000	1.09 [0.07; 16.39] 1.000	0.00 [-0.11; 0.12] 0.952
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.6 Tanner Stage, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=0.648**					
Male, N / N'	**13 / 13**	**17 / 17**	**16 / 15**			
n (%)	12 (92.3)	13 (76.5)	12 (80.0)			
SEC low vs. ETA				2.89 [0.20; 170.38] 0.711	1.15 [0.86; 1.55] 0.600	0.12 [-0.13; 0.37] 0.332
SEC high vs. ETA				0.82 [0.10; 5.98] 1.000	0.96 [0.66; 1.38] 1.000	-0.04 [-0.32; 0.25] 0.809
Female, N / N'	**27 / 27**	**23 / 23**	**25 / 25**			
n (%)	24 (88.9)	18 (78.3)	23 (92.0)			
SEC low vs. ETA				0.70 [0.05; 6.71] 1.000	0.97 [0.81; 1.15] 1.000	-0.03 [-0.19; 0.13] 0.702
SEC high vs. ETA				0.32 [0.03; 2.24] 0.349	0.85 [0.67; 1.09] 0.237	-0.14 [-0.34; 0.06] 0.177
Pubertal at Week 52						
Interaction Test	**p=0.502**					
Male, N / N'	**13 / 12**	**17 / 16**	**16 / 13**			
n (%)	12 (100.0)	13 (81.3)	12 (92.3)			
SEC low vs. ETA				0.92 [0.02; N.E.] 1.000	1.08 [0.93; 1.27] 1.000	0.08 [-0.07; 0.22] 0.298
SEC high vs. ETA				0.37 [<0.01; 5.40] 0.766	0.88 [0.66; 1.17] 0.606	-0.11 [-0.35; 0.13] 0.366
Female, N / N'	**27 / 26**	**23 / 20**	**25 / 23**			
n (%)	23 (88.5)	17 (85.0)	22 (95.7)			
SEC low vs. ETA				0.36 [<0.01; 4.82] 0.706	0.92 [0.79; 1.09] 0.612	-0.07 [-0.22; 0.08] 0.342
SEC high vs. ETA				0.27 [<0.01; 3.64] 0.503	0.89 [0.72; 1.09] 0.323	-0.11 [-0.28; 0.07] 0.239

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.1 Adverse Events, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' Baseline PASI ≤ Median	20	20	22			
N' Baseline PASI > Median	20	20	19			
Any AE						
Interaction test:	p=0.062					
Baseline PASI ≤ Median, n (%)	19 (95.0)	15 (75.0)	19 (86.4)			
SEC low vs. ETA				2.93 [0.21; 165.63] 0.681	1.10 [0.91; 1.34] 0.608	0.09 [-0.09; 0.26] 0.326
SEC high vs. ETA				0.48 [0.06; 2.95] 0.587	0.87 [0.64; 1.18] 0.445	-0.11 [-0.35; 0.12] 0.349
Baseline PASI > Median, n (%)	15 (75.0)	19 (95.0)	15 (78.9)			
SEC low vs. ETA				0.80 [0.13; 4.59] 1.000	0.95 [0.67; 1.34] 1.000	-0.04 [-0.30; 0.22] 0.769
SEC high vs. ETA				4.87 [0.42; 262.36] 0.310	1.20 [0.93; 1.55] 0.182	0.16 [-0.05; 0.37] 0.128
Any SAE						
Interaction test:	p=0.773					
Baseline PASI ≤ Median, n (%)	2 (10.0)	2 (10.0)	2 (9.1)			
SEC low vs. ETA				1.11 [0.07; 16.78] 1.000	1.10 [0.17; 7.10] 1.000	0.01 [-0.17; 0.19] 0.920
SEC high vs. ETA				1.11 [0.07; 16.78] 1.000	1.10 [0.17; 7.10] 1.000	0.01 [-0.17; 0.19] 0.920
Baseline PASI > Median, n (%)	1 (5.0)	2 (10.0)	3 (15.8)			
SEC low vs. ETA				0.29 [<0.01; 4.02] 0.565	0.32 [0.04; 2.79] 0.342	-0.11 [-0.30; 0.08] 0.265
SEC high vs. ETA				0.60 [0.04; 5.96] 0.949	0.63 [0.12; 3.38] 0.661	-0.06 [-0.27; 0.15] 0.589

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=0.047					
Baseline PASI ≤ Median, n (%)	1 (5.0)	2 (10.0)	0 (0.0)			
SEC low vs. ETA				1.10 [0.03; >999.99] 0.952	3.29 [0.14; 76.33] 0.476	0.05 [-0.05; 0.15] 0.305
SEC high vs. ETA				2.76 [0.21; >999.99] 0.441	5.48 [0.28; 107.62] 0.221	0.10 [-0.03; 0.23] 0.136
Baseline PASI > Median, n (%)	0 (0.0)	1 (5.0)	4 (21.1)			
SEC low vs. ETA				0.16 [<0.01; 1.34] 0.094	0.11 [0.01; 1.84] 0.047	-0.21 [-0.39; -0.03] 0.024
SEC high vs. ETA				0.21 [<0.01; 2.36] 0.310	0.24 [0.03; 1.94] 0.182	-0.16 [-0.37; 0.05] 0.128
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	1 (5.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.95 [0.02; >999.99] 1.000	2.86 [0.12; 66.11] 1.000	0.05 [-0.05; 0.15] 0.305
Any AE leading to study drug discontinuation						
Interaction test:	p=1.000					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	1 (4.5)			
SEC low vs. ETA				1.10 [<0.01; 42.90] 1.000	0.37 [0.02; 8.48] 1.000	-0.05 [-0.13; 0.04] 0.306
SEC high vs. ETA				1.10 [<0.01; 42.90] 1.000	0.37 [0.02; 8.48] 1.000	-0.05 [-0.13; 0.04] 0.306

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Baseline PASI > Median, n (%)	1 (5.0)	1 (5.0)	0 (0.0)			
SEC low vs. ETA				0.95 [0.02; >999.99] 1.000	2.86 [0.12; 66.11] 1.000	0.05 [-0.05; 0.15] 0.305
SEC high vs. ETA				0.95 [0.02; >999.99] 1.000	2.86 [0.12; 66.11] 1.000	0.05 [-0.05; 0.15] 0.305

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.2 Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.3 Serious Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.4 Severe Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.5 Adverse Events of Special Interest, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' Baseline PASI ≤ Median	20	20	22			
N' Baseline PASI > Median	20	20	19			
Infections and infestations (SOC)						
Interaction test:	p=0.128					
Baseline PASI ≤ Median, n (%)	18 (90.0)	13 (65.0)	15 (68.2)			
SEC low vs. ETA				4.06 [0.64; 45.84] 0.176	1.32 [0.96; 1.82] 0.135	0.22 [-0.02; 0.45] 0.069
SEC high vs. ETA				0.87 [0.20; 3.79] 1.000	0.95 [0.62; 1.47] 1.000	-0.03 [-0.32; 0.25] 0.827
Baseline PASI > Median, n (%)	12 (60.0)	15 (75.0)	12 (63.2)			
SEC low vs. ETA				0.88 [0.20; 3.83] 1.000	0.95 [0.58; 1.56] 1.000	-0.03 [-0.34; 0.27] 0.839
SEC high vs. ETA				1.72 [0.36; 8.84] 0.650	1.19 [0.78; 1.82] 0.501	0.12 [-0.17; 0.41] 0.421
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.599					
Baseline PASI ≤ Median, n (%)	3 (15.0)	6 (30.0)	3 (13.6)			
SEC low vs. ETA				1.11 [0.13; 9.49] 1.000	1.10 [0.25; 4.84] 1.000	0.01 [-0.20; 0.23] 0.900
SEC high vs. ETA				2.65 [0.47; 19.26] 0.361	2.20 [0.63; 7.65] 0.269	0.16 [-0.08; 0.41] 0.194
Baseline PASI > Median, n (%)	0 (0.0)	3 (15.0)	2 (10.5)			
SEC low vs. ETA				0.38 [<0.01; 5.01] 0.462	0.19 [0.01; 3.73] 0.231	-0.11 [-0.24; 0.03] 0.135
SEC high vs. ETA				1.48 [0.15; 19.90] 1.000	1.43 [0.27; 7.61] 1.000	0.04 [-0.16; 0.25] 0.674

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	p=1.000					
Baseline PASI ≤ Median, n (%)	1 (5.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				1.10 [0.03; >999.99] 0.952	3.29 [0.14; 76.33] 0.476	0.05 [-0.05; 0.15] 0.305
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	1 (5.0)	1 (5.0)	1 (5.3)			
SEC low vs. ETA				0.95 [0.01; 78.45] 1.000	0.95 [0.06; 14.13] 1.000	-0.00 [-0.14; 0.14] 0.970
SEC high vs. ETA				0.95 [0.01; 78.45] 1.000	0.95 [0.06; 14.13] 1.000	-0.00 [-0.14; 0.14] 0.970
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.6 Tanner Stage, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=0.806**					
Baseline PASI ≤ Median, N / N'	**20 / 20**	**20 / 20**	**22 / 22**			
n (%)	18 (90.0)	15 (75.0)	20 (90.9)			
SEC low vs. ETA				0.90 [0.06; 13.65] 1.000	0.99 [0.81; 1.21] 1.000	-0.01 [-0.19; 0.17] 0.920
SEC high vs. ETA				0.31 [0.03; 2.21] 0.334	0.83 [0.62; 1.10] 0.229	-0.16 [-0.38; 0.07] 0.165
Baseline PASI > Median, N / N'	**20 / 20**	**20 / 20**	**19 / 18**			
n (%)	18 (90.0)	16 (80.0)	15 (83.3)			
SEC low vs. ETA				1.77 [0.18; 23.86] 0.896	1.08 [0.84; 1.39] 0.653	0.07 [-0.15; 0.28] 0.546
SEC high vs. ETA				0.80 [0.10; 5.65] 1.000	0.96 [0.71; 1.30] 1.000	-0.03 [-0.28; 0.21] 0.790
Pubertal at Week 52						
Interaction Test	**p=0.516**					
Baseline PASI ≤ Median, N / N'	**20 / 19**	**20 / 19**	**22 / 20**			
n (%)	17 (89.5)	16 (84.2)	20 (100.0)			
SEC low vs. ETA				0.38 [N.E.; 5.01] 0.462	0.89 [0.77; 1.04] 0.231	-0.11 [-0.24; 0.03] 0.135
SEC high vs. ETA				0.23 [N.E.; 2.22] 0.212	0.84 [0.69; 1.02] 0.106	-0.16 [-0.32; 0.01] 0.059
Baseline PASI > Median, N / N'	**20 / 19**	**20 / 17**	**19 / 16**			
n (%)	18 (94.7)	14 (82.4)	14 (87.5)			
SEC low vs. ETA				2.50 [0.12; 159.98] 0.868	1.08 [0.87; 1.34] 0.582	0.07 [-0.12; 0.26] 0.457
SEC high vs. ETA				0.67 [0.05; 6.87] 1.000	0.94 [0.71; 1.25] 1.000	-0.05 [-0.29; 0.19] 0.678

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.1 Adverse Events, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' Europe	28	32	24			
N' Others	12	8	17			
Any AE						
Interaction test:	p=0.028					
Europe, n (%)	26 (92.9)	28 (87.5)	18 (75.0)			
SEC low vs. ETA				4.21 [0.66; 47.29] 0.163	1.24 [0.96; 1.59] 0.123	0.18 [-0.02; 0.38] 0.077
SEC high vs. ETA				2.30 [0.47; 12.70] 0.391	1.17 [0.89; 1.52] 0.298	0.13 [-0.08; 0.33] 0.238
Others, n (%)	8 (66.7)	6 (75.0)	16 (94.1)			
SEC low vs. ETA				0.13 [<0.01; 1.65] 0.155	0.71 [0.47; 1.08] 0.130	-0.27 [-0.56; 0.01] 0.063
SEC high vs. ETA				0.20 [<0.01; 4.55] 0.463	0.80 [0.52; 1.21] 0.231	-0.19 [-0.51; 0.13] 0.242
Any SAE						
Interaction test:	p=0.723					
Europe, n (%)	2 (7.1)	3 (9.4)	4 (16.7)			
SEC low vs. ETA				0.39 [0.03; 3.05] 0.525	0.43 [0.09; 2.14] 0.397	-0.10 [-0.27; 0.08] 0.292
SEC high vs. ETA				0.52 [0.07; 3.46] 0.676	0.56 [0.14; 2.28] 0.447	-0.07 [-0.25; 0.11] 0.427
Others, n (%)	1 (8.3)	1 (12.5)	1 (5.9)			
SEC low vs. ETA				1.44 [0.02; 121.21] 1.000	1.42 [0.10; 20.49] 1.000	0.02 [-0.17; 0.22] 0.803
SEC high vs. ETA				2.20 [0.03; 190.42] 1.000	2.13 [0.15; 29.82] 1.000	0.07 [-0.19; 0.32] 0.611

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=1.000					
Europe, n (%)	1 (3.6)	2 (6.3)	2 (8.3)			
SEC low vs. ETA				0.41 [<0.01; 8.45] 0.883	0.43 [0.04; 4.44] 0.590	-0.05 [-0.18; 0.08] 0.473
SEC high vs. ETA				0.74 [0.05; 10.90] 1.000	0.75 [0.11; 4.95] 1.000	-0.02 [-0.16; 0.12] 0.769
Others, n (%)	0 (0.0)	1 (12.5)	2 (11.8)			
SEC low vs. ETA				0.56 [<0.01; 7.55] 0.670	0.28 [0.01; 5.30] 0.498	-0.12 [-0.27; 0.04] 0.132
SEC high vs. ETA				1.07 [0.02; 23.96] 1.000	1.06 [0.11; 10.07] 1.000	0.01 [-0.27; 0.28] 0.958
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	1 (3.1)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.75 [0.02; >999.99] 1.000	2.27 [0.10; 53.47] 1.000	0.03 [-0.03; 0.09] 0.310
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.489					
Europe, n (%)	0 (0.0)	1 (3.1)	1 (4.2)			
SEC low vs. ETA				0.86 [<0.01; 33.43] 0.923	0.29 [0.01; 6.74] 0.462	-0.04 [-0.12; 0.04] 0.307
SEC high vs. ETA				0.75 [<0.01; 60.74] 1.000	0.75 [0.05; 11.40] 1.000	-0.01 [-0.11; 0.09] 0.838

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Others, n (%)	1 (8.3)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				1.42 [0.04; >999.99] 0.828	4.15 [0.18; 94.08] 0.414	0.08 [-0.07; 0.24] 0.296
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.2 Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.3 Serious Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.4 Severe Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.5 Adverse Events of Special Interest, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' Europe	28	32	24			
N' Others	12	8	17			
Infections and infestations (SOC)						
Interaction test:	p=0.552					
Europe, n (%)	23 (82.1)	24 (75.0)	16 (66.7)			
SEC low vs. ETA				2.26 [0.54; 10.54] 0.335	1.23 [0.88; 1.72] 0.220	0.15 [-0.08; 0.39] 0.199
SEC high vs. ETA				1.49 [0.40; 5.64] 0.698	1.13 [0.80; 1.59] 0.558	0.08 [-0.16; 0.32] 0.498
Others, n (%)	7 (58.3)	4 (50.0)	11 (64.7)			
SEC low vs. ETA				0.77 [0.13; 4.57] 1.000	0.90 [0.50; 1.63] 1.000	-0.06 [-0.42; 0.30] 0.728
SEC high vs. ETA				0.56 [0.07; 4.20] 0.786	0.77 [0.36; 1.68] 0.667	-0.15 [-0.56; 0.27] 0.487
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.746					
Europe, n (%)	2 (7.1)	8 (25.0)	2 (8.3)			
SEC low vs. ETA				0.85 [0.06; 12.61] 1.000	0.86 [0.13; 5.63] 1.000	-0.01 [-0.16; 0.13] 0.873
SEC high vs. ETA				3.59 [0.62; 38.30] 0.204	3.00 [0.70; 12.87] 0.162	0.17 [-0.02; 0.35] 0.080
Others, n (%)	1 (8.3)	1 (12.5)	3 (17.6)			
SEC low vs. ETA				0.44 [<0.01; 6.34] 0.888	0.47 [0.06; 4.01] 0.622	-0.09 [-0.33; 0.15] 0.446
SEC high vs. ETA				0.68 [0.01; 10.40] 1.000	0.71 [0.09; 5.79] 1.000	-0.05 [-0.34; 0.24] 0.730

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	N.E.					
Europe, n (%)	2 (7.1)	1 (3.1)	1 (4.2)			
SEC low vs. ETA				1.75 [0.09; 108.85] 1.000	1.71 [0.17; 17.76] 1.000	0.03 [-0.09; 0.15] 0.639
SEC high vs. ETA				0.75 [<0.01; 60.74] 1.000	0.75 [0.05; 11.40] 1.000	-0.01 [-0.11; 0.09] 0.838
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.6 Tanner Stage, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=0.642**					
Europe, N / N'	**28 / 28**	**32 / 32**	**24 / 24**			
n (%)	25 (89.3)	26 (81.3)	22 (91.7)			
SEC low vs. ETA				0.76 [0.06; 7.30] 1.000	0.97 [0.82; 1.16] 1.000	-0.02 [-0.18; 0.14] 0.769
SEC high vs. ETA				0.40 [0.04; 2.54] 0.481	0.89 [0.72; 1.09] 0.444	-0.10 [-0.28; 0.07] 0.243
Others, N / N'	**12 / 12**	**8 / 8**	**17 / 16**			
n (%)	11 (91.7)	5 (62.5)	13 (81.3)			
SEC low vs. ETA				2.46 [0.17; 145.17] 0.834	1.13 [0.84; 1.51] 0.613	0.10 [-0.14; 0.35] 0.409
SEC high vs. ETA				0.40 [0.04; 4.04] 0.605	0.77 [0.43; 1.38] 0.362	-0.19 [-0.57; 0.20] 0.341
Pubertal at Week 52						
Interaction Test	**p=0.271**					
Europe, N / N'	**28 / 28**	**32 / 29**	**24 / 23**			
n (%)	25 (89.3)	26 (89.7)	22 (95.7)			
SEC low vs. ETA				0.39 [<0.01; 5.21] 0.767	0.93 [0.80; 1.09] 0.617	-0.06 [-0.21; 0.08] 0.378
SEC high vs. ETA				0.40 [<0.01; 5.40] 0.796	0.94 [0.81; 1.09] 0.621	-0.06 [-0.20; 0.08] 0.397
Others, N / N'	**12 / 10**	**8 / 7**	**17 / 13**			
n (%)	10 (100.0)	4 (57.1)	12 (92.3)			
SEC low vs. ETA				0.77 [0.02; N.E.] 1.000	1.08 [0.93; 1.27] 1.000	0.08 [-0.07; 0.22] 0.298
SEC high vs. ETA				0.13 [<0.01; 2.07] 0.202	0.62 [0.32; 1.20] 0.101	-0.35 [-0.75; 0.04] 0.080

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.1 Adverse Events, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' Weight < 50 kg	19	18	20			
N' Weight ≥ 50 kg	21	22	21			
Any AE						
Interaction test:	p=0.833					
Weight < 50 kg, n (%)	16 (84.2)	14 (77.8)	16 (80.0)			
SEC low vs. ETA				1.32 [0.19; 10.53] 1.000	1.05 [0.79; 1.41] 1.000	0.04 [-0.20; 0.28] 0.731
SEC high vs. ETA				0.88 [0.14; 5.68] 1.000	0.97 [0.70; 1.35] 1.000	-0.02 [-0.28; 0.24] 0.867
Weight ≥ 50 kg, n (%)	18 (85.7)	20 (90.9)	18 (85.7)			
SEC low vs. ETA				1.00 [0.12; 8.51] 1.000	1.00 [0.78; 1.28] 1.000	0.00 [-0.21; 0.21] 1.000
SEC high vs. ETA				1.65 [0.17; 21.83] 0.954	1.06 [0.85; 1.32] 0.664	0.05 [-0.14; 0.24] 0.596
Any SAE						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	1 (5.3)	2 (11.1)	2 (10.0)			
SEC low vs. ETA				0.51 [<0.01; 10.59] 1.000	0.53 [0.05; 5.34] 1.000	-0.05 [-0.21; 0.12] 0.575
SEC high vs. ETA				1.12 [0.07; 17.16] 1.000	1.11 [0.17; 7.09] 1.000	0.01 [-0.18; 0.21] 0.911
Weight ≥ 50 kg, n (%)	2 (9.5)	2 (9.1)	3 (14.3)			
SEC low vs. ETA				0.64 [0.05; 6.27] 1.000	0.67 [0.12; 3.59] 1.000	-0.05 [-0.24; 0.15] 0.633
SEC high vs. ETA				0.61 [0.05; 5.94] 0.954	0.64 [0.12; 3.44] 0.664	-0.05 [-0.24; 0.14] 0.596

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=0.718					
Weight < 50 kg, n (%)	0 (0.0)	2 (11.1)	2 (10.0)			
SEC low vs. ETA				0.42 [<0.01; 5.56] 0.513	0.21 [0.01; 4.11] 0.487	-0.10 [-0.23; 0.03] 0.136
SEC high vs. ETA				1.12 [0.07; 17.16] 1.000	1.11 [0.17; 7.09] 1.000	0.01 [-0.18; 0.21] 0.911
Weight ≥ 50 kg, n (%)	1 (4.8)	1 (4.5)	2 (9.5)			
SEC low vs. ETA				0.48 [<0.01; 10.00] 1.000	0.50 [0.05; 5.10] 1.000	-0.05 [-0.20; 0.11] 0.547
SEC high vs. ETA				0.46 [<0.01; 9.52] 0.964	0.48 [0.05; 4.88] 0.607	-0.05 [-0.20; 0.10] 0.523
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	1 (5.6)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.11 [0.03; >999.99] 0.947	3.32 [0.14; 76.60] 0.474	0.06 [-0.05; 0.16] 0.303
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.311					
Weight < 50 kg, n (%)	1 (5.3)	1 (5.6)	0 (0.0)			
SEC low vs. ETA				1.05 [0.03; >999.99] 0.974	3.15 [0.14; 72.89] 0.487	0.05 [-0.05; 0.15] 0.304
SEC high vs. ETA				1.11 [0.03; >999.99] 0.947	3.32 [0.14; 76.60] 0.474	0.06 [-0.05; 0.16] 0.303

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	1 (4.8)			
SEC low vs. ETA				1.00 [<0.01; 39.00] 1.000	0.33 [0.01; 7.74] 1.000	-0.05 [-0.14; 0.04] 0.306
SEC high vs. ETA				0.95 [<0.01; 37.23] 0.977	0.32 [0.01; 7.42] 0.488	-0.05 [-0.14; 0.04] 0.306

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.2 Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.3 Serious Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.4 Severe Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.5 Adverse Events of Special Interest, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' Weight < 50 kg	19	18	20			
N' Weight ≥ 50 kg	21	22	21			
Infections and infestations (SOC)						
Interaction test:	p=0.881					
Weight < 50 kg, n (%)	14 (73.7)	11 (61.1)	12 (60.0)			
SEC low vs. ETA				1.84 [0.40; 9.25] 0.573	1.23 [0.79; 1.92] 0.501	0.14 [-0.16; 0.43] 0.358
SEC high vs. ETA				1.05 [0.24; 4.70] 1.000	1.02 [0.61; 1.70] 1.000	0.01 [-0.30; 0.32] 0.944
Weight ≥ 50 kg, n (%)	16 (76.2)	17 (77.3)	15 (71.4)			
SEC low vs. ETA				1.27 [0.26; 6.51] 1.000	1.07 [0.74; 1.53] 1.000	0.05 [-0.22; 0.31] 0.725
SEC high vs. ETA				1.35 [0.28; 6.87] 0.928	1.08 [0.76; 1.54] 0.736	0.06 [-0.20; 0.32] 0.660
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.806					
Weight < 50 kg, n (%)	1 (5.3)	5 (27.8)	3 (15.0)			
SEC low vs. ETA				0.32 [<0.01; 4.49] 0.644	0.35 [0.04; 3.09] 0.605	-0.10 [-0.28; 0.09] 0.305
SEC high vs. ETA				2.13 [0.34; 16.34] 0.572	1.85 [0.51; 6.67] 0.438	0.13 [-0.13; 0.39] 0.334
Weight ≥ 50 kg, n (%)	2 (9.5)	4 (18.2)	2 (9.5)			
SEC low vs. ETA				1.00 [0.07; 15.13] 1.000	1.00 [0.15; 6.45] 1.000	0.00 [-0.18; 0.18] 1.000
SEC high vs. ETA				2.08 [0.26; 25.61] 0.710	1.91 [0.39; 9.35] 0.664	0.09 [-0.12; 0.29] 0.406

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.228					
Weight < 50 kg, n (%)	2 (10.5)	1 (5.6)	0 (0.0)			
SEC low vs. ETA				2.64 [0.20; >999.99] 0.462	5.25 [0.27; 102.75] 0.231	0.11 [-0.03; 0.24] 0.135
SEC high vs. ETA				1.11 [0.03; >999.99] 0.947	3.32 [0.14; 76.60] 0.474	0.06 [-0.05; 0.16] 0.303
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	1 (4.8)			
SEC low vs. ETA				1.00 [<0.01; 39.00] 1.000	0.33 [0.01; 7.74] 1.000	-0.05 [-0.14; 0.04] 0.306
SEC high vs. ETA				0.95 [<0.01; 37.23] 0.977	0.32 [0.01; 7.42] 0.488	-0.05 [-0.14; 0.04] 0.306
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.6 Tanner Stage, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=1.000**					
Weight < 50 kg, N / N'	**19 / 19**	**18 / 18**	**20 / 19**			
n (%)	15 (78.9)	10 (55.6)	15 (78.9)			
SEC low vs. ETA				1.00 [0.15; 6.47] 1.000	1.00 [0.72; 1.39] 1.000	0.00 [-0.26; 0.26] 1.000
SEC high vs. ETA				0.34 [0.06; 1.71] 0.243	0.70 [0.44; 1.13] 0.170	-0.23 [-0.53; 0.06] 0.119
Weight ≥ 50 kg, N / N'	**21 / 21**	**22 / 22**	**21 / 21**			
n (%)	21 (100.0)	21 (95.5)	20 (95.2)			
SEC low vs. ETA				1.00 [0.03; N.E.] 1.000	1.05 [0.95; 1.16] 1.000	0.05 [-0.04; 0.14] 0.306
SEC high vs. ETA				1.05 [0.01; 86.30] 1.000	1.00 [0.88; 1.14] 1.000	0.00 [-0.12; 0.13] 0.973
Pubertal at Week 52						
Interaction Test	**N.E.**					
Weight < 50 kg, N / N'	**19 / 19**	**18 / 15**	**20 / 17**			
n (%)	16 (84.2)	9 (60.0)	15 (88.2)			
SEC low vs. ETA				0.72 [0.05; 7.21] 1.000	0.95 [0.74; 1.24] 1.000	-0.04 [-0.26; 0.18] 0.725
SEC high vs. ETA				0.21 [0.02; 1.51] 0.151	0.68 [0.43; 1.06] 0.106	-0.28 [-0.57; 0.01] 0.058
Weight ≥ 50 kg, N / N'	**21 / 19**	**22 / 21**	**21 / 19**			
n (%)	19 (100.0)	21 (100.0)	19 (100.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.1 Adverse Events, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' No previous systemic therapy	14	19	22			
N' Previous systemic therapy	26	21	19			
Any AE						
Interaction test:	p=0.139					
No previous systemic therapy, n (%)	13 (92.9)	17 (89.5)	16 (72.7)			
SEC low vs. ETA				4.69 [0.47; 241.16] 0.291	1.28 [0.95; 1.71] 0.209	0.20 [-0.03; 0.43] 0.086
SEC high vs. ETA				3.10 [0.46; 35.82] 0.342	1.23 [0.91; 1.66] 0.249	0.17 [-0.06; 0.40] 0.157
Previous systemic therapy, n (%)	21 (80.8)	17 (81.0)	18 (94.7)			
SEC low vs. ETA				0.24 [<0.01; 2.44] 0.363	0.85 [0.69; 1.06] 0.222	-0.14 [-0.32; 0.04] 0.132
SEC high vs. ETA				0.24 [<0.01; 2.80] 0.407	0.85 [0.68; 1.08] 0.345	-0.14 [-0.33; 0.06] 0.167
Any SAE						
Interaction test:	p=0.545					
No previous systemic therapy, n (%)	1 (7.1)	2 (10.5)	1 (4.5)			
SEC low vs. ETA				1.59 [0.02; 132.75] 1.000	1.57 [0.11; 23.14] 1.000	0.03 [-0.13; 0.19] 0.751
SEC high vs. ETA				2.42 [0.12; 152.57] 0.888	2.32 [0.23; 23.58] 0.588	0.06 [-0.10; 0.22] 0.472
Previous systemic therapy, n (%)	2 (7.7)	2 (9.5)	4 (21.1)			
SEC low vs. ETA				0.32 [0.03; 2.56] 0.390	0.37 [0.07; 1.79] 0.377	-0.13 [-0.34; 0.08] 0.212
SEC high vs. ETA				0.40 [0.03; 3.27] 0.565	0.45 [0.09; 2.20] 0.398	-0.12 [-0.34; 0.11] 0.309

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=0.216					
No previous systemic therapy, n (%)	1 (7.1)	2 (10.5)	1 (4.5)			
SEC low vs. ETA				1.59 [0.02; 132.75] 1.000	1.57 [0.11; 23.14] 1.000	0.03 [-0.13; 0.19] 0.751
SEC high vs. ETA				2.42 [0.12; 152.57] 0.888	2.32 [0.23; 23.58] 0.588	0.06 [-0.10; 0.22] 0.472
Previous systemic therapy, n (%)	0 (0.0)	1 (4.8)	3 (15.8)			
SEC low vs. ETA				0.17 [<0.01; 1.69] 0.137	0.11 [0.01; 1.94] 0.068	-0.16 [-0.32; 0.01] 0.059
SEC high vs. ETA				0.28 [<0.01; 3.81] 0.530	0.30 [0.03; 2.66] 0.331	-0.11 [-0.30; 0.08] 0.249
Any AE leading to study discontinuation						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	1 (5.3)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.16 [0.03; >999.99] 0.927	3.45 [0.15; 80.03] 0.463	0.05 [-0.05; 0.15] 0.304
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.555					
No previous systemic therapy, n (%)	0 (0.0)	1 (5.3)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.16 [0.03; >999.99] 0.927	3.45 [0.15; 80.03] 0.463	0.05 [-0.05; 0.15] 0.304

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Previous systemic therapy, n (%)	1 (3.8)	0 (0.0)	1 (5.3)			
SEC low vs. ETA				0.73 [<0.01; 59.62] 1.000	0.73 [0.05; 10.96] 1.000	-0.01 [-0.14; 0.11] 0.824
SEC high vs. ETA				0.90 [<0.01; 35.29] 0.950	0.30 [0.01; 7.02] 0.475	-0.05 [-0.15; 0.05] 0.304

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.2 Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.3 Serious Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.4 Severe Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.5 Adverse Events of Special Interest, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	40	40	41			
N' No previous systemic therapy	14	19	22			
N' Previous systemic therapy	26	21	19			
Infections and infestations (SOC)						
Interaction test:	p=0.222					
No previous systemic therapy, n (%)	13 (92.9)	14 (73.7)	14 (63.6)			
SEC low vs. ETA				7.08 [0.77; 354.45] 0.106	1.46 [1.03; 2.07] 0.062	0.29 [0.05; 0.53] 0.018
SEC high vs. ETA				1.58 [0.35; 7.81] 0.727	1.16 [0.76; 1.75] 0.524	0.10 [-0.18; 0.38] 0.485
Previous systemic therapy, n (%)	17 (65.4)	14 (66.7)	13 (68.4)			
SEC low vs. ETA				0.87 [0.20; 3.62] 1.000	0.96 [0.63; 1.45] 1.000	-0.03 [-0.31; 0.25] 0.830
SEC high vs. ETA				0.92 [0.20; 4.22] 1.000	0.97 [0.63; 1.50] 1.000	-0.02 [-0.31; 0.27] 0.906
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.328					
No previous systemic therapy, n (%)	1 (7.1)	2 (10.5)	3 (13.6)			
SEC low vs. ETA				0.50 [<0.01; 7.00] 0.980	0.52 [0.06; 4.55] 1.000	-0.06 [-0.26; 0.13] 0.518
SEC high vs. ETA				0.75 [0.06; 7.40] 1.000	0.77 [0.14; 4.14] 1.000	-0.03 [-0.23; 0.17] 0.759
Previous systemic therapy, n (%)	2 (7.7)	7 (33.3)	2 (10.5)			
SEC low vs. ETA				0.71 [0.05; 10.75] 1.000	0.73 [0.11; 4.73] 1.000	-0.03 [-0.20; 0.14] 0.747
SEC high vs. ETA				4.10 [0.64; 46.68] 0.176	3.17 [0.75; 13.42] 0.133	0.23 [-0.02; 0.47] 0.067

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.636					
No previous systemic therapy, n (%)	1 (7.1)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				1.57 [0.04; >999.99] 0.778	4.60 [0.20; 105.63] 0.389	0.07 [-0.06; 0.21] 0.299
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	1 (3.8)	1 (4.8)	1 (5.3)			
SEC low vs. ETA				0.73 [<0.01; 59.62] 1.000	0.73 [0.05; 10.96] 1.000	-0.01 [-0.14; 0.11] 0.824
SEC high vs. ETA				0.90 [0.01; 74.53] 1.000	0.90 [0.06; 13.48] 1.000	-0.01 [-0.14; 0.13] 0.942
Drug specific antibody present (PT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.6 Tanner Stage, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=0.785**					
No previous systemic therapy, N / N'	**14 / 14**	**19 / 19**	**22 / 21**			
n (%)	13 (92.9)	16 (84.2)	18 (85.7)			
SEC low vs. ETA				2.12 [0.15; 122.35] 0.940	1.08 [0.86; 1.36] 0.635	0.07 [-0.13; 0.27] 0.487
SEC high vs. ETA				0.89 [0.10; 7.64] 1.000	0.98 [0.76; 1.28] 1.000	-0.02 [-0.24; 0.21] 0.894
Previous systemic therapy, N / N'	**26 / 26**	**21 / 21**	**19 / 19**			
n (%)	23 (88.5)	15 (71.4)	17 (89.5)			
SEC low vs. ETA				0.90 [0.07; 8.83] 1.000	0.99 [0.80; 1.22] 1.000	-0.01 [-0.19; 0.17] 0.914
SEC high vs. ETA				0.30 [0.03; 2.03] 0.304	0.80 [0.58; 1.09] 0.241	-0.18 [-0.42; 0.06] 0.136
Pubertal at Week 52						
Interaction Test	**p=0.343**					
No previous systemic therapy, N / N'	**14 / 13**	**19 / 16**	**22 / 18**			
n (%)	11 (84.6)	15 (93.8)	17 (94.4)			
SEC low vs. ETA				0.34 [<0.01; 7.18] 0.752	0.90 [0.69; 1.16] 0.558	-0.10 [-0.32; 0.12] 0.387
SEC high vs. ETA				0.89 [0.01; 73.83] 1.000	0.99 [0.84; 1.18] 1.000	-0.01 [-0.17; 0.15] 0.932
Previous systemic therapy, N / N'	**26 / 25**	**21 / 20**	**19 / 18**			
n (%)	24 (96.0)	15 (75.0)	17 (94.4)			
SEC low vs. ETA				1.40 [0.02; 115.37] 1.000	1.02 [0.89; 1.17] 1.000	0.02 [-0.12; 0.15] 0.816
SEC high vs. ETA				0.18 [<0.01; 1.91] 0.230	0.79 [0.60; 1.05] 0.184	-0.19 [-0.41; 0.02] 0.079

	Treatment Groups			Comparison		
	SEC low (N=40)	**SEC high (N=40)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

Figures

Efficacy Analysis

8.1 CDLQI, Boxplot (FAS)



9.1 CDLQI (Age ≤ 16), Boxplot (FAS)